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1General Introduction
1.1 Subject of this thesis
Malignant glioma is a disease with few therapeutic options. Malignant 
glioma has been widely considered as an example of a tumour in which the expression of 
tumour-specific antigens and the generation of antigen-specific immune responses are 
critically involved. Based on these notions we predict that efficient immunotherapy is a 
feasible treatment option for this type of tumour. In order to develop tumour-specific 
immunotherapy pertinent to this thesis, we will describe various strategies including 
stand-alone immune modulation as well as vaccination-induced immune responses in 
the tumour-bearing host, and monitor therapeutic efficacy of the resulting immunity, 
e.g. by tumour reduction.
We will first describe general aspects of the immune system in relation 
to tumour immunology (1.2). Subsequently, we will focus on malignant gliomas 
(1.3), conventional treatments (1.4), gene therapy (1.5), and newly developed 
immunotherapy (1.6). The latter is the main subject of this thesis.
Section A. The basics of tumour immunology for gliomas
1.2  The basics of tumour immunology
Historical data show that the immune system clearly plays a role in cancer 
progression. For example, immunosuppression is associated with cancer development. 
In fact, cancer is 100 times more likely to occur in people who take immunosuppressive 
medications (e.g., for organ transplant or rheumatic disease) than in people with 
normal immune function (e.g. Bouwes et al., 1995; Ho and Murphy, 2008; DePry et al., 
2011). Lymphoma, skin, and cervical cancer are just a few types of cancer that have 
been associated with immunosuppression. For example, skin cancers are the most 
frequent malignancies in organ transplant recipients (Ulrich et al., 2008). Calcineurin 
inhibition may result in a 200-fold increased skin cancer risk compared with the normal 
population (Kuschal et al., 2012). Patients who have undergone renal transplantation 
have an estimated 3 to 5 times higher overall incidence of malignancy in long-term 
follow-up, than the general population, and this is explained in part to long-term 
immunosuppression. Conversely, heightened antitumour activity of the immune system 
has been suggested in the many reports of spontaneous cancer regression (Sato et al., 
2005; Galon et al., 2006; Koebel et al., 2007; Galon et al., 2012). 
Hence, numerous studies have now demonstrated that the immune 
system plays a significant role in the control of tumour development and progression 
(Vesely et al. 2011 and Schreiber et al. 2011). The components of both innate and 
adaptive immunity are involved in fighting tumour cells, however current data in general 
suggest that the pivotal role in natural antitumour immune response belongs to T-cell-
mediated responses, with a prominent role for IFN-ɣ and perforin to prevent tumour 
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formation (Shankaran et al., 2001) Patients with higher frequencies of intraepithelial 
CD8+ T cells, and a high CD8+/Treg ratio, exhibit improved survival compared with 
patients with lower frequencies (Sato et al., 2005).
In addition, it has been demonstrated that the immune system of a naive 
host can restrain cancer growth for extended time periods (Koebel et al., 2007).
Although the precise nature of the immune system’s role in cancer 
occurrence and regression is actively being studied for each type of cancer, we do know 
today that tumours are immunogenic. Malignant cell growth is caused by a variety of 
genetic defects that occur in genes that encode for proteins involved in cell growth. 
Components of the immune system, including antibodies and T cells, do recognize 
and respond to the abnormal proteins that are overexpressed, mutated or selectively 
expressed on cancer cells relative to normal tissues (Hanahan and Weinberg, 2000). 
Immune system-based cancer therapy
Immunotherapy against cancer is essentially the stimulation of the 
patient’s immune system, using a variety of distinct strategies, to treat and eventually 
even prevent future malignancies. These may include active stimulation of immune 
system by either vaccines, stand-alone treatment with biological response modifiers 
or innate immunity activating substances, or by passive infusion of immune elements 
like T cells, antibodies or cytokines. These reagents may act through one of several 
mechanisms, which include 1) by stimulating the antitumour response, either by 
increasing the number of effector cells or by producing one or more soluble effector 
mediators such as cytokines; 2) by decreasing suppressor mechanisms; 3) by altering 
tumour cells to increase their immunogenicity and make them more susceptible to 
immunologic defenses; and 4) by improving tolerance to cytotoxic drugs or radiotherapy, 
such as stimulating bone marrow function by granulocyte (macrophage) colony-
stimulating factor (G(M)-CSF). 
Cancer-specific antibodies
Antibodies are important therapeutic agents for cancer. Recently, it has 
become clear that antibodies possess several clinically relevant mechanisms of action. 
Many clinically useful antibodies can manipulate tumour-related signalling involved in 
the maintenance of the malignant phenotype. However, antibodies can also initiate 
tumour-specific immune responses. Such antibodies exhibit various immunomodulatory 
properties and, by directly activating or inhibiting molecules of the immune system, 
antibodies can promote the induction of anti-tumour immune responses. These 
immunomodulatory properties can form the basis for new cancer treatment strategies.
Antibody-based therapy has become established over the past 15 
years and is now one of the most successful and important treatment option for 
haematological and solid tumours. Tumour antigens that have been successfully 
targeted include epidermal growth factor receptor (EGFR) (by Cetuximab), ERBB2 
(by Trastuzumab), vascular endothelial growth factor (by Bevacuzimab), cytotoxic T 
lymphocyte-associated factor (CTLA-4) (by Ipilimumab) and CD20 (by Rituximab).
Many mechanisms have been proposed to explain the clinical anti-tumour 
activity of passively administered unconjugated tumour antigen-specific monoclonal 
antibodies. The ability of some antibodies to disrupt signalling pathways involved in the 
maintenance of the malignant phenotype has received widespread attention. However, 
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1the ability of antibodies to initiate tumour-specific immune responses has been less well recognized (Weiner et al., 2012). Early research on the anti-tumour effects of therapeutic antibodies focused on the potential value of passive immunotherapy 
provided through antibody-dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) and by the induction of T cell immunity through cross-
presentation.
Direct tumour cell killing can be elicited by receptor agonist activity, such 
as an antibody binding to a tumour cell surface receptor and activating it, leading to 
apoptosis. It can also be mediated by receptor antagonist activity, such as an antibody 
binding to a cell surface receptor and blocking dimerization, kinase activation and 
downstream signalling, leading to reduced proliferation and apoptosis. An antibody 
binding to an enzyme can lead to neutralization, signalling abrogation and cell death, 
and conjugated antibodies can be used to deliver a payload (such as a drug, toxin, 
small interfering RNA or radioisotope) to a tumour cell. Immune-mediated tumour cell 
killing can be carried out by the induction of phagocytosis; complement activation; 
ADCC; genetically modified T cells being targeted to the tumour by single-chain variable 
fragment (scFv); T cells being activated by antibody-mediated cross-presentation of 
antigen to dendritic cells; and inhibition of T cell inhibitory receptors, such as cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4). Vascular and stromal cell ablation can be 
induced by vasculature receptor antagonism or ligand trapping, stromal cell inhibition, 
delivery of a toxin to stromal cells, and delivery of a toxin to the vasculature (Scott et al, 
2012). Since glioblastoma is a highly vascularized tumour and has high levels of vascular 
endothelial growth factor, there has been interest in the use of the vascular endothelial 
growth factor targeting, monoclonal antibody Bevacizumab, (also called Avastin), which 
is licensed for glioblastoma in the USA, at progression after standard therapy. However, 
this monoclonal antibody has not been adopted by the European Medicines Agency, 
because of (deemed) modest response rates and lack of direct comparisons with other 
agents (Morris, 2012).
Several studies have established the importance of Fc–FcγR interactions 
in antibody-dependent cellular cytotoxicity for the in vivo anti-tumour effects of certain 
monoclonal antibodies in murine models and clinical trials. Most clinically approved 
monoclonal antibodies that mediate ADCC also activate the complement system 
and thereby initiate CDC. Optimization of antibody-based complement activities 
can enhance anti-tumour activity. Agonistic antibodies are also being explored as 
immunomodulatory cancer therapies. Low doses of agonistic antibodies may provide a 
better risk–benefit profile compared with higher doses as they show bioactivity without 
associated risk. Antibody therapeutics might also have a role in the generation of de 
novo immune responses to the antigen targeted by the antibody through promoting 
antigen presentation to Fc receptor-bearing cells. Such responses may allow for the 
effects of therapeutic antibodies to persist after the dosing is completed.
However, there are multiple mechanisms by which antibody treatment of 
patients with malignant tumours may fail to achieve a therapeutic effect. These include 
the heterogeneity of target antigen expression in the tumour (which can be present 
initially or which can develop during therapy), physical properties and pharmacokinetics 
of antibodies that have an impact on uniform penetrance into a tumour and intra-
tumour microenvironment (including, vascularity and interstitial pressure). Antibody 
dose and concentration in the tumour and possible receptor saturation kinetics can also 
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affect therapeutic impact as can signalling pathway promiscuity (which can lead to poor 
response to therapy and subsequent development of resistance), as well as immune 
escape through ineffective FcγR binding and immune suppression (Goodnow et al, 2010). 
The future promise of antibody therapeutics in cancer is dependent 
on having a better understanding of the lessons learned from laboratory studies and 
clinical trials conducted so far.
Cytotoxic and helper T cells 
T-cells represent a subset of lymphocytes that are crucial as effector cells 
and for the regulation of the immune response. The T-cell receptor (TCR) is a complex 
of membrane proteins that participates in the activation of T-cells in response to the 
presentation of antigen. Stimulation of TCR is triggered by MHC (Major Histocompatibility 
Complex) molecules on antigen presenting cells that present antigen peptides to TCR 
complexes and induce a series of intracellular signalling cascades. Engagement of 
the TCR initiates intracellular cascades that ultimately result in cellular proliferation, 
differentiation, cytokine production, and/or activation-induced cell death. These 
signalling cascades regulate T-cell development, homeostasis, activation, acquisition 
of effector’s functions and apoptosis (Lin et al., 2001). TCR activation is regulated by 
various costimulatory receptors. CD28 provides an essential co-stimulatory signal during 
T-cell activation, which augments the production of interleukin-2 (IL-2), increases T-cell 
proliferation and prevents the induction of anergy and cell death. 
In the blood, 60-70% of T cells are CD4+ and 30-40% express CD8+. CD4+ 
T cells are generally designated helper cells (Th) and activate both humoral immune 
responses (B-cell help) and cellular responses (delayed-type hypersensitivity responses 
and others). CD8+ cells show a major cytotoxic activity (Tc) against cells infected with 
intracellular microbes, and against tumour cells. A portion of the circulating CD4+ cells 
play an important regulatory role that acts to down modulate immune responses. These 
regulatory T (Treg) cells consist of natural occurring Treg cells (CD4+CD25+ Treg) and 
adaptive or induced Treg cells (Tr1). Treg cells are able to inhibit the development of 
allergen-specific Th2 and Th1 cell responses and therefore play an important role in a 
healthy immune response (Ozdemir et al., 2009).
Both CD4+ and CD8+ T cells differentiate into functionally distinct subsets 
after exposure to antigenic peptides processed and presented by antigen presenting cells 
(APCs), like dendritic cells, B cells and monocytes/macrophages. This is best described 
for the transition of CD4+ T cells from naïve to effector populations. Resting naïve CD4+ 
T cells (designated Th cells) release very low levels of cytokines. Soon after stimulation 
by antigen and APC, the Th cells begin to produce IL-2 and are designated Th0. As the Th 
cells continue to respond to the activating signal, they progress toward polar extremes 
of differentiation designated Th1, Th2, and Th17 cells, depending on the nature of the 
cytokines present at the site of activation. IL-12 produced by macrophages or NK cells 
induces differentiation toward Th1; IL-4 produced by NK1.1+ T cells, basophils, or mast 
cells induces differentiation toward Th2; and TGF-β produced by Foxp3+ regulatory 
T-cells, and IL-6 produced by yet to be defined innate immune cells or IL-21 produced 
by T cells and NKT cells induce differentiation toward Th17. Th1 cells are characterized 
by the production of IL-2, IFN-γ, and lymphotoxin, whereas Th2 cells produce IL-4, IL-5, 
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1IL-9, IL-13, and granulocyte-macrophage colony stimulating factor (GM-CSF) and Th17 cells produce the cytokines IL-6 and IL-17 (Bonilla and Oettgen, 2010 ; Chaplin, 2010). 
Every effective immune response involves T-cell activation; however, 
T-cells are especially important in cell-mediated effector immunity, which is the 
defense against tumour cells and pathogenic organisms inside body cells. They are also 
involved in rejection reactions. TCR stimulation may provoke different cell responses 
(proliferation, anergy to subsequent stimuli, cell death) in mature circulating T-cells, as 
in thymocytes. Deregulation of T-cell function, whether by defect or by excess, results 
in dire consequences for the organism i.e., immunodeficiency and autoimmunity 
respectively. It is also an extremely sensitive system, as very few peptide-MHC complexes 
on an antigen-presenting cell are needed to trigger a T-cell response. Since T-cells play 
various critical roles in orchestrating the immune responses, this knowledge should lead 
to an understanding of how breakdowns in immune regulation lead to autoimmune 
diseases and of how the immune system could be better manipulated to overcome 
afflictions such as cancer, infection and autoimmune diseases (Anderton, 2006).
Cancer and T-cells
A series of recent discoveries in molecular biology and immunology 
have resulted in new principles for the treatment of cancer, including gene transfer 
and immune therapy for activation of the host T cell system. Cytotoxic CD8+ T cells 
(CTLs) are key effector cells of the immune system and critical components of protective 
immunity against infectious diseases and cancer. After recognizing the MHC-peptide 
complex expressed on a cell, CD8+ T cell destroy the cell by perforating its membrane 
with enzymes or by triggering an apoptotic or self-destructive pathway. This CD8+ T cell 
will then move to another cell expressing the same MHC-peptide complex, and destroy 
it as well. In this manner cytotoxic T cells can kill many invasive cells. Ideally, CD8+ T cells 
could engender a very specific and robust response against tumour cells. CTLs have the 
potential to eradicate cancer cells with high specificity when present in high enough 
amounts. Therefore, induction of effective and long-term CTL immunity is a major goal 
of cancer vaccines. Efficient delivery systems and powerful adjuvants are needed to 
apply such vaccines in a clinical setting to overcome tumour-specific tolerance.
To activate such CTL in vivo a vaccination strategy is often used which 
combines vaccination with dendritic cells (DC) and adoptive T cell transfer. DC loaded 
with the material from the patients own tumour is injected to stimulate an anti-tumour 
immune response. To further amplify this response in absence of suppressive tumour-
derived factors it is necessary to stimulate and expand patient lymphocytes in vitro, so 
that large numbers of trained and activated cells can be re-infused to fight the cancer. 
Tumour immune evasion
Tumours employ a wide array of mechanisms to hide from the immune 
system, called tumour evasion. It is widely accepted that there are three stages of 
tumour immune evasion: lack of recognition, lack of susceptibility, and induction 
of immune suppression. These mechanisms are paramount to tumour survival and 
success. Once the tumour develops into the first stage, lack of recognition, the immune 
system can no longer respond properly to the tumour growth and cannot find the 
cells to eliminate. In the next phase resistance to the activity of the immune system 
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is gained by the tumour, by inactivating negative regulatory pathways and rendering 
cytotoxic molecules ineffective. And in the last stage the tumour takes control over from 
the immune system by recruiting immune suppressor cells and by excreting immune 
suppressive factors.
Lack of recognition
In the first stage of tumour immune escape, tumour antigen loss and 
down regulation of MHC class I molecules plays an important role. MHC class I molecules 
are used as recognition molecules by T cells and activate their response to certain 
peptides. Proteins produced in the cytosol of any cells are cleaved by proteasomes, the 
resulting peptides are loaded by the TAP transporter system onto MHC class I. These 
transmembrane proteins are transported to the cell membrane where interaction 
occurs with the immune system through cell-mediated responses. It was shown that 
only rarely a mutation in the MHC or beta-two microglobulin was the reason for low 
occurrence of MCH I molecules on the cell surface, but rather that the tumour has 
altered the process of peptide presentation to reduce recognition by T cells.
The tumour achieves this by reducing proteasome activity, simply 
reducing the amount of peptides being produced, which is also a helpful trait for 
survival against NK response. Also blocking the peptide processing by inactivating or 
down regulating the TAP system so that the peptides do not enter the endoplasmic 
reticulum. The tumour cells can also modify the peptide MHC I loading mechanism. 
All these methods reduce the MHC class I peptide presentation, leading to immune 
evasion (Seliger B. 2012). 
Lack of susceptibility
In the second stage the tumour becomes non-responsive to cell mediated 
responses. One principle is based on upregulation of B7 ligands on its cell surface. These 
ligands are found on normal APCs to regulate T cell response. Once a T cell is activated it 
expresses increased levels of CTLA-4, PD-1 and other receptors that have a higher affinity 
to B7 than CD28 expressed by naïve T cells. These receptors decrease proliferation, 
cytokine production and cytolytic activity. Other methods of tumour resistance include 
upregulation of FasL and B7-H1 which induce T cell apoptosis. Increased expression 
of protease inhibitors inactivate perforin and granzyme responses from cell mediated 
immunity. 
Immune suppression
The final stage of tumour evasion leads to cancer “taking over control” 
of the immune response. It does this by secreting immune suppressive cytokines and 
recruiting immune suppressor cells. There are two classes of cells most suspect in 
immune suppression, Treg cells and Myeloid derived suppressor cells. The function of 
these cells is to suppress the proliferation and function of T cells, which is achieved by 
the production of cytokines like IL-10 and TGF-beta (TGF-β). Also these cells absorb 
IL-2 which normally activates T effectors cells and NK cells. Treg cells also use CTLA-4 
mechanisms to suppress activity of neighboring cells.
Tumours also use their modified metabolisms to change their 
surroundings. For example, by arginase 1 which decreases the amount of L-arginine 
in solution so that T cells can no longer proliferate. This tumour mechanism also 
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1triggers iNOS which leads to increased reactive oxygen species (ROS), which damage surrounding T cells and decrease their effective response (Loos et al., 2010). The HER2 oncogene is frequently over-expressed in human cancers and a promising target for 
immune therapy. Studies have shown that over-expression of mouse or rat HER2 leads 
to markedly reduced levels of major histocompatibility complex (MHC) class I and 
molecules of the antigen processing and presentation machinery (APM), thus resulting in 
a phenotype promoting tumour escape from the immune system. HER2 over-expressing 
tumours may be more prone to escape from HLA-A2 restricted CTLs suggesting that in 
such cases immunotherapy approaches inducing an integrated humoral, cellular and 
innate immune response would be most effective (Mimura et al., 2011). In general, 
however, an immune response polarized towards a Thelper type-1 profile, favouring 
cell-mediated immune responses, is considered critical for immunotherapy of many 
types of cancer (Tuyaerts et al., 2007) 
1.3  Glioblastoma brain tumours
Glioblastoma multiforme (GBM), World Health Organization grade IV 
glioma, (see Figure 1.1 for molecular and pathobiological characteristics) is the most 
common and aggressive form of brain cancer in adults. In the United States alone over 
18,000 primary brain tumours are estimated to occur each year. Of these 18,000, over 
60% are diagnosed gliomas. The prognosis for this tumour is very poor. The median 
survival time of untreated tumours is only 3 months, with death most commonly due to 
cerebral edema or increased intracranial pressure. Even with the best available current 
therapy, which includes surgery, radiation, and chemotherapy, the median survival does 
not extend beyond 14 months, with 75% of GBM patients dying within 18 months of 
diagnosis (Deorah et al., 2006), and with a 2-year median survival rate between 8% and 
12% (Stupp et al., 2005). Glioblastomas account for about 17% of all childhood cancers 
(McDonald et al., 2011 ; Mahvash et al., 2011). GBM tumours are inevitably recurrent 
either locally, usually within 2 cm of the original tumour, or at distant sites. Treatment 
of these recurrent lesions by a second surgery and further chemotherapy may increase 
the symptom free interval, but the 5-year survival remains 3-5 % (Deorah et al., 2006). 
The poor prognosis of GBM is due to GBM cells infiltrating the brain and spinal cord thus 
preventing complete surgical resection. Moreover, these invasive tumour cells appear 
to be more resistant to cytotoxic drug therapy and have a higher proliferative potential 
(Furnari et al., 2007 ; Huang et al., 2007). 
Additionally, molecular profiling of GBMs have indicated that there is great 
heterogeneity within these tumours (Mischel et al., 2003), which may be due to the 
presence of a sparse population of cancer cells that exhibit stem-cell-like characteristics 
(Paugh et al., 2010; Verhaak et al., 2010). 
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Figure 1.1. The relationships between molecular profile (left columns), pathobiology (middle co-
lumn) and survival (right columns) that lead to the formation of primary (de novo) right hand pa-
thway and secondary (progressive) glioblastomas left hand pathway. (OE) Overexpressed; (amp) 
amplified; (mut) mutated. (From : Furnari et al., 2007)
Molecular basis of glioblastoma development
A number of structural genomic changes and dysregulation of signalling 
pathways in gliomas have been described. A normal developing brain requires signalling 
pathways involve Sonic Hedgehoc (Shh) and Patched (Ptch), which control mitosis 
and differentiation of cells in the internal and external granular layer in the brain. In 
approximately 25% of described human medulla blastoma there was a mutation in 
one of the many genes involved in the Wnt signalling pathway (Marino, 2005). Wnt 
is a family of paracrine/autocrine proteins that is expressed in the developing brain. 
Glioblastoma, the most common and most aggressive form, is characterized by marked 
cellular heterogeneity, high proliferative activity, aberrant microvascular proliferation, 
presence of necrosis and highly invasive growth Riemenschneider and Reifenberger 
(2009). Glioblastomas are characterized by complex genetic and epigenetic aberrations 
affect several pathways, in particular receptor tyrosine kinase/Ras, phosphoinositol 
3-kinase, p53 and pRb signalling. Aberrant Wnt signalling is molecularly linked to many 
human cancers, and mutations in other Wnt pathway members, including b-catenin 
and Axin2, and aberrant production of Wnt ligands also have been associated with 
cellular transformation and tumour development. vi/Wntless/Sprinter/. GPR177, is a 
highly conserved transmembrane protein, being a component of the Wnt secretion 
machinery, which is required for glioma cell growth (Augustin et al., 2012).
Cancer stem cells
Stem cell-like cancer cells are able to self-renew and retain the capacity 
to differentiate but lack proliferative control. These stem-like cancer cells are referred 
to as either tumour-initiating cells or cancer stem cells (CSCs), and have been identified 
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1in a number of hematopoietic malignancies and solid tumours (Hope et al., 2004; C. Li et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004). CSCs have also been shown to be more resistant to conventional cancer drugs and have been implicated in the more 
aggressive nature of tumour drug resistance after remission (Bao et al., 2006; Dean 
et al., 2005). These studies suggest that targeting CSCs may effectively reduce tumour 
recurrence and significantly improve GBM treatment and the prognostic outcome 
of GBM patients (Dirks, 2008 ; Cheng et al., 2010). Since CSCs are a biologically and 
molecularly distinct cell type within a tumour mass, CSCs might possess properties 
that, if more fully understood, would permit the rational design of novel therapeutic 
approaches for cancer. For example, Singh et al., (2004) showed that human brain 
cancer cells express CD133.
Section B. The Long way to immunomodulation treatment 
against (brain) cancer
1.4  Conventional cancer therapy: Cutting, burning 
and poisoning of tumours
Surgery 
The first report on cancer therapy dates from the Edwin Smith Papyrus, 
1600 B.C., the oldest known historical text on surgery. It mentions primitive surgical 
excision of a tumour using a knife. But it has only been for the past two hundred years 
that surgical excision became established as the preferred option for treating solid 
tumours. 
The first surgical excision was practiced in 1909 by Harvey Cushing, the 
American “Father of Neurosurgery”, as a young physician at the Johns Hopkins Hospital, 
when he operated a pediatric brainstem glioma (Dmetrichuk et al., 2011; Pendleton 
et al., 2011). He achieved remarkable increases of his patients expectancy of life – 
increased from 3 months expected survival to 6 to 12 months.
Surgery is the primary form of treatment for brain tumours in parts of the 
brain that can be removed without damaging critical neurological functions. Currently, the 
extent of surgical tumour resection (debulking) is the most important factor determining 
length of survival. Hence, the goal of surgery is to remove the entire tumour if possible, but 
a tumour is most likely to recur since in most cases not all the tumour cells are removed. 
Partial removal helps to relieve symptoms by reducing pressure on the brain and it reduces 
the residual amount of tumour to be treated by radiation therapy or chemotherapy. Any 
remaining tumour may then be treated with radiotherapy and possibly chemotherapy. 
The removal of 98 % of the tissue is considered to result in a significantly longer period 
of remission compared to lower degree of removal. Removal can be supported with a 
fluorescent dye known as 5-aminolevulinic acid to extend the chances of almost complete 
removal (Walker et al., 1978). Glioblastoma on average consist of 1011 cells, a removal of 
99 % implies a residual tumour mass of 109 cells. Even with a dye it is hard to remove all 
tumour cells, especially given the infiltrative nature of the tumour.
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Radiation therapy 
Shortly after 1895, when Röntgen first reported the use of X-rays 
for diagnostic medical purposes, radiation therapy (RT) was introduced. Radiation 
remained a primary treatment option of certain tumours, especially solid tumours. 
Today radiation therapy can be tailored to the irregular shape of the tumour, allowing a 
reduction of intensity. 
From 1987 onwards, after introduction of chemotherapy (BCNU, see 
below) irradiation could be applied to brain tumours (Walker et al., 1978). Walker and 
coworkers demonstrated in a randomized trial that radiotherapy (5000 to 6000 rads to 
the whole brain) only improved median survival to 37.5 weeks, relative to BCNU only 
(25 weeks), and radiotherapy in combination with BCNU resulted in median survival of 
40.5 weeks. 
Today the radiotherapy (RT) (2 Gy per fraction once daily, per 5 days/
wk, for 6 weeks) resulting in a total cumulative radiation dose of 60 Gy) has become 
part of the standard of care treatment for GBM (Fulton et al., 1992). Radiation therapy 
uses high-energy x-rays or other types of ionizing radiation to stop cancer cells 
from dividing. It is often used in addition to surgery or when surgery is not possible. 
Radiation therapy variants include:
Conventional radiation therapy is designed to deliver radiation to an 
entire region of the brain. Depending on the location and size of the tumour(s), the 
treatment can be either focused or whole brain radiation therapy (WBRT). For example, 
during stereotactic radiosurgery, a single, high dose of radiation is delivered to the 
tumour, minimizing damage to the surrounding brain tissue. 
Fractionation includes giving the total dose of radiation over an extended 
period. This helps to protect healthy tissue in the area of the tumour.
Moreover, a 3-dimensional image of the tumour and brain region can 
be made in order to focus the radiation beams precisely to the tumour such that the 
surrounding healthy tissue is protected.
Finally, instead of X-rays, proton beam radiation therapy uses protons. 
Protons can pass through healthy tissue without damaging it. Interstitial radiation 
therapy (brachytherapy), is an internal form of radiation therapy, which involves 
surgically implanting radioactive material directly inside the tumour.
Notably, no significant difference was found in the time to progression or 
median survival time between three-dimensional conformal radiotherapy and whole 
brain radiotherapy (Showalter et al., 2007). 
Bao et al., (2006) showed that cancer stem cells contribute to glioma 
radioresistance through preferential activation of the DNA damage checkpoint response 
and an increase in DNA repair capacity, making radiotherapy a palliative therapy.
Chemotherapy 
Chemotherapy applies chemicals (drugs) that have a toxic effect on 
tumour cells as they divide. During World War I, exposure of soldiers to nitrogen 
mustard gases resulted in pancytopenia. This observation triggered interest for 
chemotherapeutic therapy, especially in patients with hematologic malignancies. 
Today chemotherapy is a well documented treatment option. At the end of seventies 
in 1977 we have the introduction of various chemotherapeutic agents such as 
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1carmustine (BCNU or 1,3-bis(2-chloroethyl)-l-nitrosourea), procarbazine (PCB) or dacabazine (DTIC) (Eyre et al.,1986). However, we have controversial results. The efficacy of this treatment in conjunction with available adjuvant therapies could 
increase the quality and expectancy of life of GBM patients only for a few months, 
at best (Aoki et al., 2007). Therefore, chemotherapy was non standard therapy for 
GBM, and only given in the context of clinical trials. However, Stupp and co-workers 
demonstrated in a publication in 2005 that surgical resection to the extent feasible, 
followed by adjuvant radiotherapy plus temozolomide (TMZ), improved survival in 
patients with histological diagnosis of GBM, better than surgery-radiotherapy without 
TMZ. They concluded that the addition of TMZ to radiotherapy for newly diagnosed 
glioblastoma resulted in a clinically meaningful and statistically significant survival 
benefit with minimal additional toxicity (Stupp et al., 2005), and these results were 
confirmed by Athanassiou and co-workers (Athanassiou et al., 2005). TMZ is an oral 
alkylating agent, with a relatively low toxicity profile (Yung et al., 2000), which can 
easily cross the blood-brain barrier. After these publications in 2005 Temozolomide 
has been adopted as a standard therapy for the treatment of newly diagnosed 
GBM. But although for glioblastomas, the alkylating agent TMZ has become a well-
appreciated option (Koukourakis et al., 2009), it extends average survival time only for 
about 4 months. Importantly, although TMZ has an acceptable safety profile, adverse 
events may hamper its use in a considerable number of patients (Michalek, personal 
communication).
Chemotherapy is usually given in cycles: a treatment period is followed by 
a recovery period and so on. Apart from the oral, intravenous or intramuscular route, 
chemotherapy can be given via the intrathecal route into the cerebrospinal fluid or via 
wafers implanted directly in the brain. The wafers will dissolve and locally release the 
drug into the brain.
Upon chemotherapy, some cancer (stem) cells acquire drug resistance 
and survive. The surviving cell will divide and pass its drug resistance to progeny cells, 
thereby rendering the chemotherapeutic treatment of limited value. Hence, although 
chemotherapy kills most cells in a tumour, it is believed to leave tumour stem cells 
behind, which might be an important mechanism of resistance (Dean et al., 2005).
1.5  Gene therapy 
The era of gene therapy started at the end of 80s and beginning of 90s 
of the last century (Anderson, 1992, Miller, 1992). It provided many interesting clinical 
trials about gene therapy application against brain cancer and specifically against GBM 
(Curtin et al., 2005).
Cancer gene therapy is an experimental treatment that involves 
introduction of genetic material (RNA or DNA) into malignant cells to treat cancer. 
Gene therapy aims to selectively kill cancer cells while leaving healthy cells unaffected. 
This may be achieved by selective introduction of a gene, which mediates cytotoxic 
killing of tumour cells or genes, which encode immune system proteins instrumental 
in enhancing anti-tumour immunity (for example, Tai et al., 2005). For example, the 
anti-tumour activity of a viral gene-delivering vector can be enhanced by arming the 
vector with genes that either activate chemotherapeutic drugs within the tumour tissue 
or that promote anti-tumour immunity (Grandi et al., 2009). Gene transfer is currently 
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being investigated as a promising approach against brain cancer (reviewed in Fulci et 
al., 2007). 
We have seen really encouraging results for gene therapy-based 
approaches for GBM cancer treatment, but the largest limitation of gene therapy is 
the need to infect all tumour cells and/or evoke a bystander effect in the non-infected 
tumour cells. Examples include soluble cytokines, such as TNF or IL-1β, that generate an 
antitumour immune response that could involve the bystander effect of suicide-gene 
therapy.
This has been tried for example with recombinant replication-deficient 
adenoviral vectors able to transfer the HSV-TK suicide gene to human prostate cancer 
cells (Cheon et al., 2000).
Other viruses have been used that could more easily replicate up to high 
viral titers in proliferating cells. However, one of the main problems that formed was that 
the increasing dose of viral particles introduced the risk for very strong immunoreactions 
against the viral particles and some clinical trials were stopped because of this (Marshall 
1999).
1.6  Immunotherapy, the fourth pillar of cancer 
therapy
About one hundred years ago William B. Coley, an early 20th century New 
York City surgeon, observed that some of his patients with sarcoma would undergo 
spontaneous regression of their tumour, and that this regression was associated with 
antecedent bacterial infection, mostly erysipelas, or Streptococcus pyogenes, one of 
the leading causes of hospital-acquired post-operative bacterial infection and death 
[Coley, 1991; Starnes, 1992 ]. Since the function of the immune system was largely 
undiscovered at the time, he was the first to recognize the potential role of the immune 
system in cancer treatment. Hence, he intentionally injected cancer patients with a 
mixture of killed bacterial lysates, later called Coley’s Toxins, to stimulate as we know 
today a bystander immune response triggered by a local inflammatory response. William 
Coley thus became the « godfather of cancer immunotherapy » [Hall, 1997]. Anecdotal 
regression of gliomas has been noted following intracranial infections (Bowles and 
Perkin, 1999).
The principle of activation of the patient’s immune system, to better 
recognize the tumour and to eliminate invasive tumour cells that are not adequately 
removed by surgery, will be discussed in greater detail. This area in cancer therapy is 
based on knowledge accumulated in the field of vaccinology and immunology. 
It has been demonstrated that the progression of certain cancers is 
associated with the expression of tumour-specific antigens and tumour antigen-specific 
immune responses (Jager et al., 2001). Hence, theoretically, effective tumour rejection 
and immunity can be achieved by vaccination with tumour-associated antigen, the holy 
grail in tumour immunology. 
However, active immunotherapy for cancer has shown limited clinical 
success. It has been clear that even with a fully functioning immune system, it is possible 
for tumours to evade recognition through the use of elusive escape strategies (Garcia 
et al., 2003) . Although poorly understood, several mechanisms of tumour escape have 
been identified, as described in more detail in the section below on « Tumour immune 
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1evasion ». For example, a change of or loss of MHC class I receptors is associated with the genesis of various tumours, while the presence of intact MHC class I molecules has been shown to participate in cancer resistance (Gu et al., 2003). Other mechanisms 
include unresponsiveness to interferons (Garcia et al., 2003), as well as tumour-induced 
immunosuppression as a result priming for and influx of inhibitory regulatory T cells 
(Zou, 2006) and associated induction of immuno-suppressive molecules including IL-10, 
CTLA-4 and related factors.
On the other hand, there is increasing evidence that the immune 
system can be engaged to combat cancer. This is supported by the observations that a 
deregulated immune system hampers rejection of cancer, while spontaneous rejection 
or inhibition of malignant tumours is associated with a well-functioning immune system 
(Palo et al., 1977 ; von Mensdorff-Pouilly et al., 1996). A recent study in colorectal 
tumour patients demonstrated that adaptive Th1 immune gene expression and high 
immune cell densities of CD3, CD8 and CD45RO cells in tumour regions correlates 
positively with patient survival (Galon et al., 2006). 
Interestingly, it has also been suggested that autoimmune diseases may 
contribute to a better prognosis in patients with malignant tumours (Palo et al., 1977, 
Bystryn et al., 1987). In these patients, the majority of the IgG specificities identified 
share considerable homology with both human and microbial peptides (Hansen et al., 
2011). This has lead to the hypothesis that molecular mimicry may initiate the observed 
anti-tumour autoimmunity. Studies related to this have shown long-term remission of 
malignant brain tumours after intracranial infection in four patients (Bowles and Perkins, 
1999), and improved survival of cancer patients with microbial infection (Papachristou 
and Forstner, 1979 ; Pizzo et al., 1984). This brings into question whether molecular 
mimicry-induced ‘‘autoimmunity’’ can be employed to treat tumours. Importantly, 
significant homology has been shown to exist between human proteins and proteins 
from other species (Sioud 2002). Moreover, use of artificial pathogen invasion signals, 
such as CpG motifs, or other innate immunity agonists, initiates and augments antigen-
specific immune reactions (Schijns and Lavelle, 2011), and may break tolerance to self-
tumour antigens, mimicking microbial infections during immunotherapy or vaccination 
(Coley, 1991, Takeda et al., 2003). This suggests that self-tolerance to tumours may be 
broken by cross-reactivity against a homologous foreign antigen and improve median 
or overall survival.
The first active immunization attempts for glioma patients occurred in 
the 1960s (Bloom et al., 1960 ; Trouillas and lapras, 1970). It was first hypothesized 
that brain tumours were hidden from the immune system because of location in the 
central nervous system an immunologically privileged site. This proved to be incorrect, 
since immune cells are readily able to cross the blood-brain barrier. In 1983 Mahaley 
and co-workers showed impressive results which have not shown follow-up in literature 
(Mahaley et al., 1983, 1984)
At this time the era of immunology had already started and gradually 
became a very interesting and promising area of investigation for immunotherapy of 
brain cancer. 
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Section C. Aims and Outline of the present thesis
The hypothesis pertinent to this thesis is that glioma tumours can be 
therapeutically targeted by gene and/or immunotherapy in order to eliminate or delay 
further tumour development. 
During the evolution of this thesis, it became apparent that instead 
of a single-agent-targeted immunotherapy based on just one or a few proteins or 
peptide antigens, produced synthetically or by recombinant heterologous expression, 
we preferred a multi-modular approach that is based on syngeneic lysates and cells, 
mixed with lysates and cells from an allogeneic tumour. This mixture of antigens is not 
defined, but expected to overlap to a large degree with the specific tumour antigens in 
the patient. Moreover, this strategy enables triggering of an immune response against 
a broad array of tumour antigens and also allo-immune reactivity, a classical allograft-
directed immune response, typical for non-matching major histocompatibility between 
graft cells and the host. 
Research in rat model systems would enable us to gain insight into 
critical aspects of therapeutic anti-tumour intervention strategies and to analyse basic 
mechanisms of action. These investigations were aimed to provide the pre-clinical basis 
for the development of a therapeutic post-surgical glioblastoma vaccine for patients 
diagnosed with GBM. 
As mentioned above, gene therapy has been and is still considered 
a promising targeted approach for the elimination of glioblastoma. Gene therapy 
for cancer involves the use of DNA encoding a particular protein to treat malignant 
disease. The gene can be delivered to a cell using a carrier known as vector. The most 
common types of vector used in gene therapy are viruses, such as adeno-associated 
virus (AAV). In chapter 2 we analyse if chronic expression of a fusion protein, composed 
of the mouse IsK potassium channel accessory molecule linked to enhanced green 
fluorescent protein (EGFP), leads to cell death of more than 50% of transfected U87-MG 
human astrocytoma cells as early as 2 days after transfection. Cell death is analysed by 
condensed chromatin measured within 2 days post-transfection and by the appearance 
of green fluorescent cellular debris within 5 days post transfection. However, the limited 
infection efficacy of tumour cells, as observed for the high multiplicity of infection (MOI) 
requirement in vitro for a variety of viral vectors (Chapter 2), and the expected low 
tumour cell targeting in vivo, forms a tremendous challenge for targeted gene therapy. 
We therefore switched from gene therapy towards immunotherapeutic treatments, 
which form a major theme of this thesis.
In chapter 3 we give an overview of the rational, the experimental 
approach and clinical data of immunotherapeutic approaches of malignant gliomas, 
including the use of autologous and allogeneic tissue cells. We analyse if augmented 
immune reactivity is linked to improved tumour survival, which supports the concept to 
develop immune system activating treatments either as immune activating stand-alone 
immune activators, or as immune activating vaccines. 
Enhancement of immune reactivity can be induced by administration of 
immunostimulatory ligands of innate immune cells receptors such the Toll-like receptors. 
In chapter 4 we analyse the efficacy of immunotherapeutic Toll-like receptor (TLR)-
7/8 activation by Resiquimod (R848) in vivo in the CNS-1 rat glioma model syngeneic 
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1to Lewis rats. This innate immune system treatment is compared to the cytotoxic cyclophosphamide chemotherapy or to a combination of R848 plus cyclophosphamide immuno-chemotherapeutic treatment. If TLR7/8 activation by resiquimod alone is able 
to evoke partial or complete CNS-1 tumour regression, it is consequently not necessarily 
associated with a direct cytotoxic effect on tumour cells. We also determine if rats that 
may be cured from glioma tumours by innate immunostimulation can be shown to be 
fully immune to secondary glioma tumour re-challenge. Cyclophosphamide can also 
induced dramatic tumour regression but it remains to be determined if it can protect 
against secondary tumour challenge. 
In chapter 5 the beneficial anti-tumour efficacy evoked by immune 
activation is tested in a therapeutic vaccine setting in two other different rat glioma 
models. 9L is syngeneic to Fisher 344 rats and allogeneic to the SD rats, while C6 cells 
are syngeneic to SD rats and allogeneic to Fisher 344 rats. We test whether allo-immune 
reactivity is able to evoke anti-tumour immunity against a syngeneic tumour. We analyse 
if therapeutic immunization with a combination of allogeneic cells and syngeneic lysates 
induces rejection of malignant gliomas and offers a protective effect against challenge 
with syngeneic tumour cells.
In chapter 6 we use the CNS-1 glioma model to explore the protective 
efficacy of various conditions in the vaccine preparation as well as in the dosing and 
timing schedule of a vaccine preparation, which is essentially based on allo- and 
syngeneic antigens in combination with distinct innate immune activating agents. We 
will analyse if particular costimulation agents are able to confer immunity against CNS-
1 tumour development when combined with the allo- and syngeneic vaccine antigen 
preparation.
In chapter 7 we continued with the same vaccine antigen preparation, 
which is evaluated as a therapeutic immunization when combined with the cytokine 
granulocyte-macrophage colony stimulating factor (GM-CSF), following a low dose 
cyclophosphamide treatment. This prototype vaccine may form the basis for further 
evaluation in a clinical study.
In the last chapter of this thesis (Chapter 8), we discuss the importance of 
our pre-clinical findings in the different rat models and the perspective we have developed 
on the clinical application of our experience and know-how for immunotherapeutic 
immunization of GBM diagnosed patients. 
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 Summary
Intracellular K+ plays an important role in controlling ion homeostasis for 
maintaining cell volume and inhibiting activity of pro-apoptotic enzymes. Cytoplasmic 
K+concentration is regulated by K+ uptake via Na+-K+-ATPase and K+ efflux through K+ 
channels in the plasma membrane. The IsK (KCNE1) protein is known to co-assemble 
with KCNQ1 (KvLQT1) protein to form a K+ channel underlying the slowly activating 
delayed rectifier Kz outward current which delays voltage activation. In order to further 
study the activity and cellular localization of IsK protein, we constructed a C-terminal 
fusion of IsK with EGFP (enhanced green fluorescent protein). Expression of the fusion 
protein appeared as clusters located in the plasma membrane and induced degeneration 
of both transiently or stably transfected cells. [Neurol Res 2007; 29: 628–631]
Keywords: Potassium channel; apoptosis; astrocytoma; fusion protein; 
green fluorescent protein; lipofection
 
Chapter 2 
 33
2
 Introduction
Expression of rodent IsK (also named KCNE1 or minK) was originally 
found to elicit a slowly activating voltagedependent K+ outward current in Xenopus 
laevis oocytes [18]. However, figure 2.2 attempts to express currents by transfection 
of some eukaryotic cell lines failed [8]. Also puzzling was the fact that IsK has a single 
putative transmembrane domain [17], whereas cation channels have two, four or six 
such domains. Furthermore, IsK shares no sequence homology with conventional K+ 
channels: in particular, it does not contain the P domain, a conserved motif ensuring 
specificity for K+ transport [22]. It was later on realized that IsK is an accessory protein 
which must co-assemble with the KCNQ1 (also named KvLQT1) K+ channel to display 
biologic activity [2,14]. The assembly with IsK increases the voltage dependence and 
current amplitude of KCNQ1 while slowing down the activation kinetics [4]. It has been 
suggested that KCNQ1 is the pore-forming subunit, whereas IsK is a regulatory protein 
affecting the permeation properties of the channel pore [1,16]. Multiple copies of IsK (at 
least 14) have been shown to be present in the complex [20]. The exact stoichiometry 
of functional K+ channels consisting in assembled KCNQ1/IsK subunits is not known. 
However, multiple stoichiometries resulting in channels with different pharmacologic 
properties have been described [21]. Consistently, overexpression of IsK in various cell 
types resulted in modification of endogenous K+ and Cl2 channels features [1,15] and 
antisense oligonucleotides directed against IsK inhibited Kz currents in cardiac myocytes 
[13]. Noteworthily, a human homolog to IsK harbouring similar properties as its rodent 
counterparts has been described12. In order to further study the activity of the IsK 
protein, we have constructed a C-terminal fusion of IsK with EGFP (enhanced green 
fluorescent protein) with the aim to easily analyse the future of cells overexpressing IsK.
 Material and methods
The pTR-EGFP plasmid, an adeno-associated virus (AAV) vector with 
EGFP (Clonetech, Palo Alto, CA, USA) and neomycin resistance expression cassettes 
derived from pTR-UF [25] has been previously described [19]. A fragment containing 
the entire sequence of IsK9 cloned in pRc/cytomegalovirus (CMV) (Promega, Madison, 
WI, USA) was polymerase chain reaction (PCR)-amplified using the following primers: 
GCCAAGCTTGATATCCATCACACTGGCGG (5’ primer; HindII site fused to pRc/CMV 
sequence 5’ to IsK) and TTCCTGAACTGAAGCCATTGTCACCGGT (3’ primer; 3’ end of IsK 
sequence fused to AgeI site). The resulting PCR fragment was digested with HindIII and 
AgeI and inserted between the HindIII and the AgeI sites in the AAV vector plasmid pTR-
EGFP19. This results in an in-phase fusion of the EGFP coding sequence at the 3’ end of 
the IsK coding sequence (Figure 2.1). 
U87-MG cell line was obtained from American type culture collection 
(Bethesda, MD, USA). Cells were cultured in Dulbecco’s modified eagle’s medium 
supplemented with 10% fetal calf serum (FCS) (Gibco BRL, Life Technologies, Merelbeke, 
Belgium). Cells were transfected by lipofection using Vectamidine diC14-tBut (Biotech 
Tools, Brussels, Belgium) according to the manufacturer’s protocol. 
For isolation of stable clones, pTR-EGFP or pTREGFP:: mIsK plasmids 
were transfected into U87-MG cells. Twenty-four hours post-transfection, the cells 
were trypsinized and diluted (1 : 5) into complete medium containing geneticin (G418) 
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Figure 2.1: Nucleotide sequence of mIsK::EGFP fusion. Nucleotides are numbered from the first 
residue of the mIsK initiation codon. The AgeI site used to obtain an in-phase fusion of mIsK with 
the EGFP coding sequence is shown in italics. *initiation codon for EGFP; mouse IsK: nt 1–386; 
EGFP: nt 400–1116 (nt5nucleotide). Encoded amino acids are shown
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(Life Technologies) at a concentration of 650 mg/ml. Neomycin-resistant clones were 
isolated after 2 weeks and further cultured in the presence of geneticin (G418). 
For fluorescence-activated cell sorter (FACS) analysis, 10,000 cells 
were analysed in a FACStar analyser/sorter (Becton Dickinson, Mountain View, CA, 
USA) using the CellQuest program (Becton Dickinson). When appropriate, cells were 
stained with Hoechst 333425. Cultures were fixed with 4% paraformaldehyde in 
phosphate buffer for 20 minutes at 37°C. The cell monolayer was then incubated into 
a solution of Hoechst 333425 (1 mg/ml; Merck) for 15 minutes and rinsed twice with 
phosphate-buffered saline (PBS). After aspiration of the PBS, cells were coverslipped 
using FluorSave reagent (Calbiochem, La Jolla, CA, USA) and photographed using a Zeiss 
Axiophot-2 fluorescence microscope equipped with an Axiocam video camera (Carl 
Zeiss, Gottingen, Germany). Images obtained with a fluorescein isothiocyanate (FITC) 
filter (Chroma; excitation wavelength: 450–490 nm; emission wavelength: 515 nm) or 
a 4,6-diamidino-2-phenylindole (DAPI) filter (Chroma; excitation wavelength: 365 nm; 
emission wavelength: 420 nm) were acquired using the KS-300 software (Carl Zeiss) and 
analysed using Adobe Photoshop 6.0. 
Statistical analysis 
Data were analysed using chi-square test with Yates’ correction or Mann-
Whitney test using the GraphPad Instat software.
 Results
The pTR-EGFP plasmid [19] encoding green fluorescent protein (GFP) 
under the control of the CMV promoter was used to produce a C-terminal fusion of 
the IsK protein with GFP (Figure 2.1). The resulting plasmid vector, pTR-mIsK::EGFP, 
also expressed the neomycin resistance gene in a separate transcription unit, allowing 
selecting cell clones expressing the fused coding sequence. Two days following transient 
transfection of the pTRmIsK:: EGFP plasmid into U87-MG glioma cells, the fusion protein 
appeared as a weak punctate fluorescence (Figure 2.2B) whereas cells containing pTR-
EGFP harbored an homogenous cytoplasmic signal (Figure 2A). Interestingly, nuclear 
staining with Hoechst 333425 revealed that cells expressing mIsK harbored nuclear 
hallmarks of apoptosis such as chromatin marginalization/condensation whereas cells 
transfected with pTR-EGP displayed a normal nuclear aspect (Figure 2.2C,D). Cellular 
toxicity was further evident 5 days post-transfection because mIsK-expressing cells 
were shrunk (Figure 2.2F) with the presence of fluorescent ellular debris around the 
transfected cells (Figure 2G) supporting their continuing degeneration. Conversely, pTR-
EGFP-transfected cells looked healthy (Figure 2.2E). Similar results were obtained with 
U373-MG and HEK293T cells overexpressing mIsK (data not shown). All these qualitative 
data thus suggest that IsK expression is deleterious and triggers cell degeneration. In 
line with these morphologic observations, quantitative studies demonstrated that the 
amount of GFPpositive U87-MG cells with nuclear signs of apoptosis was significantly 
increased 2 days following the transfection of pTR-mIsK::EGFP as compared with control 
cultures transfected with the pTR-EGFP vector (Table 2.1). This effect seemed directly 
related to mIsK expression because nuclear abnormalities were markedly higher 
in the GFP-positive cells than in the overall cell population (Table 2.1). Such nuclear 
alterations preceded cell death because the percentage of GFP-positive cells was 
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significantly reduced 5 days following transfection of pTR-EGP::mIsK as compared with 
pTR-EGFP (Table 2.1). Noteworthily, these differences were not due to a difference in 
transfection efficiency between the two vectors used, because 2 days post-transfection, 
the proportion of GFP-positive cells was similar in cultures transfected by both pTR-
EGFP::mIsK and pTR-EGFP vectors (Table 2.1). Similar data were obtained for U373- MG 
and HEK293T cells (data not shown). In agreement with these results, we found that 
the proportion of stable neomycin-resistant clones of U87-MG cells fully expressing 
EGFP was significantly lower after transfection of pTR-EGFP::mIsK as compared with 
transfection of pTR-EGFP control vector (Table 2.1).
Figure 2.2: Transient transfection of pTR-EGFP and pTR-mIsK::EGFP into U87-MG cells. U87-MG 
cells were transfected with pTR-EGFP (A, C and E) or pTR-mIsK::EGFP (B, D, F and G) plasmids. 
Two days post-transfection, cells were fixed, incubated with Hoechst and examined under fluo-
rescence microscopy using a FITC (A–G) or a DAPI filter (C and D). Images obtained using FITC and 
DAPI filters were fused (C and D). (G) Fluorescence in combination with bright-field microscopy. 
Dashed arrow: chromatin condensation triggered by mIsK::EGFP fusion protein expression; full 
arrow: pTRmIsK::EGFP-transfected cell; asterisk: cell debris; scale bar550 µm
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Discussion
The mouse IsK potassium channel accessory molecule was fused to EGFP. 
Transient expression of the fusion protein into human cell lines resulted in appearance 
of green fluorescent clusters on the cell membrane. Chronic expression of the fusion 
protein led to cell death of more than 50% of transfected U87-MG human astrocytoma 
cells as early as 2 days after transfection. Cell death was evidenced by condensed 
chromatin observed 2 days post-transfection and by the appearance of green fluorescent 
cellular debris in the transfected culture 5 days post-transfection. Furthermore, stable 
transfectants expressing GFP could not be obtained using the fusion construct.
Overexpression of IsK in various cell types resulted in modification of 
endogenous K+ and Cl- channels features [1,15]. Depending on the cellular background, 
overexpression of IsK is expected to either reveal endogenous previously silent 
channels or modify the activity of already active channels. It has been shown that a 
drop in intracellular K+ creates a permissive state for apoptosis progression in various 
models [11,23]. Consistently, raising extracellular K+ concentration as well as K+ channel 
blockers have been shown to inhibit apoptosis [24]. Furthermore, apoptosis has been 
shown to be directly triggered by valinomycin, a selective K+ ionophore, in thymocytes 
[5], vascular smooth muscle cells [7], tumour cells [6] and cortical neurons [24]. In the 
latter case, chromatin condensation and cell body shrinkage have been described. 
Exposure to the K+ channel opener cromakalim also induced neuronal apoptosis [24]. In 
Table 2.1: Transfection of human astroglioma cells with mISK::EGFP
Transient Stable
2 days 5 days
n/N GFP+ Apoptotic 
cells 
Apoptotic 
cells among 
GFP+ 
% GFP+ % GFP+ clones
pTR-EGFP 5/164 7/164 
(4.26%)
4/164 
(2.43%)
0/7 (0%) 6.58 ± 
4.31%
3/4 (75%)
pTR-EGFP::mIsK 18/814 29/814a 
(3.56%)
47/814b 
(5.77%)
 18/29c 
(62.06%)
1.87 ± 
0.62%d
0/12e (0%)
U87-MG cells were lipofected with pTR-EGFP and pTR-EGFP::mIsK plasmids. Two days post-trans-
fection, cells were fixed and treated with Hoechst. Random fields from three separate transfecti-
ons were examined under fluorescent microscopy. For each field, the percentage of GFP-positive 
cells (green fluorescence) and the percentage of apoptotic cells with fragmented chromatin (blue 
fluorescence) were counted. Five days post-transfection, the percentage of green fluorescent 
cells was evaluated by FACS analysis. Values are expressed as mean ¡ SD. Neomycin-resistant 
clones were isolated after 2 weeks and further cultured for 8 weeks in selective medium. The 
total number of clones and the number of fluorescent clones were counted under fluorescence 
microscopy using a FITC filter. n: number of fields; N: total number of cells examined; ND: not 
detected. Statistical analysis: chi-square test with Yates’ correction: a, 0.83; b, 0.118; c, 0.0115; e, 
0.0096; Mann-Whitney test: d, 0.057.
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accordance with these data, it has been suggested that cytoplasmic loss of Kz leads to 
caspase activation [3]. 
In conclusion, our results are consistent with activation of apoptotic 
pathways following IsK-mediated increase in K+ efflux. Indeed, the observed cell 
shrinkage, appearance of cell debris and chromatin condensation are consistent with the 
hallmarks of apoptosis induced by low intracellular K+concentration [24]. Alternatively, 
it could be that localized accumulation of GFP by clustering of multimerized K+ channels 
causes toxicity. Indeed, it has been reported that overexpression of GFP can induce 
apoptosis [10]. 
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Immunotherapy of Malignant Gliomas  
Using Autologous and Allogeneic Tissue Cells
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 Summary 
Immunotherapy of brain tumours is rapidly emerging as a potential clinical 
option [1-3]. The quality and magnitude of immune responses evoked by the new 
generation anti-tumour vaccines is in general highly dependent on the source or choice 
of peptide antigens, and as well, a suitable immunopotentiator. Poorly immunogenic 
antigens, such as those present in tumour cell lysates, may not reliably provide 
stimulation like recombinant or DNA-encoded protein antigens might be expected to. In 
addition, the efficacy of the vaccine may depend on inherent counteracting measures of 
the tumour which dampen immune surveillance and immune effector activity triggered 
by immunization [4]. Our body has many means of limiting an immune response to our 
own (self) proteins. In particular, patients with gliomas exhibit a broad suppression of cell-
mediated immunity [5-8]. Unfortunately, for most tumour vaccines the induction of local 
or systemic immune effector cells does not necessarily translate into objective clinical 
responses or increased survival [9]. Here we review immunotherapeutic approaches 
against gliomas and recent pre-clinical and clinical initiatives based on cellular or active 
immunization of the patient’s immune system using autologous and allogeneic tissues 
or cultured cells. Available evidence shows that single modality cancer therapies likely 
remain suboptimal. Combination regimens targeting the immune system at multiple 
coordinated levels must be developed, and possibly combined with strategies to inhibit 
immune suppressive factors if significant clinical benefit is to be achieved.
Keywords: Astrocytoma, allogeneic, biotherapy, brain tumour, CTL, 
glioma, immunotherapy, immunization.
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 Introduction
Glioblastoma multiforme (GBM) is the most common and malignant of 
all gliomas, with 75% of patients dying within 18 months of diagnosis. Brain tumours 
are graded according to their likely rate of growth, from grade I (benign) to grade IV 
(most malignant), with grades III and IV considered high-grade gliomas. Grade IV glioma 
is also known as glioblastoma multiforme (GBM). The prognosis for patients with this 
tumour is very poor. Glioblastoma overall survival rates are less than 3.3% at 5 years 
[10]. In the United States alone over 18,000 primary brain tumours are estimated to 
occur each year. Of these 18,000, over 60% are diagnosed gliomas. The median survival 
time of untreated GBM tumours is 3 months, with death most commonly due to 
cerebral edema or increased intracranial pressure. Even with the best available current 
therapy, which includes surgery, radiation, and chemotherapy, the median survival time 
is 14.6 months [11]. Due to their highly infiltrative nature complete surgical resection 
is difficult. These tumours are, therefore, inevitably recurrent either locally, usually 
within 2 cm of the original tumour, or at distant sites. Treatment of these recurrent 
lesions by a second surgery and further chemotherapy may increase the symptom 
free interval, but the 5- year survival remains 10%. The present review discusses 
various typical immunotherapeutic strategies in a comprehensive way, with a focus 
on active therapeutic immune intervention. All these therapies will serve as additions 
to, rather than a replacement of current medical practice. Due to many examples it is 
impossible to cover all preclinical approaches and past or ongoing clinical trials. We 
will, therefore, address only the most promising or remarkable strategies, but omission 
from or inclusion into this review should not be interpreted as rejection or support of 
a particular approach; they are examples. We propose that immune adjuvant therapies 
need to be explored to improve median or overall survival.
 The long road to current glioma therapeutic 
Vaccine approaches
The first report on cancer therapy dates from the Edwin Smith Papyrus, 
1600 B.C., the oldest known historical text on surgery. It mentions primitive surgical 
excision of a tumour using a knife. It has only been for the past two hundred years that 
surgical excision became established as the preferred option for treating solid tumours. 
Radiation therapy was introduced shortly after 1895, when Roentgen first reported the 
use of x-rays for diagnostic medical purposes, and remained a primary treatment option 
of certain tumours, especially solid tumours. Today radiation therapy can be tailored 
to the irregular shape of the tumour, allowing a reduction of intensity. During World 
War I, exposure of soldiers to nitrogen mustard gases resulted in pancytopenia. This 
observation triggered interest for chemotherapeutic therapy, especially in patients 
with hematologic malignancies. Today chemotherapy is a well documented treatment 
option. For glioblastomas, the alkylating agent temozolomide has become a well-
appreciated option [12]. 
About one hundred years ago William B. Coley, an early 20th century New 
York City surgeon, observed that some of his patients with sarcoma would undergo 
spontaneous regression of their tumour and that this regression was associated with 
antecedent bacterial infection (erysipelas, or streptococcus pyogenes in the first 
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patient) which eliminated malignant cells [13, 14]. He intentionally injected cancer 
patients with a mixture of killed bacterial lysates, later called Coley’s Toxins, to stimulate 
a cytokine storm. William Coley thus became the godfather of cancer immunotherapy 
[15]. He was the first to recognize the potential role of the immune system in cancer 
treatment. Activation of the patient’s immune system to better recognize the tumour 
and to eliminate invasive tumour cells that are not adequately removed by surgery 
will be discussed in greater detail. This area in cancer therapy is based on knowledge 
accumulated in the vaccine and immunology fields. 
Immunization attempts for glioma patients date back to the early 1960s 
[16]. Two investigative teams hypothesized that brain tumours were hidden from the 
immune system because of location in the central nervous system. To ensure that 
immune cells located systemically could “see” the tumour, they placed autologous 
glioma cells into the thighs of patients. The vaccines given into the thighs actually 
started growing there and metastasized to regional nodes [16, 17]. Ten years later, 
Bloom and colleagues administered irradiated, whole autologous tumour cell vaccines. 
Again, there was no effect, but the results may well have been different had they used 
an adjuvant, such as that used by Trouillas and Lapras [18] who immunized 20 patients 
with autologous tumour and Freund’s complete adjuvant. These early attempts at 
active immunotherapy had obstacles consisting of potentially radiation resistant cells, 
and the absences of, or inappropriate, immune adjuvant. Degrees of sophistication in 
vaccine development have occurred in the past 50 years; and at last the benefits of 
active immunotherapy are finally documented.
 Key considerations for development of 
immunotherapy Approaches
Tumour Directed Immune Responses
Distinct from classical preventive vaccines, which mostly require the 
generation of antibodies, the goal of most therapeutic GBM vaccines is to stimulate 
tumour-specific cytotoxic T cells (CTL) to function at the tumour site. Over the past 20 
years we have only begun to learn how to accomplish this. A key factor for the success 
of a vaccine concerns the requirement of expression of unique tumour antigens, 
preferably in the context of class I Major Histocompatibility Complex (MHC), on suitable 
target tumour cells. Upon stimulation of the immune response, the host can specifically 
target these antigens, by producing antibodies, or by activating immune effector cells 
which recognize specific antigens in context of MHC Class I antigens. Studies have 
shown that human glioma cells do express variable levels of class I MHC antigens, and 
that IFN-􀀁 upregulates these class I antigens [19]. In addition, Fas is expressed on glioma
cells [20], providing a possible mechanism for tumour cell death [20]. Therefore under 
the appropriate conditions, glioma cells can be a target of CTL. 
Remarkably, recent animal experiments in various tumour models showed 
that apart from CD8-positive cytotoxic T cells, which are considered the current “gold 
standard” effector cell in tumour immunotherapy, CD4 T cells can eliminate tumours 
that are resistant to CD8-mediated rejection [21]. Indeed, CD4 T cells collaborated 
with natural killer (NK) cells to achieve this antitumour effect. These findings suggest 
that adaptive CD4 T cells can also be successful effector cells, and in some cases, even 
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outperform CD8 positive T cells as mediators of cell death. This observation of efficient 
tumour elimination by CD4 T cells, using indirect mechanisms that do not require MHC 
expression by the tumour cell, suggests that it might be possible to attack even poorly 
MHC expressing tumours by designing strategies to elicit CD4 T cell responses against 
the tumourigenic proteins [21].
Adoptive Transfer of Effector T Cells
Adoptive transfer of lymphocytes into patients is classified as a variant of 
passive immunotherapy. Adoptive transfer of lymphocytes into brain tumour patients is 
not a new concept. Indeed, thinking that the blood brain barrier inhibited the passage 
of immune cells into the brain, one of the first clinical trials involved the adoptive 
transfer of autologous, unstimulated lymphocytes intrathecally into glioma patients, 
accompanied with or without interferon [22]. Since the advent of recombinant growth 
factors, adoptive immunotherapy now in principle, is based on the concept of infusing 
ex vivo expanded effector cells after their in vitro activation against tumour antigens 
and/or culture in growth factor containing media, back into the patient. The whole 
gamut of effector cells have been tested including autologous or allogeneic cells that are 
nonspecifically or specifically activated [23, 24]. In newly diagnosed malignant gliomas, 
this approach revealed several objective clinical responses without adverse effects [25]. 
Expansion of autologous tumourspecific T lymphocytes in vitro with IL-1, IL-2, and/or 
IL-4, followed by injecting directly into the tumour site gave response rates that were 
not consistently encouraging [26]. A further variant of this approach included genetic 
manipulation of such ex vivo isolated cells by the introduction of immunostimulatory 
transgenes [27].
Tumour Associated Antigens (TAAs)
One important step in producing a therapeutic vaccine is the identification 
of appropriate glioma-associated antigens. Limited knowledge of molecularly defined 
antigens explains why initial approaches used tumour lysates derived from autologous 
irradiated glioma cells as the source of tumour antigens. This approach warrants specific 
activation of the immune response against a broad set of potential tumour associated 
antigens, which may enhance immune therapy but may also result in immune reactions 
against unwanted antigens [28]. Glioma associated, rather than glioma specific, appears 
to be the more correct terminology since the antigens appear to be present at very 
low levels on normal brain cells, but overexpressed on glioma cells. Importantly, for 
the majority of studies no evidence of adverse autoimmunity was noted after such 
immunizations. The premise was that by providing the entire tumour cell, all the 
appropriate antigens would be made available to the antigen presenting cells of the 
immune system. Unfortunately, these procedures did not lead to successful therapies 
[26]. The advent of molecular biology enabled approaches aimed to identify the 
specific glioma-associated antigens (GAA) at the molecular level [3, 20, 29, 30]. Jadus 
and colleagues analysed adult and pediatric brain tumour cell lines and some primary 
tissues for tumour-associated antigens [30, 31]. The glioma cell lines were characterized 
for 20 tumourassociated antigens by quantitative reverse-transcriptase real time 
polymerase chain reactions (qRT-PCR), and where antibodies were available, the protein 
expressions were confirmed microscopically using flourescently-tagged antibodies or by 
intracellular flow cytometry. In general, the glioma cell lines had high mRNA expression 
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for the antigens and also made the proteins. Thus, primary malignant brain tumours and 
the cell lines express many tumour associated antigens; a truncated list of them is given 
in Table 3.1. From these data we conclude that either primary tumour specimens or cell 
lines could serve as suitable sources for antigens for vaccine development. In general, 
the surgical specimens from the adult glioblastomas had a more robust antigenic profile 
than those from the pediatric tumour specimens. Since many of the tumour associated 
antigens display HLA-restriction, we also conclude that given the known HLA type of the 
tumour patient, one might predict which antigens might likely be associated with his 
tumour [30]. Certainly in conjunction with cytogenetic information, especially genomic 
imbalances, one might predict overexpression of certain antigens. 
Interestingly, recent genomic studies have revealed the genes of human 
glioblastomas and provided insight into associated molecular pathways [32-34]. The 
genetic subtypes are associated with prognosis. These analyses may provide further 
refinement on potential glioma-associated target antigens. The Cancer Genome Atlas 
(TCGA) Research Network Comprehensive genomic characterization defines human 
glioma genes and core pathways [35]. 
The tumour antigens most suitable to activating the host specific T cell 
response are still under investigation. Prominent tumourassociated antigens that 
others have considered suitable for vaccine development include tenascin (glioma-
specific extracellular matrix), gp240 (chondroitin sulfate-associated antigen found in 
glioma), MAGE 1 and MAGE 3 [36, 37]. For development of their vaccines, Okada et 
al. focused on epitopes that specifically bound to the class I HLA-A2 such as EphA2, 
IL-13Ra2, YKL-40 and GP- 100 [29]. More specifically, the IL-13 Ra2 and EphA2-derived 
epitopes were shown to stimulate immune activity. The successful use of these antigens 
may also largely depend on the immunopotentiator system used for switching on and 
maintaining the specific immune reaction directed towards the antigen of interest [38]. 
This will be addressed later.
Activation of Antigen Presenting Cells
The activation of the cytotoxic T cells generally requires the stimulatory 
interaction with T helper cells, which recognize antigen in context of Class II expression. 
Therefore cells that express high levels of class II antigens are most efficient antigen 
presenting cells (APC) for triggering helper T cells. Although macrophages and microglia 
Table 3.1. Tumour-Associated Antigens Overexpressed in Primary Malignant Brain Tumours
Aim-2 Ezh2 HNRPL Prame Sox11 Ube2V
Art-1 Fosl1 IL-13Ra2 PTH-rP SSX-2 Whsc2
Art-4 Gage-1 Mage-1 Sart-1 Survivin Wt-1
B-cyclin Galt-3 Mart-1 Sart-2 Tert YKL-40
CD133 GnT-V MELK Sart-3 TRP-1
EGFRvIII Gp100 MRP-3 Sox 10 TRP-2
Epha2 Her2 NY-Eso-1 Sox 2 Tyrosinase
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express Class II, dendritic cells (DC) are the most efficient antigen presenting cells 
[39]. Dendritic cells are also called “nature’s adjuvant”, and represent the key APCs for 
induction of primary immune responses. As sentinels they sample peripheral tissue for 
potential antigens and bring them to draining peripheral lymph nodes to present the 
processed antigens to potential antigenspecific T lymphocytes.
Therefore events that trigger the maturation and activation of these cells 
under natural conditions at the tumour site, or in the cervical lymph nodes are considered 
valuable for natural tumour surveillance. By contrast, maturation of APCs at the site of the 
vaccine inoculums or in the local draining lymph node are likely important for producing an 
effective vaccine [38]. There is substantial evidence that DCs exposed to tumour antigens 
under the right circumstances are potent stimulators of cytotoxic T cells. 
Dendritic Cell Vaccines
In recent years there have been numerous attempts to use dendritic 
cells in therapeutic “vaccines” [3, 40-42]. The isolation of dendritic cells by elutriation 
enabled the handling and in vitro loading with antigens. Unfortunately, there is no 
consensus on the best protocol to isolate and use DCs; different DC subtypes may 
exert distinct functions and efficacy. Recently, several dendritic cell vaccines have been 
tested in glioblastoma immunotherapy. These were based on either crude tumour 
lysates or acid-eluted peptides from cell cultures derived from surgically removed 
glioblastoma multiforme [9, 43-45]. In some patients, a peripheral CTL response was 
detected. However, only sporadic objective responses and modest increases in the 
patient’s survival were observed, with no long-term survivors, from these approaches 
[9, 43-45]. Importantly, no evidence of adverse autoimmunity was noted after these 
immunizations. 
Siesjo et al. showed that co-administration of autologous tumour cells 
with autologous DC decreased tumour growth [46]. Liau et al. demonstrated that 
autologous DC incubated with autologous tumour protein increased survival, and 
increased tumour-specific cytotoxic T cells within the tumour [9]. These initial studies 
that were performed in only a few patients led to clinical trials. Different methods to 
activate these DC were explored. Expanding the immune response was first approached 
by using non-specific immunomodulators, such as BCG, IL-2, interferon (IFN)-α, which 
had been registered as approved immunostimulants. 
Immunopotentiators Co-Administered with Tumour 
Antigens
As mentioned earlier the success of glioma immunotherapy will depend 
on better understanding of glioma biology but also from lessons learned from the 
vaccine and immunology fields [47]. It is beyond the scope of this review to mention 
the plethora of distinct immunopotentiators used in various pre-clinical and clinical 
settings, in most cases with different types of antigen formats. 
Here we briefly mention a few types which employ in most cases 
immunostimulants that were approved for human application. In a rat model, IL-4 
was shown to have the most potent therapeutic results, mediating local endothelial 
cell activation, recruiting immune T cells, and stimulating antibody production [45]. 
IFN-α was also a possible candidate because this cytokine stimulated endothelial cells 
to produce CXCL-10, a chemokine shown to induce homing of cytotoxic T cells (Tc1) to 
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the tumour site [48]. Granulocyte macrophage-colony stimulating factor (GM-CSF) has 
also been used as an effective adjuvant to attract large numbers of antigen presenting 
cells to the vaccination site [25]. The heat shock protein (HSP) 70, in particular, has 
been shown to directly activate NK cells and indirectly stimulate the dendritic cell 
population; in addition, this extracellular secreted product induces the release of IFN-γ 
from peripheral blood leucocytes of tumour patients thereby further stimulating the 
immune response [49]. Other studies showed that poly I:C, the ligand for the toll-like 
receptor (TLR)3, was effective in triggering the maturation and functional activity of 
DC [50]. Further studies used lysine and carboxymethyl cellulose stabilized poly I:C 
(poly ICLC) to activate cells, however no significant advantage to survival in humans 
was reported [29]. Yet another approach used CpG-oligonucleotide (ODN), which binds 
to TLR9, and thereby stimulates immune responsiveness [7]. Although no registered 
effective treatments are currently available, sporadic positive clinical responses were 
observed following immunization with vaccines prepared from the patients’ autologous 
irradiated glioma tumour cells mixed with GM-CSF, irradiated GM-CSF secreting K562 
cells, or IL-4-secreting fibroblasts (www.clinicaltrials. gov NCT00694330) [25, 45, 51]. In 
general, increases in patient survival were observed, however these approaches yielded 
no longterm survivors [9, 43, 45]. Importantly, no evidence of adverse autoimmunity 
was noted after these immunizations. 
Collectively, these studies emphasize the importance of both the correct 
activation of the cell population presenting the antigen, as well as the accurate delivery 
of the targeted antigen, as part of the vaccine approach. It should be realized that a 
potent new antigen is not enough to make a vaccine. The antigen should be presented 
to the immune system in a formulation which activates the desired immune pathway 
required for tumour eradication. Vaccine immunopotentiators comprise a diverse group 
of molecules or formulations, which have been used routinely as critical components 
of inactivated antimicrobial vaccines for almost a century. Advances in vaccine research 
are expected to emerge from better knowledge of immune pathways and antigen 
delivery [52]. Apart from the historic examples of immunopotentiator technologies a 
variety of other options have not been explored as yet because of restrictions for use in 
human subjects [47]. 
Immunotherapeutic Concepts 
The human body has evolved a complex immune system to eliminate 
pathogens and abnormal cells with minimal damage to healthy tissues. The immune 
system has multiple levels of regulation to guarantee the appropriate balance 
between immune activation and immune suppression. Over the last two decades the 
fundamentals of this regulation have become clearer. This knowledge now provides 
new opportunities for rational intervention based on a tailored response of the immune 
system against tumours that may lead to clinical benefit. 
Since the observations by William Coley there has been a long held belief 
that the immune system can prevent the emergence and growth of cancer. Indeed, 
Galon and coworkers elegantly demonstrated that an adaptive immune response 
influences the behavior of human colon cancer tumours by in situ analysis of tumour-
infiltrating immune cells [53, 54]. Also, in ovarian cancer the presence of intraepithelial 
tumour infiltrating lymphocytes is associated with significantly longer clinical remission 
after chemotherapy and with improved overall survival [55]. Similar observations have 
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been made for other tumours, including renal carcinoma [56], prostate cancer [57] and 
breast carcinoma [58]. The observation that improved survival is linked to the capacity 
to mount natural immune responses supports the concept to stimulate the patient’s 
immune effector responses by active immune programming. 
As for most traditional vaccines the quality and magnitude of immune 
responses evoked by new generation immunotherapeutic anti-tumour approaches is 
in general highly dependent on the choice of vaccine antigen and the provision of a 
suitable immunopotentiator or concurrent immune activation strategy; especially 
for poorly immunogenic antigens, such as tumour cell lysates, recombinant or DNA-
encoded protein antigens [38, 47]. 
Despite decades of failed attempts to develop effective cancer vaccines, 
several candidates are now progressing towards commercial approval. Several distinct 
technological concepts have been pursued to achieve immunotherapeutic cancer 
treatment, which are summarized in Table 3.2. 
i) Classical vaccines consisting of tumour antigens, isolated either from 
tumour cell lines or ex vivo tumour tissue obtained by surgical removal, and formulated 
or co-administered together with an effective immunopotentiator into a vaccine 
formulation. This vaccine is injected parenterally and able to unlock the required 
immune response [1, 29] 
ii) The source of tumour associated antigens (TAA) may also be generated 
by recombinant biotechnology procedures, such as laboratory- based expression from 
mammalian, bacterial, yeast, insect or plant cells, or as synthetic protein peptides. 
iii) The loading of TAAs, either contained in surgically removed tumour 
cells or isolated as tumour-derived peptides, or as synthetic or recombinant molecular 
mimics, on the patient’s own dendritic cells, which are isolated from the patient by 
leukapheresis, and after a culture period in the laboratory, transfused back into the 
patient [9, 40]. These autologous dendritic cells are activated in the culture dish by a 
mixture of recombinant cytokines or immunostimulatory ligands.
iv) Instead of protein antigens, investigators have used the genes encoding 
these antigens, either in RNA or DNA format or inserted in replicating viral or bacterial 
vectors which produce the TAAs in the patient after parenteral injection. Such genetic 
vaccines contain immunostimulatory sequences which directly activate immune cells 
after recognition by specific receptors. In addition, the provision of gene-encoded 
antigens allows for intracellular expression and correct processing of candidate antigens 
by the patients antigen presenting immune cells. 
v) As a variation of the above strategy, the same genes can be delivered 
directly into isolated dendritic cells by transfection in culture dishes before infusion. 
This approach assures the correct targeting of the gene-encoded TAAs into the patients 
dendritic cells in the laboratory before infusion. 
vi) Instead of providing TAAs in the context of a favorable immune system 
activating conditions, clinical trials have been designed with patient-derived tumour-
specific T cells. These cells have been developed in the patient and are isolated and 
expanded in the laboratory in specialized culture media supplemented with T cell 
growth promoting molecules before reinfusion back into the patient. 
vii) Another strategy involves the administration of immunostimulatory 
agents which strengthen the endogenous immune response of the patient in order 
to better attack the tumour. For example, this approach comprises intravenous 
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Table 3.2. Survey of Immunotherapy Approaches
Tumour Associated 
Antigens (TAA)
Immunopotentiation Category
1 From lysates extracted 
from cell lines or 
tumour tissue
Classical vaccine adjuvants, or 
cytokines such as interleukin 
(IL)-12, GM-CSF, TNF, haptens, 
BCG, etc
Classical vaccine
2 Recombinant proteins 
or peptides
Classical vaccine adjuvants, or 
cytokines such as interleukin 
(IL)-12, GM-CSF, TNF, haptens, 
BCG, etc
Modern vaccine
3 Antigens from 1 or 
2 loaded on patient-
derived autologous 
dendritic cells
Activating cytokine (or cocktail) Dendritic cell 
vaccine
4 RNA, DNA, or viral/
microbial vector 
encoding the TAA
Direct parenteral 
injection, without or with 
immunopotentiators
Genetic vaccine
5 RNA, DNA, or viral 
vector encoding the 
TAA
Transfection into dendritic cells Dendritic cell 
vaccine
6 Endogenous TAAs 
expressed/released by 
the tumour
Patient-derived or allogeneic 
T lymphocytes cultured in 
medium facilitating T cell 
survival and expansion, 
sometimes gene modified T 
cells expressing transgenic 
T cell receptors specific for 
defined TAA
Adoptive T cell 
transfer
7 Endogenous TAAs 
expressed (released) by 
the tumour
Cytokine or immunostimulant 
administration (IFN, IL-2, IL-12, 
TLR agonists etc.)
Non-specific 
stand-alone 
immunostimulation
8 Endogenous TAAs 
released from the 
tumour after local 
destruction of tumour 
tissue by ablation
Local inflammatory responses 
resulting from apoptosis or 
necrosis of tumour tissue, 
optionally combined with 
immunostimulants
Tumour necrosis 
therapy (TNT) by 
non-specific local 
immune activation
9 One of the categories 
of exogenous or 
endogenous TAAs 
described above
Blockade of endogenous 
immunosuppressive cells 
or molecules (PD-1, CTLA-4, 
TGF-β, IL-10, regulatory T cells, 
etc.)
Inhibition of local or 
systemic immune 
suppression
10 Two or more 
combinations of the 
above approaches
Multi-modal
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administration of recombinant cytokines (IL-2, IL-12) or microbe-derived 
immunostimulants, including toll-like receptor agonists, like synthetic CpG motifs [59], 
stabilized synthetic RNA oligonucleotides (ODN) [60] or resiquimod® [61]. 
viii) The above approach activates the systemic immune activity and may 
enforce the critical local anti-tumour effector responses to a limited extent. Therefore, 
alternative strategies involve local immune manipulation by local administration of 
immune activating agents in combination with local destruction of tumour tissue, and 
associated liberation of TAAs following surgical ablation or tumour targeting by “magic 
bullets” such as TAA-specific or tumour cell DNA-targeting antibodies . Examples include 
the radiotherapeutic strategy, called Cotara®, that employs the isotope 131Iodine 
conjugated to an antibody that binds the necrotic core found in all solid tumours [62], 
or antibody-targeted delivery of chemokines by chemokine/antibody fusion proteins, 
which results in high local tumour-associated concentrations of chemokines that attract 
monocytes, neutrophils and lymphocytes [63]. Yet another variant of this concept 
includes locoregional or intratumour application of oncolytic viruses, e.g. NDV [64] 
or HSV [65], which cause a proinflammatory immune response in the vicinity of the 
tumour tissue. 
ix) All above-mentioned approaches are based on expanding tumour–
specific immune effector elements. In addition, it is known that during immune 
surveillance reactions, local or systemic immunosuppressive regulation contributes 
to the escape of solid brain tumours and that such processes may also contribute to 
the inhibition of suboptimal, vaccination-triggered immunotherapy [5-7, 66]. Hence, 
inhibition of immunosuppressive molecules, such as CTLA- 4 [67] PD-1 [68-71], TGF-􀀁 
[72], IL-10, or immunosuppressive regulatory T cell [50, 73, 74], may also contribute to 
anti-tumour immunity. Abrogation of immunosuppression can be achieved by a stand–
alone approach, or as a push-and-pull tactic in combination with one of the active 
immunotherapeutic approaches mentioned earlier [75]. 
x) Combinations of two or more of the above-mentioned approaches. 
Tumour Mediated Immune Suppression 
Despite stimulatory strategies, the production of active immunotherapy 
in cancer patients at an advanced stage of disease may be hampered by the suppression 
of systemic immune responsiveness in these patients [4]. Radiation and chemotherapy 
can induce generalized immune suppression because these treatments reduce the 
production of immune competent cells. Such therapies can provide the natural selection 
process resulting in the development of resistant tumours [4, 76, 77]. Furthermore, the 
administration of highly immunosuppressive glucocorticoids to control brain edema 
would tend to point toward vaccine administration early after diagnosis rather than 
later, after patients develop systemic immune suppression. Evidence collected long 
ago showed that glucocorticoids such as dexamethasone transcriptionally inhibit IL-2 
synthesis in T lymphocytes. They interfere with nuclear factor activating protein-1 
binding to the IL-2 promoter and also with calcineurin dependent pathways for T 
cell activation [78]. Since endogenous immune cell activation and proliferation must 
be engendered upon successful immunization and is reliant upon mRNA and protein 
synthesis [79], vaccination would be optimal if given to patients who are not steroid-
dependent.
In addition to drugs, the tumour itself can regulate immune reactivity. It 
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has been recognized for some time that patients with malignant gliomas demonstrate 
a profound immune suppression when compared to normal persons, suggesting that 
gliomas produce an immune inhibitory environment [20, 80]. Such immune suppression 
is mediated by soluble cytokines and growth factors. For example, transforming growth 
factor (TGF)-β, and interleukin (IL)-10 have been reported to be secreted by glioma 
cells [81, 82]. These cytokines functionally impair T cell activity and are responsible 
for the development of immunotolerizing T regulatory (T reg) cells [83]. Gliomas also 
produce prostaglandin E2 (PGE2), and IL-6, both potential immune suppressive agents, 
as well as macrophage chemoattractive protein (MCP-1) [29, 84, 85]. In addition, local 
synthesis of Vascular Endothelial Growth Factor (VEGF) inhibits DC maturation on the 
one hand, and induces tumour-promoting angiogenesis on the other hand [86]. Apart 
from these soluble factors, gliomas may express membrane-bound Fas ligand (FasL), 
which induces apoptotic cell death of infiltrating immune cells when interacting with 
Fas, and/or PD-1, an inhibitory co-receptor, a B-7 family member, which attenuates T 
cell receptor signalling of infiltrating lymphocytes [29]. These mechanisms can shut 
down anti-tumour immunity and can be viewed as a counterattack by the tumour. 
CD8- and CD4-positive T cells become inhibited after expression of CTLA-
4 and subsequent interaction with its ligands, CD80 or CD86. Hence, the use of the 
anti-CTLA-4 antibody has resulted in better and more sustained anti-tumour responses 
[87]. Another recent approach to reversing this immune suppression is the use of small 
molecule inhibitory drugs to block the common signalling pathway to these suppressive 
activities, including the Signal Transducers and Activators of Transcription 3 (STAT3) 
activation pathway [80]. Thus it has to be appreciated that multiple factors must be 
taken into account when considering an immune therapy approach. Regardless of the 
stimulatory concepts attention should be given to factors which promote immune escape. 
In addition, immunosuppressive enzymes may provide another way for 
tumour cells to evade immune responses. Ninety percent of human glioblastomas are 
positive for indoleamine 2,3, dioxgenase (Ido-1) [4, 88]. Ido expression is accompanied 
by a lack of accumulation of specific T cells at the tumour site.
Recent Encouraging Pre-Clinical Results 
As mentioned earlier, initial tumour vaccine approaches used tumour 
lysates derived from irradiated glioma cells as the source of tumour antigens or whole 
irradiated tumour cells themselves. However, while the tumour cells contain a plethora 
of tumour associated antigens, they may be present at relatively low levels. Additionally, 
tumour specimens can contain normal, nonmalignant cells as well as tumour cells. 
Nevertheless, in a rat model where systematic subcutaneous administration of either 
allogeneic or xenogeneic tumour cells, or that combined with syngeneic cell lysates, 
proved safe and protective in early and advanced malignant glioma growth [89]. These 
results suggest that injections of allogeneic cells and/or lysates, or xenogeneic cell lines, 
can activate the immune system and can break anti-self/tumour. Also, these cells likely 
contained critical antigenic determinants shared with the implanted tumour, leading 
to a reduction in tumour growth. These data therefore, support the potential viability 
of this cancer vaccine strategy as an adjuvant treatment to prevent tumour relapse 
in cancer patients after standard surgical removal of the tumour. The impact of such 
data may be far reaching when translation of this strategy to patients proves possible. 
Indeed, alloresponsive effects may prove to be powerful. 
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Immunotherapy Approaches Utilizing Allogeneic Cells for 
Cancer Treatment 
Table 3.3 provides examples of open or pending clinical trials utilizing 
allogeneic cells for immunotherapy of cancer. There are cellular therapy trials using 
allogeneic effector T cells a) sensitized to tumour associated antigens or patient 
human leukocyte antigen, b) genetically modified T cells with targeting elements for 
brain tumour antigenic receptors as well as to T cell receptor (TCR) signalling, or T cells 
sensitized to highly antigenic viral proteins. For the latter, cytomegalovirus-specific T 
cells are used because of subclinical reactivation in CMV-exposed brain tumour-bearing 
individuals [90- 92]. Since the allogeneic effector cells are administered directly into 
the brain they are protected, at least for a short while, from destruction by the host’s 
immune cells. The use of allogeneic cells also obviates the use of immune cells from 
immunosuppressed cancer patients. The peripheral blood mononuclear cells of glioma 
patients has been documented to contain higher numbers of T regulatory cells [8]; as 
well, the CD4 to CD8 ratios of T cells are about 1:1 instead of 2:1 as it is in normal 
individuals [93]. 
Other immunotherapy approaches listed in Table 3.3 involving allogeneic 
cells employ whole tumour cell vaccines using allogeneic tumour cells with TGF-β 
Table 3.3. Immune Therapies Using Allogeneic Cells or Tissue
Site/Investigator Description Disease Study Phase-
Enroolment
References
City of Hope, 
Duarte, CA/ B 
Badie
Allogeneic T Cells 
modified with chimeric 
IL-13α2 -TCR ζ
Brain tumour I - 10 [97]
Penn State Univ, 
Hershey, PA/ K 
Lucas
Allogeneic, CMV 
specific CTL
Brain tumour I/
II - 10
[98]
UCLA, Los 
Angeles, CA/L 
Liau & C Kruse
Alloreactive CTL and 
IL-2
Brain tumour I - 15 [93, 99]
NovaRx, San 
Diego, CA/H 
Fakhrai
Allogeneic Tumour 
Cell Vaccine with TGF2 
knockdown
Non-small cell 
lung carcinoma 
and brain 
tumour
II -75 [100]
Baylor, Houston, 
TX/ J Fay
Autologous DC pulsed 
with Allogeneic 
Melanoma Tumour
Melanoma I/II - 33 Clinicaltrials.gov, 
NCT00313235
IDM Res Lab, 
Sanofi-Aventis, 
Paris, France/ M 
Salcedo
Autologous DC pulsed 
with Allogeneic 
Melanoma Tumour
Melanoma I/II - 15 [101]
Univ Pittsburgh, 
Pittsburgh, PA/ G 
Chatta
Autologous DC pulsed 
with Allogeneic 
Prostate Tumour
Prostate cancer I - 12 Clinicaltrials.gov, 
NCT00970203
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knockdown, or the use of autologous dendritic cells that are pulsed with antigens 
derived from allogeneic tumour cells. While the majority of clinical trials still remain in 
the Phase I or I/II arena, no phase III clinical trials have been completed at this time. The 
results from a handful of immunotherapy trials are finally being reported. A prominent 
example is DCVax®- Brain, an immunostimulant cancer vaccine, based on experimental 
autologous cellular therapy, produced by the American pharmaceutical company 
Northwest Biotherapeutics, Inc., which exhibits promising efficacy (www.clinicaltrials.
gov NCT00045968) [9]. DCVax-Brain vaccine is manufactured using a patient’s dendritic 
cells loaded with a tumour cell lysate prepared from surgically resected tumour tissue. 
The clinical data from a cohort of 141 newlydiagnosed glioblastoma patients treated in 
a Phase II study is still being collected, however, assessments from their Phase I trials 
suggest overall safety, with delayed time to disease recurrence and increased survival, 
especially in glioblastoma patients with stable disease at entry [see http://www.nwbio.
com/clinical_dcvax_ brain.php]. Indeed, for those patients treated in the Phase I trials, 
the company is reporting that the median survival is 33.8 months, with 9 of 19 patients 
still alive at 8-82 months from initial surgery. A multiinstitutional Phase II trial where 
82 patients were treated was supported by Pfizer Pharmaceutical company, Celldex 
Therapeutics [see http://www.celldextherapeutics.com/]. The trial is described at (www.
clinicaltrials.gov NCT00458601) and they report interim positive results from the Phase 
2b study. This involves a non-cell based vaccine using an EGFRviii peptide conjugate, CDX- 
110, given in conjunction with temozolomide [94, 95]. Newly diagnosed WHO Grade 
IV glioma patients were treated. The trial is still active for follow-up, but not currently 
recruiting patients. The company ImmunoCellular Therapeutics, Ltd (http://www.imuc.
com/) has supported a Phase I study using ICT- 107 for glioblastoma. This is a dendritic 
cell-based vaccine that targets multiple glioma associated antigens [44, 96]. In a June, 
2010 company report they say that the median overall survival had not yet been reached 
at the 26.4 months analysis point, with 12 out of 16 treated newly diagnosed patients 
alive (http://www.imuc.com /pdf/Brain-Cancer-Vaccine-Looks-Promising-in-Small-Trial-1.
pdf# zoom=100). Other clinical trials involving immunotherapy for brain gliomas can be 
found at www.clinicaltrials.gov by refining search terms using key words at that site. 
Conclusion 
To conclude, the results of the most recent clinical trials suggest that 
systemic immunotherapy using dendritic cells or peptide vaccines are capable of 
inducing an immune response in malignant glioma; increased patient survival has 
been reported, though no phase III clinical trials are completed to this time. Apart 
from better targeted radiotherapy and more fine tuned surgery, we will experience a 
gradual continuing increase of immunological insight that will enable novel intervention 
strategies. Successful vaccine approaches will likely result from the “golden” combination 
of antigen( s) and immunopotentiators [97-101]. 
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 Summary
The efficacy of immunotherapeutic TLR7/8 activation by resiquimod 
(R848) was evaluated in vivo, in the CNS-1 rat glioma model syngeneic to Lewis rats. The 
immune treatment was compared with cytotoxic cyclophosphamide chemotherapy, 
and as well, was compared with the combination of cytotoxic and immunotherapeutic 
treatments. We found that parenteral treatment with the TLR7/8 agonist, resiquimod, 
eventually induced complete tumour regression of CNS-1 glioblastoma tumours in Lewis 
rats. Cyclophosphamide (CY) treatment also resulted in dramatic CNS-1 remission, while 
the combined treatment showed similar antitumour effects. The resiquimod efficacy 
appeared not to be associated with direct injury to CNS-1 growth, while CY proved to 
exert tumouricidal cytotoxicity to the tumour cells. Rats that were cured by treatment 
with the innate immune response modifier resiquimod proved to be fully immune to 
secondary CNS-1 tumour rechallenge. They all remained tumour-free and survived. 
In contrast, rats that controlled CNS-1 tumour growth as a result of CY treatment did 
not develop immune memory, as demonstrated by their failure to reject a secondary 
CNS-1 tumour challenge; they showed a concomittant outgrowth of the primary 
tumour upon secondary tumour exposure. Rechallenge of rats that initially contained 
tumour growth by combination chemo-immunotherapy also failed to reject secondary 
tumour challenge, indicating that the cytotoxic effect of the CY likely extended to the 
endogenous memory immune cells as well as to the tumour. These data demonstrate 
strong therapeutic antitumour efficacy for the immune response modifier resiquimod 
leading to immunological memory, and suggest that CY treatment, although effective as 
chemotherapeutic agent, may be deleterious to maintenance of long-term antitumour 
immune memory. These data also highlight the importance of the sequence in which a 
multi-modal therapy is administered.
Keywords: TLR agonist, brain tumour, glioma, immunotherapy.
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 Introduction
Glioblastoma multiforme (GBM) is the most common malignant brain 
tumour in adult patients. Due to its highly infiltrative nature GBM is notoriously difficult 
to treat and complete surgical resection is difficult. GBM tumours are inevitably recurrent 
either locally, close to the original tumour, or at distant sites. Moreover, chemotherapy 
and/or radiotherapy have shown only limited success. As a result the overall prognosis 
for this tumour has changed little over the last two decades. Today the average survival 
time for a newly diagnosed patient is between 12 and 15 months and new forms of 
therapy are desperately needed to change the clinical course of this highly malignant 
tumour. GBM therefore requires additional forms of therapy to prolong the lifespan and 
quality of life of patients. Immunotherapy is now emerging as a novel fourth option for 
clinicians.
 Immunotherapy stimulates and teaches the patient’s immune system 
to recognize and eradicate malignant tumour cells. If successful it has the added 
advantage of generating a memory response to prevent tumour reoccurrences after 
cessation of treatment. Our immune system has evolved to protect our body by 
eliminating pathogens and abnormal cells with minimal damage to healthy tissues. It 
is complex and has multiple levels of regulation to guarantee the appropriate balance 
between immune activation and immune suppression. Over the last two decades the 
fundamentals of this regulation have become more clear. 
It has been amply shown that the immune system can prevent the 
emergence and growth of cancer. For example, an adaptive immune response influences 
the behavior of human colon cancer tumours as evidenced by in situ analysis of tumour-
infiltrating immune cells. [1,2] Also, in ovarian cancer the presence of intraepithelial 
tumour infiltrating lymphocytes is associated with prolonged clinical remission and 
improved survival. [3] Similar observations have been made for other tumours, such as 
renal carcinoma, [4] prostate cancer [5] and breast carcinoma. [6] These observations 
in patients are further supported by the observations in experimental systems that an 
impaired immune system is less able to protect the host against the development of 
spontaneous and chemically-induced tumours. [7-9] In addition, individuals with cancer 
sometimes develop spontaneous reactivity against the antigens of the tumour. [10] 
Hence, it can be concluded that tumours can be recognized and eliminated as a result 
of natural tumour-specific immune responses that develop in the host. 
The observations that the capacity to mount natural immune responses is 
linked to improved survival supports the concept to develop immune activating tumour 
vaccines, stand alone immune activators, or biological response modifiers. Presently, 
such strategies are tested in clinical trials for the treatment of different types of solid 
tumours, including glioblastoma, as recently reviewed by Hofman and coworkers. [11] 
To date, these approaches have provided only modest clinical results. Nevertheless, they 
have shown promise by successfully generating antigen specific effector T cells capable 
of reacting with the tumour, and significant survival advantage or improved quality of life 
in subgroups. Remarkably, effector immune cells may fail to produce tumour regression 
because newly triggered and successfully expanded tumour-specific lymphocytes are 
actively inhibited within the draining lymph nodes or upon entrance into the tumour. 
In recent years it has become well-established that many tumours, including GBM, use 
various mechanisms of immune suppression or evasion, including immunediting, and 
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the generation of T regulatory (Treg) and myeloid derived suppressor cells (MDSC). [12] 
These cells act to inhibit the beneficial effects of immune activation [13] 
by direct cell contact mechanisms or by secretion of inhibitory molecules, such as IL-10, 
and TGF-b. [14,15] As a result, the suppression of immunity in tumours may present 
a major challenge to clinicians interested in using tumour vaccines or other methods 
of immune activation to treat tumours at the time of diagnosis. Immunotherapy may 
be further complicated in situations where the immune system promotes tumour 
development by selecting for tumour escape variants with reduced immunogenicity. 
[16] 
Hence, successful immunotherapy for the treatment of solid tumours 
may require two entirely different steps: (1) the use of potent immune activators such 
as single immunostimulants or tumour vaccines comprising suitable adjuvants; and (2) 
reagents that can reverse immune suppression induced by the tumour. In the last two 
decades there has been a strong interest in using toll-like receptor (TLR) agonists as 
immunostimulants and adjuvants for therapeutic vaccines because of their stimulatory 
effects on innate immune responses which precedes the shaping of adaptive immune 
effector and memory cells. [17,18] TLRs are socalled pattern recognition receptors that 
are found on a variey of innate immune cells [17] and able to recognize pathogen-specific 
molecular patterns (PAMPS). They discriminate these PAMPS from invading pathogens 
as non-self molecules, which represent a signal for the receptor-expressing immune 
cells to become activated and produce pro-inflammatory cytokines and costimulatory 
molecules resulting in recruitment and activation of immune cells. 
The imidazoquinoline-based small molecules imiquimod and resiquimod 
are synthetic ligands that have been shown to activate human TLR 7 and 8, and TLR7 
in mice and rats. TLR8 is not functional in mice. These TLRs also recognize viral and 
synthetic single-stranded RNAs. The TLR7/8 agonist R837 (imiquimod) has been 
licensed as a key ingredient in Aldara cream for the topical treatment of genital warts, 
basal cell carcinoma and bladder cancer. [19,20] In mouse studies, imidazoquinolines 
were able to act as adjuvants promoting adaptive immune response to co-administered 
prophylactic antigens. [22,23] This observation is in line with the notion that single-
stranded RNA induces an antigen-specific immunity characterized by a potent cytotoxic 
T cell response. [24] 
However, very little is known about how systemically administered 
TLR7/8 agonists affect immune responses in general and anti-tumour immunity to glial 
brain tumours. Interestingly, Xiong and Ohlfest recently showed that topical imiquimod 
(Aldara) applied on the skin has therapeutic and immunomodulatory effects against 
intracranial tumours in a mouse model. [25] Weekly application increased survival of 
mice against implanted syngeneic GL261 glioma tumours. Resiquimod is related to 
imiquimod, as they are both synthetic small molecules that activate Toll-like receptor 
(TLR) 7. [26]
 In the present study, we investigated the anti-tumour immune effects of 
parenterally injected resiquimod (R848) in a CNS-1 glioma model in immunocompetent 
Lewis rats. This model represents a valuable in vivo system for preclinical studies 
because of histopathological and pathological features which highly resemble human 
GBM. [27] Our results show that TLR7/8 agonist resiquimod (R848) affects immune 
responses leading to growth arrest of large established glioma tumours, and that R848 
treatment, at the concentrations used, does not inhibit CNS-1 tumour growth directly. 
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Remarkably TLR7/8 activation by R848, as a therapeutic stand-alone therapy, is able 
to reject smaller established CNS-1 tumours, leading to solid, immunological memory 
against tumour rechallenge. Hence, this TLR7/8 activation approach provides a new 
opportunity for rational therapeutic immune interventions based on strengthened 
anti-tumour immune responses that may translate into successful clinical outcome in 
patients affected by glioblastoma.
 Results
Therapeutic adminstration of the TLR7 immunostimulant resiquimod 
arrests growth of large (35-day old) CNS-1 tumours. We sought to determine 
immunotherapeutic strategies for controlling the malignant growth of syngeneic CNS-
1 glioma tumour cells in Lewis rats using the newly described small molecule TLR7/8 
agonist resiquimod, also referred to as R848. 
To examine whether immunocompetent Lewis rats, which had developed 
large syngeneic CNS-1 tumours, would benefit from R848 treatment (100 µg/kg, 30µg/
dose), we started to treat established, large five week-old, 10- 20,000 mm3, CNS-1 
tumours, at 38 days after tumour implantation. Indeed, resiquimod treatment was 
able to arrest or slow tumour growth in 2/3 animals, as shown in Figure 4.1, however, 
complete regression of these large tumours was not noted within the observation 
period. 
We next decided to investigate the antitumour activity of resiquimod 
against lower tumour burden in rats with less advanced CNS-1 tumours. In a subsequent 
pilot dose-finding experiment we noticed a dose-dependent inhibition of CNS-1 tumour 
growth, when treatment was started earlier at day 10 after tumour implantation. 
Injection of a low dose of immunostimulatory resiquimod (3.3 µg/kg = 1 mg/dose) 
did not inhibit CNS-1 tumour growth, while a higher dose of either 10 or 50 µg/dose, 
representing 33.3 and 166.6 µg/kg respectively, clearly evoked reduction in tumour 
growth (data not shown). We therefore decided to test robustness of this protective 
Figure 4.1. Indication of inhibition of established large CNS-1 tumours in Lewis rats (n = 3) trea-
ted with resiquimod starting at day 38. Individual growth as a function of time after implanation is 
shown for each individual animal. The arrow indicates the start of resiquimod treatment.
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treatment in a larger experiment. Figure 4.2A shows that administration of R848, at 
a dose of 100 mg/kg (this is about 30 µg/ dose), when given three times per week 
(Monday, Wednesday and Friday) profoundly reduces tumour growth, relative to a 
control group receiving no treatment (p < 0.001) . We stopped the therapeutic weekly 
treatment regimen after day 42 (week 6) and further continued to monitor tumour 
Figure 4.2. Therapeutic administration of TLR7/8 agonist resiquimod strongly inhibits tumour 
growth. CNS-1 tumour development after implantation in groups of rats (n = 8) treated with 
either resiquimod (A), Cyclophosphamide (B) or a combination of resiquimod and cyclophosp-
hamide (C). Individual growth as a function of time is shown. The stippled lines show individual 
tumour growth of untreated controls.
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growth. 
Therapeutic administration of high dose cyclophosphamide alone or in 
combination chemo-immunotherapy of CY with resiquimod protects against CNS-1 
tumour growth. We next examined whether resiquimod immunotherapy combined 
with chemotherapy further improves anti-tumour immunity. Hence, in a parallel 
arm of the same animal experiment we investigated the therapeutic efficacy of the 
cytotoxic alkylating agent cyclophosphamide (CY), given once every two weeks, which 
is a well-know direct cytostatic antitumour agent, but has also been shown to mediate 
immune suppression or even tumour regression by abrogation of immunosuppressive 
Figure 4.3. CNS-1 cells (200,000 cells per well) were exposed for 24 hours to increasing con-
centrations per well of either resiquimod (A), or CY (B-. Viability was measured (in triplicate) in 
a standard (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assay, and was 
expressed as a percentage of viability measured for cells cultured in medium only (control). Re-
presentative data of two experiments are shown.
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T regulatory cell function. [28] In addition, we tested the combined treatment of CY 
plus R848 to investigate beneficial synergy of CY with active immunotherapy, as a 
chemo-immunotherapy variant. [29,30] Figure 4.2 shows that inhibition of CNS-1 
glioma tumour growth was observed for a group which received CY alone (Fig. 2B) or 
resiquimod in conjunction with CY at a 100 mg/kg dose (Fig. 2C; p < 0.001). The combined 
administration of CY and R848 seemed to further inhibit tumour development as noted 
by earlier tumour regression. Poly I:C injected in a similar regimen, at a dose of 30 or 50 
µg, did not inhibit CNS-1 growth (data not shown). A lower dose of 30 mg/kg of CY alone 
also failed to inhibit tumour growth. 
TLR7 agonist does not directly inhibit CNS-1 tumour growth. To examine 
whether parenterally injected resiquimod may have been able to directly affect CNS-
1 tumour growth we tested the cytotoxicity of resiquimod in vitro, in parallel to 
cyclophosphamide and poly I:C, a prototype TLR3 agonist. Figure 4.3 shows a direct 
cytotoxicicty of cyclophosphamide when used at high dose, and no apparent direct 
growth inhibition by resiquimod, at concentrations reflecting the in vivo dose. The 
effective concentration of resiquimod of 30 µg/dose used in vivo is not directly cytotoxic 
in vitro and is therefore very unlikely to evoke direct contralateral tumour killing, while 
the in vivo concentration of 100 mg/kg (30 mg/dose) is clearly cytotoxic for CNS-1 cells 
cultured in vitro (200,000 cells /well). 
CNS-1 glioma cells do not express TLR 7/8. We checked expression 
of TLR7 and TLR8 by CNS-1 cells using RT-PCR, but where unable to detect receptor 
expression, while expression of both receptors could be detected in rat spleen tissue 
(Fig. 4).
Glioma tumours cured by resiquimod therapy alone evoke 
immunological memory when rechallenged with syngeneic CNS-1 tumour. To examine 
whether immunocompetent Lewis rats, which had rejected CNS-1 cells as a result of 
resiquimod treatment, had developed immunological memory against CNS-1 tumour 
cells, they were re-challenged at day 49 after the first tumour implantation (one week 
after treatment arrest and wash out of R848) using a tumour dose of CNS-1 which 
evoked tumour growth in naive age-matched control rats. 
As shown in Figure 4.5 all recipients of R848 therapy which had eliminated 
the first CNS-1 tumours, completely rejected the secondary CNS-1 challenge, with no 
evidence of measurable secondary tumour growth (Fig. 5B, p < 0.01), while the same 
dose of CNS-1 tumour cells induced reproducible tumour development in all untreated 
Figure 4.4. Lack of detection of TLR 7 and TLR 8 expression in both rat glioma CNS-1 cells and 
murine glioma GL261 cells. However, in rat spleen tissue, used as positive control, expression of 
both TLR7 and TLR8 can be detected.
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Figure 4.5. Individual CNS-1 tumour development as a function of time after secondary tumour 
implantation (A-D) in groups of rats (n = 8) treated either with Resiquimod alone (B), Cyclop-
hosphamide alone (C) or a combination of Resiquimod and cyclophosphamide (D). The CNS-1 
implanted, untreated age-matched group is shown in A (n = 4). Mean tumour growth of group A 
is shown as a stippled line for the untreated control group in B, C and D. Panels E, F and G show 
the growth of the recurrent individual primary CNS-1 tumours at the original inoculation site, for 
the resiquimod treated (E), Cyclophosphamide treated (F) and combination group (G) at the days 
post primary tumour challenge.
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age-matched Lewis rats (Fig. 5A). This observation was confirmed in a subsequent 
experiment as evidenced by a complete rejection of a secondary tumour challenge, 
after cessation of treatment for a period of three months, in a group of four R848 
treated Lewis rats, which had rejected the first CNS-1 tumour. Again this additional 
tumour challenge evoked progressive tumour growth in naive age-matched controls. 
Glioma tumours controlled by treatment with CY alone or by CY-resiquimod 
combination therapy fail to evoke immunological memory against rechallenge with 
syngeneic CNS-1 tumour. 
Lewis rats that had initially rejected CNS-1 cells as a result of CY treatment 
alone, or after CY-R848 combination treatment, were tested for immunological memory 
against CNS-1 tumour cells, by a re-challenge at day 49 after the first tumour implantation. 
Upon secondary tumour challenge both, the CY only treated, as well as the CY-R848 
combination treated hosts, did displayed an initial inhibition of secondary tumour 
development (Fig. 5C and D, p < 0.01 and < 0.05, respectively), but eventually progressive 
CNS-1 growth was noted in most animals, This indicated a deleterious effect of the CY 
on the endogenous immune cell component that was initially engendered, sensitized 
to and keeping the CNS-1 tumour cell growth suppressed. Further substantiating this 
conclusion, the CY-treated rats, alone as well as in combination therapy, also showed a 
recurrence of their primary tumour, which apparently was not completely resolved (Fig. 
5F and G, respectively). In both groups, seven out of eight animals showed progressive 
tumour growth. 
Safety. In our studies we did not observe any signs of toxicity in rats 
treated with the systemic resiquimod.
 Discussion
In the present study we demonstrate that immunotherapy based on 
the innate immune cell activator resiquimod, is effective as a treatment modality for 
eradication of established CNS-1 glioma tumours. 
Our CNS-1 glioma cell implants are syngeneic, haplotype RT-1l, for Lewis 
rats and represent an excellent in vivo glioma model, because of its glial phenotype, 
reproducible in vivo growth rates and histological features that closely resemble human 
glioma. [31] It has been demonstrated that CNS-1 tumour cells are immunoreactive for 
glial fibrillary acidic protein (GFAP), S100 and vimentin, as well as neuronal adhesion 
molecule, retinoic acid receptor α, intracellular adhesion molecule and neuron specific 
enolase. [31] This model therefore provides an excellent in vivo model in which to 
investigate immunotherapeutic intervention strategies against glioblastoma multiforme 
in immunocompetent hosts.
Natural immune responses against glioma tumours are often elicited 
as demonstrated by histological evidence of local inflammation and tumour-specific 
lymphocytes, likely directed against tumour specific antigens. However, the GBM tumour 
microenvironment is characterized by the presence of a variety of immunosuppressive 
cells and their inhibitory products, which may eventually result in the escape of the 
tumour from immune surveillance. [32-35] However, when an effective therapeutic 
dose of resiquimod was injected three times per week, we observed a dramatic 
reduction in tumour volume. While most untreated or control tumour-bearing animals 
had to be sacrificied, either due to massive tumour volumes or due to ulceration of 
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the tumour, the groups receiving a dose of more than 10 mg resiquimod per injection 
eventually showed complete regression of the tumour volumes. When therapeutic 
treatment was arrested, at day 49 after implantation, the tumour had shrunk to minute 
or nonmeasurable sizes. In vitro studies revealed that resiquimod (0.01 or 0.1 mg/ml), 
in contrast to CY, did not directly inhibit CNS-1 tumour cell growth. 
These results may seem contradictory with other data showing that 
when tumour cells express TLR7/8, activation of this TLR type leads to cell survival and 
chemo resistance. [36] We have therefore checked expression of TLR7/8 by CNS-1 cells 
by RTPCR, but where unable to detect receptor expression by PCR. However, even if 
TLR7/8 activation by resiquimod would have stimulated tumour growth the net effect 
in vivo would apparently still be tumour regression. 
Interestingly, all rats proved immune to re-challenge with CNS-1 glioma 
cells (Fig. 5) as evidenced by complete inhibition of tumour development. Immune 
memory against rechallenge was confirmed for rats which received the additional 
tumour inoculation even after three months of treatment arrest, while naive rats 
developed tumours. In view of the short half-life of the imiquimod family members 
of only few hours it is very unlikely that resiquimod had some remnant activity after 
a three month resting period before administration of a tumour rechallenge. The 
complete inhibition of secondary tumour growth suggest that immunotherapeutic 
treatment during the first tumour growth, using resiquimod, a known innate immune 
response agonist activating TLR7/8, results in tumour regression that results in the 
development of T cells with immune memory. Hence this innate immune triggering 
acts as an in situ therapeutic vaccine, alerting the adaptive immune system to recognize 
and eliminate the syngeneic secondary CNS-1 brain tumour. In future studies we will set 
out to decipher the exact mechanism underlying this intriguing observation of in situ 
immune memory priming. 
In addition, we evaluated the effects of CY on CNS-1 tumour development. 
Cyclophosphamide (CY), although primarily used as cytotoxic therapy and expected 
to suppress the immune system, has been shown to abrogate immunosuppressive T 
reg function, and beneficially synergize with active immunotherapy when used at an 
appropriate dose and timed correctly. [29,37,38] 
CNS-1 tumours regressed, as a result of CY treatment, and even faster 
after combined CY-R848 chemo-immunotherapeutic treatment. Importantly, the 
administration of CY, after the animals had developed immunity to CNS-1, was deleterious 
(Fig. 4). The explanation for why, after tumour rechallenge, the animals that were treated 
with CY only or by the CY-R848 combination were not able to inhibit secondary tumour 
development relates to the CY also causing damage to the CTL that had developed 
in situ at the beginning of the treatment. Additionally, it provides an explanation for 
why the CY-treated rats also exhibited recurrence of the primary tumour. These data 
highlight the need to carefully arrange the administration of combined therapeutics 
involving cytotoxic chemotherapeutic agents with immunotherapeutic agents so one 
agent does not interfere with the effects derived from the other. However, the delay in 
tumour growth after rechallenge of the cyclophosphamide group, suggests that there 
is an immune effect, which is most likely dependent on T cells, although a memory 
response by B cells cannot be excluded formally. In both senarios T cells are necessary 
for T help and likely also for T cell effector function. The effect of T cell depletion will be 
subject of follow-up studies addressing the biological mechanism of action responsible 
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for rechallenge immunity. 
These results provoke two intriguing questions. How does R848 eradicate 
CNS-1 tumours, and how does immune memory develop during this treatment? In 
addition, it is of interest to know how CY hampers antitumour immunity. The exact 
mode of action and associated immune pathway responsible for the observed 
resiquimod-mediated anti-tumour immunity needs to be defined in detailed follow-up 
studies. Most likely resiquimodbased immunotherapy is able to activate a spontaneous, 
natural, innate anti-tumour immune response, that under normal circumstances is 
unable to control tumour growth, likely as a result of delayed or actively suppressed 
immune control. Non-specific immune attack of the tumour evoked by TLR7/8 activating 
resiquimod, but not by poly I:C treatment activating TLR3 (data not shown), may release 
tumour antigens into the surrounding tumour environment which are sampled by 
locally attracted antigen presenting cells and which allow presentation to and priming 
of adaptive immune lymphocytes, in the draining lymph nodes. Alternatively, or in 
parallel, an in situ “vaccination” occurs as a result of R848 therapy. TLR7 activation by 
the related imiquimod causes human and rodent dendritic cells to become tumouricidal.
[39] Eventually, a sufficient number of tumour-specific naive adaptive immune cells, 
such as cytolytic T cells, are triggered and expanded in draining lymph nodes as a result 
of parenteral R848 immunotherapy and enabled by activated antigen-presenting cells. 
These presumed cytolytic T cells selectively recognize and eliminate the tumour and 
provide immunological memory, as illustrated by the rejection of secondary tumour 
cell implants. However, dedicated follow-up studies need to address to involvement of 
anti-tumour killer macrophages or NK cells, or IFNs for the resiquimod-induced glioma 
growth regression and immune memory. 
In conclusion, our data show that injection of the innate immune cell 
receptor agonist resiquimod as a therapeutic TLR7/8 activating stand-alone therapy, 
is able to cure established CNS-1 tumour growth in Lewis rats. They suggest that 
immunotherapeutic parenteral treatment of established glioma tumours by resiquimod, 
as defined in the protocol, significantly improves anti-brain tumour immunity in a way 
that leads to immune memory, which is superior to CY treatment alone. Our studies 
have thereby identified a promising novel antitumour immunotherapy which may lead 
to clinical benefit. 
 Materials and Methods
Tumour Model. Rat CNS-1 cells (2 x 105 cells/200 ul) were implanted 
subcutaneously (SC) using a 21 gauge needle into the right flank of 8–12 week-old 
(300 g body weight) male Lewis rats. For each treatment group and control, 4–8 rats/
group were used. The same tumour implantation procedure was performed during 
re-challenge experiments, on the contralateral side, for rats which had controlled the 
tumour growth after first exposure. All animal studies were approved by an independent 
ethical committee. 
Monitoring Tumour Growth. The sizes of the CNS-1 tumour volumes 
were measured using a caliper three times per week on Mondays, Wednesdays and 
Fridays to monitor the effects of each treatment group. 
Completion of Experiment. Tumour implanted rats were sacrificed if 
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they showed unfavorable signs of discomfort, as defined by the ethical committee. 
For example if they appeared moribund due to weight loss, lethargy, ruffled fur, or 
when tumours showed ulceration. A mixture of Rompun and ketamine was used for 
anesthesia, followed by a dose of sodium pentobarbital for euthansia. 
Chemicals and reagents. 
Immunomodulators and potentiators. Rats were subcutaneously (SC) 
injected in the flank, contralateral to the tumour-implanted side, with resiquimod 
(R848) (purchased from Invivogen, catalog number tlrl-r848), a Toll-like receptor 7/8 
agonist, in a range of 3.3–166.6 µg/kg, corresponding to 1–50 µg/dose, three times 
per week on Mondays, Wednesdays and Fridays. Resiquimod(R-848, S-28463) was 
shown to be more soluble and more potent in inducing cytokine expression than its 
family member imiquimod which has a half-life of 2–3 h in humans [40].
In a parallel arm of the experiment we evaluated the effect of 
cyclophosphamide administration on CNS-1 glioma development. Cyclophosphamide 
(CalBiochem, cat. no. 239785) was given at 30–100mg/kg. CY was injected once every 
two weeks on Fridays. 
Cytotoxicity Assay. The direct cytotoxicity of resiquimod, CY and Poly I:C 
(Invivogen, cat. no. Tlrl-pic, tlrl-pic-5), which was included as a reference TLR-3 agonist, 
was determined by exposing CNS-1 cells at a concentration of 10,000 cells per well in a 
96-well plate in DMEM culture medium (cat. no. 30–2002, ATCC), supplemented with 
10% fetal bovine serum (FBS; Lonza, cat. no. DE14–801E), for 24 h. The viability of CNS-1 
cells, measured in triplicate, was measured in a standard (3-(4,5- Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT) bromide assay, absorbance was read at 590 nm, and was 
expressed as a percentage of viability measured for cells cultured in medium only. 
TLR 7 and TLR 8 detection by RT-PCR. 
Samples collection. Normal spleen tissue was obtained by surgical 
resection from a male non-treated Lewis rat and cut in pieces of 1 mm3 with a sterile 
surgical blade. CNS-1 and GL-261 cell lines were cultured as described above and a 
pellet of 1 x 106 cells was used. Cells or tissue sample were put in lysis buffer using the 
SV Total RNA Isolation System (Promega Corp., Leiden, The Netherlands). 
RNA extraction and reverse transcription. After extraction of total RNA it 
was reverse-transcribed by using the Thermoscript RTPCR System (Life Technologies, 
Inc., Paisley, UK) as previously described [41]. 
Oligonucleotide primers used for PCR amplification: Primers for the PCR 
amplification were obtained by Real Time Primers LLC, PA, USA, according to successful 
approach for TLR-7, [42] or as customized primers for TLR-8 obtained from Real Time 
Primers LLC, PA, USA. 
PCR. PCR was performed according to the manufacturer’s 
recommendations, with Platinum® PCR SuperMix (Life Technologies, Inc., Paisley, UK). 
Aliquots of the RT products were subjected to PCR in a total volume of 50 µl, with 
100 nM adequate paired primers. PCR products were visualized on a 2% agarose gel 
with GelRedTM Nucleic Acid Gel Prestaining Kit (Biotium, CA, USA), visualized on an 
UV transilluminator and photographed using a Canon Powershot G10 photograph, 
equipped with a conversion lens 032 LA-DC58K. 
Statistical analysis. ANOVA followed by the students t-test was used to 
compare groups, with a p value of < 0.05 (*), p < 0.01 (**), p < 0.001 (***), considered 
statistically significant. 
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 Summary 
In the present study we investigated whether allogeneic glioma cells 
can be utilized to evoke prophylactic or therapeutic immune-mediated elimination of 
syngeneic glioma in two rat strains. Fisher 344 and Sprague—Dawley (SD) rats were 
injected with two syngeneic glioma cell lines, 9L and C6, respectively, resulting in 
progressive tumour growth. 9L is syngeneic to the Fisher 344 and allogeneic to the SD 
rats, while C6 cells are syngeneic to SD rats and allogeneic to Fisher 344 rats. Both rat 
strains were subcutaneously injected with their respective allogeneic tumour cells, 
which proved unable to grow progressively. The allogeneic cells were either rejected 
immediately in SD rats or within 25 days in Fisher rats, after limited tumour outgrowth. 
Both rat strains were subsequently challenged with their respective syngeneic glioma 
tumour cells and once more 10 days later with a fivefold higher dose. SD rats, even after 
reinjection with five times the original dosage of C6 cells, remained tumour free for at 
least 360 days. Similarly, Fisher rats, after initially rejecting allogeneic tumours, failed to 
develop syngeneic tumours.
To determine anti-tumour immunity against established glioma tumours 
under more demanding therapeutic conditions, rats were first injected subcutaneously 
with their respective syngeneic tumour and vaccinated once or repeatedly (at 5-day 
intervals) with a mixture of the allogeneic or xenogeneic cells, with or without a lysate 
from the same syngeneic tumour, which served as a therapeutic vaccine preparations. 
The control group received either no treatment or syngeneic instead of allogeneic cells. 
In both strains of rats, we demonstrated that the therapeutically vaccinated groups 
were able to significantly reduce tumour growth, while complete rejection of tumours 
was noted in the SD rats. Immunization with syngeneic tumour cells alone failed to 
evoke anti-tumour immunity.
We conclude that therapeutic immunization with a combination of 
allogeneic cells and syngeneic lysates induces rejection of malignant gliomas and offers 
a protective effect against challenge with syngeneic tumour cells. This immunization 
approach may prove useful as a post-surgery adjuvant therapy in future cancer 
treatment protocols, or even as a stand-alone therapeutic tumour vaccination.
Keywords: Immunomodulation; GBM; Rejection; Therapeutic vaccine; 
Tumour.
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 Introduction
In the United States alone over 18,000 primary brain tumours are 
estimated to occur each year. Of these 18,000, over 60% are diagnosed gliomas. 
Glioblastoma multiforme (GBM) is the most common and malignant of all gliomas, with 
75% of patients dying within 18 months of diagnosis [1]. The prognosis for this tumour 
is very poor. The median survival time of untreated tumours is 3 months, with death 
most commonly due to cerebral edema or increased intracranial pressure. Even with 
the best available current therapy, which includes radiation, chemotherapy and surgery, 
the median survival does not extend beyond 14 months. These tumours are inevitably 
recurrent either locally, usually within 2 cm of the original tumour, or at distant sites. 
Treatment of these recurrent lesions by a second surgery and further chemotherapy 
may increase the symptom free interval, but the 5-year survival remains 10% [1—3].
It has been shown that the progression of certain cancers is associated 
with the expression of tumour-specific antigens and tumour antigen-specific immune 
responses [4]. Hence, theoretically, effective tumour rejection and immunity can 
be achieved by vaccination with tumour-associated antigen, the holy grail in tumour 
immunology. However, active immunotherapy for cancer has shown minimal clinical 
success. It has been clear that even with a fully functioning immune system, it is 
possible for tumours to evade recognition through the use of elusive escape strategies 
[5]. Although poorly understood, several mechanisms of tumour escape have been 
identified. For example, a change of or loss of MHC class I receptors is associated with 
the genesis of various tumours, while the presence of intact MHC class I molecules 
has been shown to participate in cancer resistance [6]. Other mechanisms include 
unresponsiveness to interferons [5], as well as tumour-induced immunosuppression 
as a result priming for and influx of inhibitory regulatory T cells [7] and associated 
induction of immunosuppressive molecules including IL-10, CTLA-4 and related factors.
On the other hand, there is increasing evidence that the immune 
system can be engaged to combat cancer. This is supported by the observations that a 
deregulated immune system hampers rejection of cancer, while spontaneous rejection 
or inhibition of malignant tumours is associated with a well-functioning immune system 
[8,9]. A recent study in colorectal tumour patients demonstrated that adaptive Th- 1 
immune gene expression and high immune cell densities of CD3, CD8 and CD45RO cells 
in tumour regions correlates positively with patient survival [10]. Interestingly, it has 
also been suggested that autoimmune diseases may contribute to a better prognosis 
in patients with malignant tumours [11,8]. In these patients, the majority of the IgG 
specificities identified share considerable homology with both human and microbial 
peptides [12]. This has lead to the hypothesis that molecular mimicry may initiate the 
observed anti-tumour autoimmunity. Studies related to this have shown long-term 
remission of malignant brain tumours after intracranial infection in four patients [13], 
and improved survival of cancer patients with microbial infection [14,15]. This brings 
into question whether molecular mimicry-induced ‘‘autoimmunity’’ can be employed 
to treat tumours. Importantly, significant homology has been shown to exist between 
human proteins and proteins from other species [16]. Moreover, use of artificial 
pathogen invasion signals, such as CpG motifs, or other innate immunity agonists, 
initiates and augments antigen-specific immune reactions [17], and may break tolerance 
to self-tumour antigens, mimicking microbial infections during immunotherapy or 
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vaccination [18,19]. Alternatively, xenogeneic antigen from endothelial cells is able to 
break immune tolerance against autologous angiogeneic endothelial cells [14]. This 
suggests that self-tolerance to tumours may be broken by cross-reactivity against a 
homologous foreign antigen.
In the present study, we combine the principles of immune-based 
allorecognition and administration of syngeneic tumour antigen to overcome tolerance 
to selftumour- associated antigens and to develop a novel approach to the treatment 
of tumours. It is well known that genetically identical individuals can accept tissue from 
one another, while tissue transplanted into heterozygous individuals will produce an 
immune response and eventual tissue rejection. Recognition of intact, same-species, 
nonself major histocompatibility molecules, on the surface of donor cells results in 
direct, immune-mediated elimination, is referred to as acute allograft rejection [20,21]. 
Indirect allorecognition results from recognition of donor histocompatibility molecules 
that are internalized, processed, and presented by self-MHC molecules on host antigen 
presenting cells. After xenotransplantation, tissues or cells are transferred across 
species, which causes even faster rejection by processes analogous to those seen in 
allografts. Hence, identical twins and genetically close family members are less likely to 
reject transplanted tissue since they have similar HLA loci [22]. This is based on the fact 
that the MHC class I genes are expressed co-dominantly, and in most cases are inherited 
in intact form without recombination [23]. Therefore, homozygous, syngeneic rats could 
theoretically accept a brain tumour from a homozygous donor. However, more critically, 
they would reject a brain tumour from a heterozygous donor based on direct or indirect 
allo-immune rejection [20,21]. MHC class I molecules play an important role in the 
immune surveillance of tumours by monitoring of mitochondrial DNA integrity. One of 
the roles of MHC I molecules is to eliminate cells carrying mitochondrial mutations [6]. 
Human glioma cells carry multiple mutations in both the mitochondrial DNA and in the 
mitochondrial complex [24]. Hence, gliomas of the same histological type/grade are 
likely to carry similar mutations in their DNA and have similar abnormal surface proteins 
associated with both MHC class I molecules and the cell membrane. Experimental data 
suggests that not only MHC class I molecules are involved in immune surveillance 
against cancer, but also that the altered phenotype of the MHC class I molecule is linked 
to a variety of different tumours. Therefore, if two heterozygous individuals develop a 
tumour of a similar type and histological grade, then transplantation of tumour tissue 
from one individual to another will not only induce rejection of the transplanted tissue, 
but may also prime the immune system to peptides shared between these tumours and 
other tumours sharing similar peptides.
In this paper we show in vivo proof of principle experiments demonstrating 
that allogeneic tumours can be used to vaccinate against an established syngeneic 
tumour, resulting in inhibition of tumour growth or complete tumour elimination. 
Application of this technique in human patients may not only lead to eventual rejection 
of the primary tumour, but may also lead to a lasting immunologic memory, preventing 
the patient from developing tumour recurrence. 
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 Materials and methods
Cell lines and cell culture 
The cell lines used in this experiment were the rat glioma cell lines 
(9L, C6, RG2), and the human glioma cell lines (U87, LN229). All lines were obtained 
from the American Type Tissue Collection (ATTC), and grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (GIBCO, Grand Island, NY) supplemented with 10% heat-killed 
fetal calf serum (FCS), 5% penicillin—streptomycin, and Hepes buffer in a humidified 
incubator at 37 ◦C in a 5% CO2 atmosphere.
Cell lysate antigen preparation
1.0×106 cells were placed in a 5-ml tube in culture medium and centrifuged 
for 5 min at 2.5×103 rpm. The supernatant was discarded and 150 l of sterile distilled 
water was added to the tube. The cell/water solution was mixed well and transferred 
to a 1.0-ml Eppendorf tube and centrifuged at 1.0×104 rpm for 10 min. The supernatant 
was not discarded and this preparation was used for cell lysate injections.
In vivo studies
All animal protocols were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Southern California. All rats were 
maintained in a specific pathogen free (SPF) environment. For the experiment, we used 
Sprague—Dawley (SD) and Fisher 344 rats. All rats were males and between the ages 
of 4—6 weeks. Rats were obtained from Harlan (Indianapolis, IN). In the subcutaneous 
tumour model, C6 and 9L were collected using only DMEM to wash them from the 
tissue culture flasks. Syringes were then prepared containing 100,000—150,000 cells 
suspended in 150μl.
Sprague—Dawley rats were divided into two major groups (Table 5.1). 
SD-A (three rats) were injected with the 9L allogeneic cell line, while SD-B (nine rats) 
were implanted with the C6 glioma, a syngeneic like glioma cell line for SD rats. SD-A 
rats, which never formed tumours, were tested for immune memory by challenging 
them with syngeneic C6 cells (100,000 cells). They were re-challenged with 500,000 C6 
cells 10 days later, and checked for formation of a flank tumour.
Once a palpable flank tumour developed in the SD-B rats, they were 
further divided into two groups. The control group (SD-B1; n = 5 rats) received no 
injections. In the therapeutic treatment group (SD-B2; n = 4) rats were injected with 
a combination of allogeneic 9L cells, allogeneic 9L lysate, and syngeneic C6 lysate. On 
day 27, four of the five SD-B1 were sacrificed. At this time, one of the control rats, rat 
number (#) 9, started receiving the same treatment protocol as SD-B2 rats.
Fisher rats were also divided into two major groups (Table 5.2). The 
control group (Fisher-A; three rats) were injected with the allogeneic C6 cell line. They 
initially formed tumours that were subsequently rejected. They were tested for immune 
memory by challenging them after 40 days with 100,000 syngeneic 9L cells followed by 
a rechallenge 10 days later with 500,00 cells and checked for tumour growth.
In the therapeutic group (Fisher-B; n = 8), rats were first implanted with 
the syngeneic 9L cell line. Once a palpable flank tumour developed in the Fisher-B rats, 
they were further subdivided into three subgroups. Fisher control group (n = 3) rats 
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received injections of syngeneic 9L cells, syngeneic RG2 (rat glioma) cells, or medium 
only (Fisher B1). One Fisher treatment group (n = 5) rats received a combination of 
allogeneic C6 cells only or allogeneic C6 cells and lysate (Fisher B2), or xenogeneic 
human glioblastoma cell lines U87 and LN229 cells (Fisher B3) (Table 5.2).
Tumour growth analysis
All tumours were detected and confirmed through visual inspection and 
palpation. Once discovered, the area around the tumour was further exposed by careful 
shaving with an electric razor. At the time of injection, tumour size was measured in 
millimeters using Vernier calipers. Measurements were taken in the cranial/caudal 
(length), superior/inferior (height), and medial/lateral (width) direction. Tumour 
volume was calculated by length×width×height×0.5. The mean tumour volume for each 
treatment group was calcu lated. For SD rats the tumour volumes of the treatment 
groups were compared to relevant control groups at 27 days postinjection, and for 
Fisher rats at 35 days, using the Student’s t-test calculation as described before [25]. 
Differences were considered significant if a p value was <0.05.
Harvesting subcutaneous tumour tissue for immunohistochemistry
All experimental animals were euthanized with an overdose of 
pentobarbital. Tumours were removed and dissected under sterile conditions, cut into 
four pieces and stored at −80 ◦C. All tumour sections were cut at 7 μm and stained by 
immunohistochemistry as described before [26]. Briefly, tumour samples taken from the 
Fisher 344 rats were frozen in optimum temperature compound (OTC) and cut into 7 μm 
sections on a cryostat. These sections were dried, fixed with acetone, and washed well 
with PBS for 1—2 min. Blocking was done using the immune serum from the species 
Table 5.1. Experimental design of animal studies in Sprague—Dawley rats
Immunization Vaccine Group 
size
Tumour 
challenge
Outcome
Prophylactic 
(group A)
Allogeneic 9L cells 
(100,000 cells)
n = 3 Syngeneic C6 
(100,000 cells) at 
20 days after 9L 
‘‘immunization’’ 
and C6 500,000 
cells, again 10 
days later
Immediate, 
complete 
allogeneic 9L 
and subsequent 
syngeneic C6 
tumour rejection
Therapeutic 
(group B2)
Allogeneic 9L cell lysates 
(50,000 cells), syngeneic 
C6 cell lysates (50,000 
cells), and 9L allogeneic 
cells (50,000 cells). Rats 
#5—8 and later #9
n = 4—5 
(rat #9)
C 6 (100,000 cells) Complete C6 
tumour rejection
Control group 
(group B1)
Saline or no injections 
rats #1—4 and initially 
#9
n = 5—4 
(rat #9)
C 6 (100,000 cells) Progressive C6 
tumour growth
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the secondary antibody was obtained from. Slides were washed thoroughly again and 
then stained with primary antibody against either CD4, CD57 (Nora Castro Lab Ltd., 
Burlingame, CA), CD8, dendritic reticulum cells (DRC) (Dako Corporation, Carpenteria, 
CA), CD20, or CD68 (Ventana, Tucson, AZ). Slides were washed again and a secondary 
biotinylated antibody was added. They were rinsed again and placed in a solution of 3% 
hydrogen peroxidase and nine parts 1% sodium azide in PBS. Slides were then rinsed 
and ABC was added for 30—40 min. They were washed with PBS and developed using 
diaminobezidine tetrahydrochloride and counterstained. Photographs of all slides were 
taken by light microscopy.
Table 5.2. Experimental design of animal studies in Fisher rats
Immunization Vaccine Group 
size
Tumour 
challenge
Outcome
Prophylactic 
(group A)
Allogeneic Allogeneic C6 cells 
(100,000 cells)
n = 3 Syngeneic 9L 
(100,000) cells at 
40 days after C6 
‘‘immunization’’, 
and 500,000 9L 
cells, again 10 
days later
Minimal 
9L tumour 
outgrowth 
and ultimate 
rejection
Therapeutic 
(group B1) 
‘‘control group’’
Syngeneic 
or medium
100,000 cells 
RG2 cells (rat #1), 
100,000 cells 9L cells 
(rat #2) or medium 
only (rat #3)
n = 3 Syngeneic 9L 
(100,000) cells 
Non-reduced 
tumour growth
Therapeutic 
(group B2)
Allogeneic 
cells/
lysates 
and/or 
syngeneic 
lysates
Mixture of (150,000) 
C6 allogeneic cells 
(rat #4) and C6 
(100,000) allogeneic 
cells plus allogeneic 
lysate (100,000 
cells) (rat #5). And 
syngeneic 9L cell 
lysate (100,000 cells) 
(rat #8)
n = 3 Syngeneic 9L 
(100,000) cells
Reduced 
9L tumour 
outgrowth, 
except for 
rat #8
Therapeutic 
(group B3)
Xenogeneic 
cells
9L syngeneic lysate 
(100,000 cells) plus 
U87 cells (50,000) 
plus LN229 cells 
(50,000) (rat #6) U87 
(50,000) plus LN229 
(50,000) xenogeneic 
cells (rat #7)
n = 2 Syngeneic 9L 
(100,000) cells
Reduction in 
tumour size
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 Results
Immunization with allorejected, non-syngeneic tumours in both Fisher 
and Sprague—Dawley rats primes for prophylactic immunity against syngeneic tumour 
challenge.
Most experimental studies of glioblastoma make use of small laboratory 
animal models. The most frequently used immunocompetent host models employ 
two different strains of rat, the Sprague—Dawley and the Fisher 344 rats [27]. C6 is a 
syngeneic-type cell line for the SD rats, while the 9L and RG2 cell lines are syngeneic 
for the Fisher 344 rats [27,28]. In a prophylactic setting we examined whether the SD 
and Fisher 344 rats initially injected with an allogeneic cell line would be able to reject 
a syngeneic cell line. SD rats were seeded with the allogeneic 9L cell line (SD-A). Each 
of the SD rats completely rejected the 9L tumour without visible or palpable tumour 
growth. Twenty days later, all ‘‘immunized’’ SD rats, were injected in the contra-lateral 
hind flank with syngeneic C6 tumour cells, that readily formed a tumour in naïve SD rats, 
using 100,000 cells first, and a fivefold higher tumour cells (500,000 cells) 10 days later. 
The rats were monitored every 3 days for any sign of visual or palpable tumour growth. 
In these SD rats, no visual or palpable tumour developed. Remarkably, at 360 days, all 
SD rats immunized with the allogeneic tumour cells remained tumour free (data not 
shown).
A similar procedure was used to prophylactically immunize three Fisher 
rats. They were injected with the allogeneic C6 cell line (Fisher-A). Although initially 
wellcircumscribed tumours did form, they were subsequently rejected within 40 days. 
These animals were subsequently seeded with 100,000 syngeneic C6 cells first, and a 
fivefold higher amount of C6 cells (500,000 cells) 10 days later. The rats were monitored 
every 3 days for any sign of visual or palpable tumour growth. In these Fisher rats, a 
relatively small (<1 cm×<1 cm×1 cm) growth developed at the injection site. This growth 
was noticeable only after palpation, and became progressively smaller and completely 
undetectable by 10 days. At 360 days, all immunized Fisher rats remained tumour free 
(data not shown).
These results demonstrate that in both strains, allorejection of non-
syngeneic tumours induces effective prophylactic immunity against syngeneic tumour 
challenge.
Allo-response-based therapeutic vaccination against C6 tumours in 
Sprague—Dawley rats
In order to assess anti-tumour immunity in a therapeutic situation, SD rats 
(n = 9) were each injected with the C6 cell line, which resulted in undiminished tumour 
growth in untreated animals. All SD rats developed visible tumours within 10 days. At 
this point, five rats were kept as a control group (SD-B1), while the remaining four rats 
were placed into treatment groups (SD-B2). On day 27, rats #1—4 were sacrificed and 
an attempt was made to ‘‘rescue’’ rat #9. At this time, rat #9 entered the treatment 
group and started to receive the same therapeutic vaccine injections as given to the 
SD-B2 group.
The uncontrolled tumour growth in the control group and the diminished 
tumour growth in the treatment group are depicted in Fig. 1. In the treatment group 
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(SD-B2, rats #5—8), individual rats were immunized with a mixture of allogeneic and 
syngeneic lysates, as well as allogeneic 9L cells per subcutaneous (s.c.) injection. One 
rat (#5) was treated very early. After 5 days, it had a palpable flank tumour and received 
only one therapeutic injection, contra-lateral to the tumour, of a mixture consisting of 
allogeneic 9L lysates (50,000), syngeneic C6 lysates (50,000), and 9L allogeneic cells 
(50,000). Remarkably, within 5 days after injection, the tumour resolved. Rats #6—8 (SD-
B2 rats) all developed visible tumours within 18 days post-injection. At this time, they 
each received a first injection of a mixture containing 50,000 allogeneic 9L lysate cells, 
plus 50,000 syngeneic C6 lysate cells and 50,000 9L allogeneic cells. These injections 
were repeated on days 23 and 28. Rat #6 received an additional treatment at day 33, 
15 days after initiation of immunotherapeutic treatment. The untreated rats (SD-B1, 
rats #1—4) were sacrificed 27 days post-injection because of their tumour size. When 
compared to the tumour progression in the untreated rats (rats #1—4), rats #5—8 (SD-
B2) eventually showed complete resolution of their tumours by day 50.
Rat #9 began the experiment within the non-treated group, and then was 
treated after sacrificing rats #1—4 (day 27). Rat #9 received five injections every 5 days 
with a mixture of allogeneic 9L lysates (50,000) plus C6 syngeneic lysates (50,000) and 
9L allogeneic cells (50,000). This animal was sacrificed for histological analysis at day 
55, when the tumour size had reduced to 11% of the size measured at the initiation of 
immunotherapeutic immunization. 
Figure 5.1. Graph charting tumour progression in nine SD rats with subcutaneously implanted 
syngeneic tumour (C6). Rats were placed in either control or treatment groups as previously des-
cribed. Tumour progression was determined through measurements of tumour volume (mm3). 
Rats #1—4 received no treatment after C6 tumour implantation. Rats #5—8 received one or more 
therapeutic vaccination(s) with allogeneic 9L cells and lysates with syngeneic C6 lysate. Rat #9 
was allowed to form a relatively large tumour before it was transferred to the treatment group to 
become immunized similar to rats #5—8.
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Allo-response-based therapeutic vaccination against 9L tumour growth 
in Fisher 344 rats
Fig. 2 shows tumour growth and response to the immunotherapeutic 
treatment of eight Fisher rats (Fisher-B) implanted with 9L cells. Rats #1—3 (Fisher B1) 
received therapeutic contra-lateral flank injections at day 10, with either syngeneic RG2 
(100,000 cells; rat #1) or 9L (100,000 cells; rat #2), or medium alone (rat #3). There 
was notable reduction in tumour growth over time, while a more pronounced tumour 
growth was noted in the RG2 treated rat (#1). By contrast, rats #4—7 (Fisher B2 and B3) 
were immunized therapeutically with, either C6 allogeneic cells only (rat #4), a mixture 
of C6 allogeneic cells and C6 allogeneic lysate (rat #5), U87 and LN229 xenogeneic cells 
only (rat #7) or mixed with 9L cell lysate (rat #6). In particular rats #5—7 showed a 
significant reduction in tumour outgrowth (p < 0.05), while rat #8, receiving 9L syngeneic 
lysate only, demonstrated no inhibition of tumour growth (Fig. 2).
All Fisher 344 rats were sacrificed at day 40, when some of the rats started 
to develop hind limb paralysis. The tumours from each of these rats were removed 
and processed for immunohistological staining of immune cells. Within the tumours 
of the positive treatment groups we noted significantly greater numbers of CD4, CD8, 
B-lymphocyte (CD20), macrophages (CD68), and dendritic cells when compared to the 
control tumours (Fig. 3).
Figure 5.2. Graph charting tumour progression in Fisher 344 rats with subcutaneously implanted 
syngeneic tumour (9L). Control rats were injected with syngeneic RG2 cells (rat #1), syngeneic 
9L cells (rat #2), or medium alone (rat #3). Rat #1 formed an extremely large tumour. Treatment 
group rats received allogeneic C6 cells alone (rat #4), allogeneic C6 cells and lysate (rat #5) (group 
B2), syngeneic 9L lysate and xenogeneic U87 and LN229 cells (rat #6), or xenogeneic U87 and 
LN229 cells alone (rat #7) (group B3). Rat #8 was treated with syngeneic 9L cell lysate alone. Tu-
mour progression was determined through measurements of tumour volume (mm3).
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 Discussion
Anti-tumour immunotherapy based on an effective therapeutic vaccine, 
with an acceptable safety profile, is the greathope for cancer treatment. A vaccine 
will theoretically programthe patient’s immune system to attack malignant, andeven 
metastasized, tumour antigen-expressing cells, and ideally trigger immunological 
memory to provide a durableanti-tumour immune response. To achieve this goal, 
many different vaccination strategies are currently being investigatedin animal models 
and clinical trials. Examples include immunizations based on patient-derived dendritic 
cellsloaded in vitro with tumour antigens or peptide fragments [29,30], virus-modified 
or cytokine transfected autologousor allogeneic tumour cells [31], plasmid DNA and 
viral orbacterial vector delivering genetically encoded tumour antigens,as well as the 
more classical antigen in adjuvant strategies.
In the present study, we demonstrate in two rats strains that allorejection 
of non-syngeneic tumours induces effective prophylactic immunity against subsequent 
syngeneic tumour challenges. In addition, we show that for established syngeneic 
tumours, therapeutic immunization with different mixtures, containing either allogeneic 
cell lysates plus syngeneic cell lysates, and allogeneic cells, evokes effective reduction 
in tumour growth in SD rats. Similarly, in Fisher rats, established tumour growth can be 
inhibited significantly by therapeutic immunization using either allogeneic or xenogeneic 
cells only, or a vaccine containing xenogeneic cells in a combination with lysates of 
syngeneic tumour cells. By contrast, immunization of Fisher rats with syngeneic cells 
Figure 5.3. Representative tumour sections taken from control (A, C, E, G, and I) and treated (B, 
D, F, H, and J) Fisher 344 rats. Sections were cut at a thickness of 7 m and, according to the previ-
ously described protocol [27], stained with an antibody directed against either the CD4 receptor 
(A and B), CD8 receptor (C and D), B-lymphocytes (CD 20) (E and F), macrophages (CD 68) (G and 
H), or a dendritic cell marker (DRC) (I and J). Small white arrows indicate the location of cells 
staining positively for the respective marker. The magnification of both control and treatment 
sample is 40×.
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or syngeneic lysate alone failed to reduce tumour outgrowth. Our results support the 
conclusion that it is feasible to program effective tumour antigen-specific responses 
as a result of anti-allogeneic or xenogeneic cell immunization. In general, cell- or cell 
lysate-based tumour vaccines may be more attractive when compared to single antigen 
or polypeptidebased vaccines, since they theoretically evoke a broader multi-targeted 
therapeutic response. Due to the polyclonal immune response induced, they are less 
likely to result in therapeutic escape than most cancer treatments in use today.
In the prophylactic setting the SD rats rejecting the 9L tumour (SD-A) and 
the Fisher 344 rats rejecting the C6 tumour (Fisher-A) were reinjected in the contra-
lateral flank with a higher dose of 500,000 cells of syngeneic cell line (9L for Fisher and 
C6 for SD). Both strains remained tumour free at 360 days. These results suggest that 
the injection of allogeneic cell lines evokes protection against subsequent challenge 
with syngeneic cell lines, demonstrating that the injection of the allogeneic cells lead 
to an immune response and the development of immune memory. Since C6 and 9L cell 
lines likely share critical tumour antigens, the development of C6 tumours is inhibited. 
The observed time line difference between SD and the Fisher rats in terms of allogeneic 
tumour rejection (SD rats rejected the 9L cell line without development of a tumour, 
while Fisher 344 rats took about 40 days to completely reject the C6 tumour), may be 
explained by a less effective immune response in Fisher rats. This may possibly result 
from less 9L immunogenicity, or is due to reduced susceptibility of 9L cells to immune 
attack; 9L is a gliosarcoma cell line, while C6 is a glioma cell line. On the other hand, C6 
cells may be more immunogenic for SD rats than the 9L cells for Fisher rats.
In the more demanding therapeutic setting, untreated SD rats injected 
with C6 gliomas developed significant tumours within 5—15 days. These tumours grew 
without rejection, and rats had to be sacrificed eventually due to unacceptable tumour 
size and limb paralysis. The treated SD rats initially developed C6 tumours at comparable 
rates and sizes as the control group. However, these tumours gradually decreased in size 
and were no longer detectable 25 days after the initiation of therapeutic vaccination with 
a mixture of allogeneic and syngeneic cells and syngeneic cell lysates. Strikingly, even rat 
#9, rescued relatively late from the untreated control group, showed significant reduction 
in the size of tumour after treatment began. Together, these results demonstrate that 
repeated subcutaneous injection of this cocktail leads to a reduction in tumour size by 
triggering immunological awareness, likely directed at tumour antigens shared between 
the syngeneic and allogeneic cells.
There is some debate in the literature about the C6 cell line and whether 
or not it is syngeneic to any strain of rat [27]. However, even if the cell line may not 
be strictly syngeneic, it developed into subcutaneous flank tumours in SD rats without 
rejection. Those rats not given treatment were sacrificed when tumour size became 
incompatible with life. All of the Fisher 344 rats developed flank tumours at 15 days. 
Unlike the SD controls, the Fisher controls either received injections with two different 
syngeneic cell lines (9L and RG2) or with medium alone. There was no inhibition of 
tumour growth in these rats. This demonstrates that the injection of whole syngeneic 
tumour cells does not evoke an effective anti-tumour immune response, as a result of 
immunological tolerance to syngeneic cells. Indeed, when these rats were sacrificed, 
tumour sections did not stain positively for CD4, CD8, macrophages, B-lymphocytes, 
and dendritic cells. By contrast, the tumours in the treated Fisher 344 rats showed 
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different growth profiles. Rat #4 received allogeneic C6 cells only and showed growth 
inhibition after day 35. Especially, rats #5—7 showed decreased tumour growth when 
compared to syngeneic or medium treated controls. Rat #5 was treated was treated 
with both allogeneic C6 cells and lysate. Rat #6 was treated with 9L syngeneic lysate 
and xenogeneic U87 and LN229 cells. Rat #7 was treated with xenogeneic LN229 
and U87 cells. Rat #8, which was treated with 9L syngeneic cell lysate, had an initial 
delay in tumour growth. However, this effect was not lasting, as by day 25 the tumour 
was similar in size to controls. These data suggest that syngeneic lysate may exert a 
temporary protective effect, however, a lasting protective effect was noted more 
clearly for allogeneic cells plus lysate, and for cell injections involving the xenogeneic 
U87 and LN229 tumour cell lines. Interestingly, the protective effect of the allogeneic 
cells appeared more pronounced when a lysate was added as compared to whole cell 
preparation only, as suggested by comparing rat #4 versus #5.
When tumour-rejecting rats were sacrificed, their tumour sections stained 
generally more positive for CD4, CD8, macrophages, B-lymphocytes, and dendritic cells, 
in contrast to the control group, which had tumours with intact architecture and a 
paucity of all of the above-mentioned immune cells. These results demonstrate that 
immunocompetent rats, which develop syngeneic tumours without rejection, show less 
or no immune cell infiltration, suggesting an escape from immune recognition due to 
immune ignorance [32].
When comparing the therapeutic vaccinations in SD and Fisher rats it is 
also worthy to note that while all of the treated SD rats rejected the C6 tumour, none of 
the Fisher rats has complete tumour remission within 40 days. This may be explained by 
the fact that syngeneic lysate was not added to either the allogeneic or the xenogeneic 
cells in Fisher rats, as it was done in the SD rats. Hence, addition of syngeneic lysate may 
significantly contribute to tumour rejection and will be examined in follow-up studies.
Collectively, pooled results from these experiments confirm that 
experimental vaccines based on allogeneic or xenogeneic cells only or combined 
with syngeneic cell lysates, are safe and protective in early and advanced malignant 
glioblastoma. These results lead us to conclude that ‘‘non-self’’ injections of allogeneic 
cells and/or allogeneic lysate, as well as xenogeneic cell lines, can break self-anti-
tumour tolerance. These cells likely contain antigen determinants shared with the 
syngeneic tumour, leading to a reduction in tumour growth. The exact immunological 
mechanisms underlying the observed anti-tumour immunity remains to deciphered in 
further studies. Although these were small pilot treatments, in a limited number of 
animals per therapeutic effect, the inhibition of tumour growth within the treatment 
groups was statistically significant when compared with control or untreated animals. 
Our results support the viability of this cancer vaccine strategy as an adjuvant treatment 
to prevent tumour relapse in cancer patients.
The impact of these data may be far reaching when translation to 
patients is possible to certain degree. Glioblastoma multiforme is the most common 
and malignant of all gliomas, and cannot be cured by surgery, radiation therapy, 
chemotherapy, with 75% of patients dying within 18 months of diagnosis [33]. The use 
of allogeneic/syngeneic/or xenogeneic cell lines and lysates may lead to a reduction in 
tumour size and perhaps rejection, thereby increasing survival. In the future, allogeneic 
cell lines and lysates may also be used as vaccine components for other cancers.
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 Summary
The efficacy of a various immunotherapeutic immunosation stragedies 
for maligant blioma brain cancer was evaluated in the syngeneic CNS-1 Lewis rat 
glioma model. A prototype glioma cancer vaccine, which was composed of multivalent 
antigens derived from allogeneic and syngeneic cells and lysates, formed the prototype 
preparation of antigens. These antigens reflect the autologous antigens derives from the 
patient’s surgically removed tumour tissue, as well as allogeneic antigens form glioma 
tumour tissue surgically removed from donor patients. This antigen mixture provides 
a broad spectrum of tumour associated antigens (TAA) and helps to prevent escape of 
tumour immune surveillance when given as a vaccine. This antigen preparation was 
administered in a therapeutic setting with distinct single or multiple co-stimulation-
favouring immunostimulants and evaluated for inhibition of tumour growth. Our 
prototype vaccine was able to arrest progression of the tumour growth when co-
delivered in a specific regimen together with the costimulating multi-TLR agonist, 
Bacille Calmette Guerin (BCG) and interleukin-2, or with the Toll-Like receptor (TLR) 7/8 
activator resiquimod.
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 Introduction
Glioblastoma multiforme (GBM) is an invasive malignant tumour of 
the central nervous system. Conventional therapy options include surgery, radiation, 
and chemotherapy, but with them the prognosis for GBM patients is limited to a 
mean survival time of only 14.6 months [1]. Immunotherapy is emerging as a novel 
complementary treatment option for a variety of malignancies including GBM. The 
use of successful passive immunotherapies based on the administration of immune 
elements, such as antibodies has proven very successful against various types of cancer. 
Well-known examples include antibodies that target tumour expressing receptors for 
epidermal growth factor (EGF), called Herceptin, those that target HER-2 [2], and those 
that are directed against angiogenic, tumour blood vessel growth-promoting vascular 
endothelial growth factor (VEGF), known as Avastin [3]. Recently, the antibody directed 
against an immune response inhibitory molecule, called cytotoxic T lymphocyte 
associated protein 4 (CTLA4), known as Yervoy®, has shown promising clinical efficacy 
in melanoma patients [4].
Apart from these passive antibody-based therapies, a range of active 
immunotherapies are in late stage development and are close to reaching approval as 
standard of care. These clinical studies clearly demonstrate that the immune system 
is able to discriminate cancer cells from normal cells following recognition of tumour 
associated antigens (TAA). Indeed a recent approval for a prostate cancer vaccine named 
Provenge®, was obtained from the FDA in April 2010, for the treatment of asymptomatic 
or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate 
cancer [5]. This recent approval has rejuvenated interest in the field as a whole.
In the present study we demonstrate a prototype brain cancer vaccine 
against gliomas which is composed of multivalent antigens derived from allogeneic 
and syngeneic cells and lysates. Our prototype is reflected in a clinical situation by 
autologous antigens derived from the patient’s surgically removed tumour tissue. In 
addition, glioma tumour tissue surgically removed from donor patients provides a 
second source of allogeneic antigens that can be isolated and subsequently stored for 
later use. This material provides a new source of TAA that may display HLA-restriction 
that may overlap with that on the patient’s glioma. They may serve to enhance the 
overall immune response. If processed under Good Manufacturing Conditions, it may 
provide an “off-the shelf” application. Relevant unique or shared TAAs overexpressed by 
tumour cells are present among thousands of irrelevant immunotolerant non-tumour 
associated antigens. The broad range of TAAs is preferred over vaccines with a mono- or 
oligo-valent antigenic content. These vaccines will prevent escape of tumour cells due 
to antigenic loss, or active MHC downregulation. In addition, a tumour antigen mixture 
also circumvents the use of monovalent synthetic peptides, which are restricted for 
use in patients with defined HLA types. By including TAAs of allogeneic origin, we 
additionally trigger allogeneic immune reactions. The haplotypes of CNS-1 and RG2 are 
fairly close, i.e., RT1l vs RT1lvl, yet provide a mismatch that may be considered abberant 
self, and also induce an alloresponse. This may provide better protection due to the 
“non-self” immune recognition of these antigens.
Although allogeneic tumour antigens may provoke immune responses 
to non-self antigens in classical allogeneic immune rejections, glioma tumours, 
once established, are known to actively suppress the host’s immune system, by well 
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characterized mechanisms [6], which often leads to subsequent evasion of immune 
surveillance. We therefore decided to test various signalling and costimulation-favouring 
immunostimulants in combination with our prototype vaccine antigen formulation for 
anti-tumour activity in an aggressive rat glioma brain tumour model, CNS-1, that is 
syngeneic in Lewis rats.
Here we demonstrate that our prototype vaccine is able to arrest 
progression of tumour growth when co-delivered in a specific regimen with the 
costimulatory-enhancing multi-TLR agonist, Bacille Calmette Guerin (BCG) adjuvant 
with interleukin-2, or with the TLR 7/8 activator resiquimod.
 Materials and Methods
Tumour model
Glioma cells: Both CNS-1 tumour cells and RG2 (ATCC, CRL-2433) rat 
glioma cells were cultured in Dulbecco’s modified Eagle (DMEM) medium containing 
10% bovine fetal serum (FBS), 5% antibiotics Penicillin, Streptomycin, and amphotericin 
B (Hyclone) in 175-mm2 flasks. The CNS-1 haplotype is RT1l and RG2 is RT1lvl.
Animals: Rat CNS-1 cells (2 × 105 cells/200 ul) were implanted 
subcutaneously (SC) using a 21 gauge needle into the right flank of 8-12 week-old (300 
gram body weight) male Lewis rats. For each treatment group and control, 4-8 rats/group 
were used. All animal studies were approved by an independent ethical committee.
Monitoring tumour growth
The sizes of the CNS-1 tumour volumes were measured using a caliper 
three times per week on Mondays, Wednesdays and Fridays to monitor the effects of 
each treatment group. 
Completion of experiment
Tumour implanted rats were sacrificed if they showed signs of discomfort, 
as defined by the ethical committee. For example if they appeared moribund due 
to weight loss, lethargy, ru(ed fur, or when tumours showed ulceration. A mixture 
of Rompun and ketamine was used for anesthesia, followed by a dose of sodium 
pentobarbital for euthansia.
Vaccine
The vaccine antigen preparation was composed of a mixture of haptenized 
CNS-1 cells and RG2 cells (1 × 10e6 CNS-1 syngeneic and 1 × 10e6 RG2 allogeneic glioma 
cells), together with lysates produced from 3 × 10e6 CNS-1 syngeneic cells and 3 × 10e6 
allogeneic RG2 glioma cells. The haptinization method has been described before [7]. 
This vaccine preparation was kept as a constant factor and given in combination with 
various other anti-tumour or immunostimulatory agents as specifed in Figures 6.1A & 
6.2A. The TLR7/8 agonist resiquimod was co-administered 3 times a week on Mondays, 
Wednesdays and Fridays.
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Chemicals and Reagents
Immunomodulators and potentiators
Rats were subcutaneously (SC) injected in the flank, contralateral to the 
tumour-implanted side, with resiquimod (R848) (Invitrogen, TLRL-R848), a Toll-like 
receptor 7/8 agonist, at a dose of 100 μg/ kg, corresponding to 30 μg/dose, three times 
per week on Mondays, Wednesdays and Fridays.
In a parallel arm of the experiment we evaluated the effect of 
cyclophosphamide (CY) administration, in diverse regimens and dosing as specified, on 
CNS-1 glioma development. Cyclophosphamide (CalBiochem, 239785) was given at 30 
mg/kg 3 times per week, or at 100 mg/kg once every week (See also Figure 6.1A and 
6.2A).
We also tested the vaccine antigen preparations combined with Bacilles 
Calmette-Guérin, interleukin-2 (IL-2), or a B7.1 fusion protein. 
The Bacilles Calmette-Guérin (BCG), substrain Connaught, (Immunocyst®, 
Sanofi Pasteur) is an agonist of TLRs 2, -4 -9, and was used at 2 × 10e5 CFU per dose.
Interleukin-2 (IL-2) was injected daily at a dose of 75,000 IU/day from 
Monday to Friday starting on the day of vaccine injection.
Figure 6.1: A vaccine was prepared from allogeneic and syngeneic antigens and administered 
in a fractionated regimen together with BCG and IL-2 to determine the effects on CNS-1 glioma 
growth. A) Treatment schedule representing one cycle of the various immunotherapeutic injecti-
ons. B) Average values of tumour growth as a function of time post-implantation for the different
treatment groups.
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A B7.1 fusion protein consisting of the extracellular domains of human 
B7.1 and the Fc portion of human IgG1, called B7.1-Fc, was produced as described 
[8]. This protein induced complete regression of Colon 26 tumours in a mouse model 
and slowed tumour growth dramatically in mice with established poorly immunogenic 
RENCA and Madison109 tumours [8]. The B7.1-Fc protein was diluted in sterile PBS at 
250 μg/200μl concentration.
For statistical analysis, we used ANOVA nonparametric testing followed 
by student’s t tests to compare groups. P values of < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) were considered statistically significant.
 Results
Efficacy of a BCG-containing vaccine administered at day 17 
after implantation
CNS-1 tumour cells (2 × 105 cells / 200 μl) were implanted in syngeneic 
male Lewis rats and after 17 days were either left untreated (control group; n = 4) or 
administered with a therapeutic immunomodulatory regime or some of its components, 
as specified in the treatment schedule of Figure 6.1A.
The vaccine antigen preparation consisted of a mixture of haptenized 10e6 
syngeneic and 10e6 allogenic RG2 glioma cells together with lysates produced from 3 × 
10e6 synegeic CNS-1 cells and 3 × 10e6 allogenic RG2 gliomacells (n = 4). When monitoring 
tumour growth over time with a caliper, we observed no significant difference in tumour 
volumes between the control group (G1) and the rats receiving cyclophosphamide (CY) 
only at a dose of 100 mg/kg (G2) (Figure 6.1). From other experiments we had learned 
that the vaccine antigen preparation showed no anti-tumour efficacy by itself under the 
conditions described (for illustration see also figure 6.3, the antigen only group indicated 
by closed circles). By contrast, when this vaccine antigen preparation was administered 
together with the multiple TLR agonist BCG plus IL-2, an inhibition of tumour growth was 
noted (G6). Similarly, the same treatment schedule supplemented with CY (30 mg/kg on 
day 19, and 80 mg/kg on day 31) also inhibited tumour growth (G4). Remarkably, also five 
daily injections of B7.1-FC fusion protein alone (Monday to Friday, starting day 17 post 
implantation), showed some inhibition of tumour growth (G3), though not statistically 
significant relative to control groups. However, when combining the beneficial vaccine 
preparation plus CY (30 mg/kg) treatment with an additional regimen of B7.1-Fc antibody 
injections no inhibition of tumour growth was noted (G5).
A BCG-containing vaccine shows better eThcacy amongst 
the diverse vaccine prototypes tested
In a subsequent experiment, CNS-1 tumour cells (2 X 105 cells / 200 
μl) were implanted in 8-12 week-old syngeneic male Lewis rats and were either left 
untreated (control group; n = 4) or administered with a therapeutic immunomodulatory 
treatment regimen or some of its components, as specified in the treatment schedule 
depicted in Figure 6.2A. Instead of waiting until day 17 post tumour implantation, we 
now started at day 10 after tumour inoculation.
As before, the vaccine antigen preparation consisted of a mixture of 
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haptenized syngeneic CNS-1 and allogeneic RG2 glioma cells (10e6 each) with lysates 
produced from syngeneic CNS-1 cells and allogeneic RG2 glioma cells (3 × 10e6 each) (n = 
4). When monitoring tumour growth over time with a caliper, we observed no significant 
difference in tumour volumes between the untreated control group (G1) and the rats 
receiving low dose cyclophosphamide (CY, 30 μg/dose) in week two (G4), B7.1-Fc fusion 
protein only (G3), B7.1-Fc protein plus CY (G2) or vaccine plus CY only (G5) (Figure 6.2A). 
By contrast, when this vaccine antigen preparation was administered together with the 
multiple TLR agonist BCG plus IL-2 and CY (100 μg/dose), a significant inhibition (p < 
0.05) of tumour growth was noted (G6). This vaccine preparation was administered 
in a fractionated schedule starting with allogeneiic cells on the first day, followed by 
syngeneic cells the second day, and allogeneic and syngeneic lystates on the third and 
fourth days, respectively (G6). Remarkably, also ex vivo tumour tissue isolated from a 
syngeneic established CNS-1 tumour plus CY (G7) showed some inhibition of tumour 
growth (although not statistically significant) relative to control groups (Figure 6.2B).
Figure 6.2: A vaccine was prepared from allogeneic and syngeneic cells administered in a frac-
tionated regimen together with BCG and IL-2. A) Treatment schedule representing the cycle of 
the various immunotherapeutic injections. AC, allogenic cells, SC, syngeneic cells, AL, allogeneic 
lysate, SL, syngeneic lysate, Ly, is lysate only. B) Average values of tumour growth as a function of 
time post-implantation for the different treatment groups.
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Figure 6.3: A vaccine was prepared from the standardized allogeneic and syngeneic cells admi-
nistered with or without the TLR7/8 agonist, resiquimod, injected 3 times a week on Mondays, 
Wednesdays and Fridays. Average values of tumour growth as a function of time post-implantati-
on for the different treatment groups.
Figure 6.4: Individual tumour growth curves as a function of time post-implantation.
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Therapeutic treatment with a vaccine containing 
immunostimulatory TLR7/8 agonist shows marked 
inhibition of glioma tumour growth
In view of the beneficial effect of vaccination in the context of the multi-
TLR agonist BGC, we decided to evaluate the effect of a TLR7/8 agonist in our CNS-1 
tumour model. CNS-1 tumour cells (2 X 105 cells /200 μl) were implanted in 8-12 week-
old syngeneic male Lewis rats and either left untreated (control (CTRL) group; n = 8) or 
treated at day 10 after implantation with a vaccine antigen preparation consisting of 
a mixture of haptenized syngeneic CNS-1 and allogeneic RG2 glioma cells (10e6 each) 
with lysates produced from syngeneic CNS-1 and allogeneic RG2 glioma cells (3 × 10e6 
each) (n = 8), given alone or combined with the TLR7/8 agonist, resiquimod (R848). This 
vaccine preparation was given 3 times a week on Mondays, Wednesdays and Fridays. 
When monitoring tumour growth over time with a caliper, we observed no significant 
difference in tumour growth between control and vaccine antigen only treated rats 
(Figure 6.3). By contrast, when this antigen preparation was administered together with 
a TLR7/8 agonist (30 μg/dose) significant inhibition (p, 0.001, ***) of tumour growth, 
with complete tumour regression was noted (Figure 6.3). Remarkably, administration of 
TLR7/8 agonist alone in the same regimen also inhibited tumour (p, 0.001, ***) (Figure 
6.3).
Inhibition of tumour progression with large established 
glioma tumours by a vaccine containing the TLR7/8 
immunostimulant
As mentioned above, Lewis rats treated with a vaccine without 
immunostimulatory TLR7/8 agonist showed little inhibition of tumour growth relative to 
untreated control rats, while the TLR7/8 containing vaccine strongly suppressed tumour 
growth when given 3 times per week starting at day 10 after implantation. We therefore 
decided to examine the effect of therapeutic vaccination of animals which showed no 
inhibition of tumour growth at day 34 after implantation. We administered the TLR7/8 
containing vaccine to animals with large (12-14,000 mm3) tumours, starting at 38 days 
after tumour implantation. The TLR7/8 agonist-containing vaccine was injected 3 times 
a week on Mondays, Wednesdays and Fridays, in both untreated control rats (n = 4) and 
rats immunized with idential antigen only (n=4). We noted in both groups a slower rate 
of growth of gliomas with large tumour volumes, but the TLR7/8 containing vaccine 
was best able to evoke a significant (p < 0.001, ***), arrest of tumour volume growth 
in the rats that were treated before with the antigen only vaccine preparation, relative 
to rats which were untreated (Figure 6.4). As well, no signs of vaccination-induced 
adverse effects or toxicity were observed, confirming data from another study that 
immunotherapy is well tolerated with limited toxicity [9]. These untoward effects point 
to the relative safety and tolerability of vaccines.
 Discussion
In the present study we show that a prototype vaccine, consisting of 
a mixture of allogeneic and syngeneic glioma cells and their lysates, administered 
together with either a multiple TLR2, -4 and -9 agonist BCG [9], or the TLR7/8 agonist 
resiquimod, is able to inhibit CNS- 1 glioma brain tumour growth in syngeneic Lewis 
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rats. For early stage tumours, a complete regression of tumour growth volume was 
noted, while for large established 38-day old tumours (14,000 mm3 volume), inhibition 
of tumour growth was noted for the TLR7/8 containing vaccine. These data confirm 
the well-know phenomenon that large glioma tumours are more difficult to control 
relative to smaller tumours. Nevertheless, if the latter is most relevant to the large 
tumour burden that may be present in individuals with gliomas in unresectable sites 
(e.g. parietal or tempero-parietal tumours), instituting vaccination with TLR agonists 
may be valuable in providing additional quality survival time.
During glioma tumour development a proportional increase in local 
and systemic immunosuppression has been documented [6,9,11,12]. Gliomas are 
known to contain T regulatory cells, which normally act as suppressor cells, regulating 
homeostatis and preventing autoimmune reactions. However, regulatory T cells also 
inhibit T effector functions, activated naturally by vaccination [13,14], and thereby 
facilitating tumour immune evasion and subsequent tumour progression. At the 
molecular level this is associated with an increase in production of immune inhibitory 
cytokines including transforming growth fcator (TGF)-beta, and/or interleukin-10 [15]. 
In general, immunosuppression can be counteracted by either strong stimulation of 
proinflammatory immune pathways, by blocking immune inhibitory elements triggered 
by the tumour itself, or by a combined “push-pull” approach [16]. We therefore evaluated 
well-known costimulation-enhancing immunostimulants, such as TLR-agonists [17], 
and inhibitors of immune system signals, such as what the B7.1 and cyclophosphamide 
immunomodulators provide. They were administered in conjunction with our standard 
vaccine antigen preparation.
We noted beneficial antitumour activity with daily injection of the B7.1Fc 
fusion protein starting at day 17 after tumour implantation as a monotherapy. This 
soluble costimulator protein was fused to the Fc portion of the antibody. It has been 
developed and tested for the immunotherapy of solid tumours in mouse tumour models 
[8]. This B7.1-Fc protein was found to be capable of activating T cells in vitro and in vivo 
[8]. B7.1 is able to engage with two known receptors. CD28, which triggers a stimulatory 
signal to activate naive T cells after binding by B7.1 (4), and its counterreceptor, CTLA-
4, which triggers a negative signal to stop T-cell activation. Since B7.1 has high affinity 
to CTLA-4, soluble B7.1-Fc may block CTLA-4 signalling instead of cross-linking CTLA-4, 
thereby sustaining the activation of tumourspeci fic T cells [18,19]. Crosslinking of T 
cell activating CD28 may be less important than blocking the inhibitory CTLA-4, since 
activated T cells recognizing tumour antigens require less costimulation [20]. When B7.1 
antibody was combined with other immune system activating treatments, we observed 
no synergistic activities, which illustrates that the timing and choice of modalities during 
combined immunotherapy is criticical for a beneficial antitumour effect.
Also, cyclophosphamide, when dosed carefully, has been demonstrated to 
facilitate immunotherapy of established tumours through the elimination/inactivation 
of suppressor T cells [21- 23]. In our investigations, a protocol of cyclophosphamide (CY) 
only, administered at a dose of 100 mg/kg given on day 19 post transplantation did not 
affect tumour growth (Figure 6.1), while three lower doses of 30 mg/kg each starting 
on day 17 given within a week period, did not show a beneficial anti-tumour activity 
(Figure 6.2). By contrast, CY treatment alone may even exacerbate tumour growth, 
relative to the untreated control group, which may likely result from suppression of 
endogenous anti-tumour immune reactions in parallel to inadequate direct tumour 
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growth inhibition, resulting in a net increase in tumour growth volume. Nevertheless, 
when combined with other immune adjuvants or vaccines, beneficial effects were noted 
despite coadministration of CY. The best efficacy was noted in treatment schedules 
containing the vaccine antigen preparation plus BCG and IL-2. Bacillus Calmette- Guérin 
(BCG) is a mycobacterium which contains various agonists of Toll-like receptor 2 (TLR2) 
and TLR4 in its cell wall skeleton (CWS), and also BCG DNA which acts as a TLR9 agonist 
[10,24]. Intravesical immunotherapy with BCG, as monotherapy, causes significant 
reductions in cancer tumour progression and is currently the standard treatment for 
superficial bladder cancer [25]. However, the exact mode of action of successful BCG 
therapy remains elusive, although massive cytokine expression and influx of innate 
immune cells have been documented, which may be involved in tumour elimination.
Apart from BCG, we also examined the effect of the TLR7/8 agonist 
resiquimod as an adjuvant in a separate animal study. TLR7/8 agonists exert pleiotropic 
effects on various immune cells which leads to stimulation of proinflammatory cytokine 
and chemokine production, as well as up-regulation of costimulatory molecules on 
antigen presenting cells [26]. The TLR7/8 agonist resiquimod has been shown to act as 
a vaccine adjuvant in investigational vaccine models [25,27], and to generate clinical-
grade mature DCs [28].
In our CNS-1 model, the TLR7/8 agonist resiquimod showed superior 
antitumour effects against early tumour growth and remarkably, administration 
of TLR7/8 agonist alone inhibited tumour growth. The exact mode of action for the 
observed resiquimod-mediated anti-tumour immunity needs to be defined in detailed 
follow-up studies. Most likely the observed resiquimod-based immunotherapy, even 
in absence of additional tumour antigens, is able to activate a spontaneous, natural, 
innate anti-tumour immune response, that under normal circumstances is unable to 
control tumour growth. Hence, such dedicated followup studies need to address to 
involvement of anti-tumour killer macrophages or NK cells, or IFNs for the resiquimod-
induced glioma growth regression. In addition, the TLR7/8 vaccine preparation evoked 
an arrest of tumour volume growth in rats carrying large tumours that were treated 
before with the antigen only vaccine preparation.
Although the presented results are promising the should always be 
interpretaed with caution. Subcutaneous tumours may be exposed to markedly distinct 
immune conditions than in the brain, and so the physiologic as well as clinical relevance 
has to be validated in further studies.
Our vaccine preparation contains multiple tumour associated antigens 
(TAA) prepared from syngeneic and allogeneic cells. Although the precise identity of 
antigens is unknown we chose this antigen preparation for our vaccination strategy, rather 
than one or a few molecular targets, in order to target multiple TAAs simultaneously. 
This approach minimizes the chances for classical tumour-escape of immune control, as 
a result of selective growth of antigen-loss variants. With this approach we guaranteed 
that multiple relevant TAAs gain enhanced exposure to the immune system, while 
the self-antigens in this mixture are neglected as a result of immunological tolerance. 
By including cell associated antigens, we increased the chance of crosspresentation 
by MHC class I molecules for priming of cytolytic CD8+ T cells. By including TAAs of 
allogeneic origin, we additionally trigger allogeneic immune reactions. The haplotypes 
of CNS-1 and RG2 are fairly close, i.e., RT1l vs RT1lvl thus providing a mismatch that 
may be considered abberant self, and also induce a vigorous alloresponse. Allogeneic 
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(major histocompatibility complex MHC-mismatched) tumour cells have shown better 
protection in a number of models likely due to the “non-self” immune recognition of 
these antigens [29-31].
Immunotherapy against TAA theoretically carries the risk of autoimmune 
reactions. Autoimmunity is possible, especially in view of our manipulations aimed 
at blocking immune response inhibitors coupled with the use of immunostimulating 
adjuvants. In the present studies, however, we have not observed any adverse reactions 
using our animal well-being scoring system. These observations are in line with well-
documented observations, that therapeutic tumour vaccination is, in general, well-
tolerized with minimal or no adverse events. 
In conclusion, we noted beneficial antitumour activity of daily injection 
of the B7.1-Fc fusion protein as monotherapy, and with vaccine preparations that were 
administered with BCG and IL-2 only, or with the TLR7/8 agonist resiquimod. Altogether 
these data illustrate the importance of a beneficial immunomodulatory protocol. 
Different immunomodulators may result in distinct antitumour efficacy. Hence, we 
conclude from our data that only specific combinations of the right antigenic mixtures 
in conjunction with a suitable immunopotentiator is able to arrest aggressive glioma 
tumour growth in this experimental tumour model. Our data highlight the need for 
continued, more extensive exploration into such combinations.
 References
1. Stupp R, Roila F, ESMO Guidelines Working Group (2009) Malignant glioma: ESMO 
clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 4: 
126-128.
2. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl 
J Med 357: 39-51.
3. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, et al. (2008) Time course of 
imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 
88: 339-347.
4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved 
survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 
711-723. 
5. Buonerba C, Ferro M, Di Lorenzo G (2011) Sipuleucel-T for prostate cancer: the 
immunotherapy era has commenced. Expert Rev Anticancer Ther 11: 25- 28.
6. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and 
sources of immunosuppression. Gene Ther Mol Biol 10: 133- 146.
7. Henry N, Claman HN, Miller SD (1976) Requirements for Induction of T Cell Tolerance 
to Dnfb: Efficiency of Membrane-Associated DNFB. J Immunol 117: 480-485. 8. Liu 
A, Hu P, Khawli LA, Epstein AL (2005) Combination B7-Fc Fusion Protein Treatment 
and Treg Cell DepletionTherapy. Clin Cancer Res 11: 8492-8502.
9. de Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, et al. (2006) Dendritic 
cell vaccination in patients with malignant gliomas: current status and future 
directions. Neurosurgery 59: 988-999.
10. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, et al. (2003) Simultaneous 
blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell 
Chapter 6 
 111
6
activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. 
Infect Immun 71: 4238-4249.
11. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in 
patients with primary malignant brain tumours. J Neuroimmunol 100: 216–32.
12. Ge L, Hoa N, Bota DA, Natividad J, Howat A, et al. (2010) Immunotherapy of brain 
cancers: the past, the present, and future directions. Clin Dev Immunol 2010: 
296453.
13. El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T 
cells in tumour-infiltrating lymphocytes of human glioblastoma multiforme. Neuro 
Oncol 8: 234-243.
14. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, et al. (2006) Increased 
regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular 
immune defects in patients with malignant glioma. Cancer Res 66: 3294-3302.
15. Qiu B, Zhang D, Wang C, Tao J, Tie X, et al. (2011) IL-10 and TGF-β2 are  overexpressed 
in tumour spheres cultured from human gliomas. Mol Biol Rep 38: 3585-3591.
16. Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, et al. (2002)  A push-
pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 
inhibitor while augmenting help with granulocyte/macrophage colony-stimulating 
factor and CD40L. Proc Natl Acad Sci U S A 99: 13020-13025.
17. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19: 24-32.
18. Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, et al. (1999) Potent activity of 
soluble B7-IgG fusion proteins in therapy of established tumours and as vaccine 
adjuvant. Cancer Res 59: 4964 - 4972.
19. Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, et al. (1999) Induction of 
therapeutic T-cell immunity by tumour targeting with soluble recombinant B7- 
immunoglobulin costimulatory molecules. Cancer Res 59: 2650-2656.
20. Croft M, Bradley LM, Swain SL (1994) Naive versus memory CD4 T cell response to 
antigen. Memory cells are less dependent on accessory cell costimulation and can 
respond to many antigen-presenting cell types including resting B cells. J Immunol 
152: 2675-2685.
21. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an 
established tumour depends on elimination of tumour-induced suppressor T cells. 
J Exp Med 155: 1063–1074.
22. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, et al. (2004) 
CD4+CD25+ regulatory T cells suppress tumour immunity but are sensitive to 
cyclophosphamide which allows immunotherapy of established tumours to be 
curative. Eur J Immunol 34: 336–344.
23. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. (2007) Metronomic 
cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and 
restores T and NK effector functions in end stage cancer patients. Cancer Immunol 
Immunother 56: 641-648.
24. Hoppstädter J, Diesel B, Zarbock R, Breinig T, Monz D, et al. (2010) Differential cell 
reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung 
interstitial macrophages. Respir Res 11: 124.
25. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder 
cancer. Urol Clin North Am 19: 573-580.
26. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and 
Chapter 6
112
TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-
875.
27. Tomai MA, Vasilakos JP (2011) TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev 
Vaccines 10: 405-407.
28. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, et al. (2008) Maturation 
of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands 
combined with prostaglandin E2 results in high interleukin-12 production and cell 
migration. Cancer Immunol Immunother 57: 1589-1597.
29. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG (1996) Allogeneic 
murine melanoma cell vaccine: a model for the development of human allogeneic 
cancer vaccine. Melanoma Res 6: 299-306.
30. Hrouda D, Todryk SM, Perry MJ, Souberbielle BE, Kayaga J, et al. (2000) Allogeneic 
whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 86: 742-
748.
31. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, et al. (2011) Gene 
expression profiling in acute allograft rejection: chllanging the immunologic 
constant of rejection hypothesis. J Transl Med 9: 174.
 113
114
 115
CH
A
PTER7
Therapeutic efficacy of a glioma vaccine 
based on allo- and syngeneic antigens 
coadministered with granulocyte 
macrophage colony stimulating 
factor (GM-CSF) after a low dose 
cyclophosphamide regimen 
Apostolos Stathopoulos1,2,7*, Chrystel Pretto2, 
Laurent Devillers2, Denis Pierre2, Florence M. Hofman3, 
Alan L. Epstein3, Hooman Farghadani8, Carol A. Kruse4, 
Martin R. Jadus5, Thomas C. Chen2,7 and Virgil E.J.C. Schijns2,6*
1 Dept. of Neurosurgery, Arlon Hospital, Arlon, Belgium, tstath@hotmail.com
2 Epitopoietic Research Corporation (ERC), Namur, Belgium,
3 Departments of Pathology and 7Neurosurgery, University of Southern California, 
Keck School of Medicine, Los Angeles, California,
4 Department of Neurosurgery, University of California, Los Angeles, California and 
the Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095
 5 Veterans Affairs Medical Center, Long Beach, CA 90822, box 113, 5901 E7th St, 
and Chao Cancer Center, University of California, Irvine, Orange CA 
6 Cell Biology & Immunology Group, Wageningen University, PO Box 338, 6700 AH 
Wageningen, The Netherlands. Virgil.schijns@wur.nl*
* Corresponding authors
Submitted for publication.
Chapter 7
116
 Summary
In an aggressive rat glioma tumour model, we demonstrate therapeutic 
efficacy of a prototype brain cancer vaccine, which is composed of multivalent antigens 
derived from allogeneic and syngeneic cells and lysates. We decided to test our prototype 
anti-tumour vaccine antigen formulation in combination with the locally administered 
immunostimulatory cytokine granulocyte colony-stimulating factor (GM-CSF), which is 
approved as a prescription medication in humans. This vaccine prototype suppressed 
tumour growth resulting in complete regression, and immunological memory against 
secondary tumour inoculation.
In a clinical situation our therapy is reflected by a vaccine composed 
of autologous antigens, derived from the patient’s surgically removed tumour tissue, 
which is administered in conjunction with antigens from glioma tumour tissue surgically 
removed from allogenic donor patients. This allogenic tumour material provides a 
second source of antigens that can be isolated and subsequently stored in a tissue bank 
for “off-the shelf” use. Such a therapeutic vaccine can be administered post-standard 
surgery and radiation plus chemotherapy in order to prevent tumour recurrence.
Thus, we demonstrate that our prototype therapeutic vaccine, when 
co-delivered in a specific regimen together with the GM-CSF as immunological 
adjuvant, is able to arrest progression of glioma tumour growth, when therapeutically 
administered following low-dose cyclophosphamide. 
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 Introduction
Active immunotherapy against cancer represents an exciting treatment 
option, involving the stimulation of the patient’s immune system against tumour 
antigens. However, therapeutic immunization against malignant glioma brain tumours, 
glioblastoma multiforme (GBM), is a formidable challenge. Although, natural brain 
parenchyma infiltrating CD8-positive T cells have been detected in these brain tumours 
[Yang et al., 2011; Schneider et al., 1992) and even anecdotal rejection following bacterial 
infection (Bowles and Perkins, 1994), GBM, once established, normally evades immune 
detection, as a result of decreased MHC antigen expression and active suppression 
of local and systemic immune reactions (Fecci et al., 2006). Apart from tumour-
mediated immune suppression the patient’s immune reactivity is further suppressed by 
iatrogenic chemotherapy (J. Ohlfest personall communication) and due to post-surgical 
corticosteroid treatment. In combination this tilts the balance towards an immune 
suppressive state (Fadul et al., 2011) as evidenced by significant lymphopenia, with a 
decrease in total CD4+ T cells and a functional increase in regulatory T cells.
Glioblastoma mutiforme (GBM) is the most common and most aggressive 
malignant brain tumour known as gliomas, with a very poor prognosis due to marginally 
effective standard therapy, involving tumour-debulking surgery, followed by radiotherapy 
and chemotherapy. This cancer is very difficult to treat and most patients die within a year 
due to tumour recurrence. Consequently, novel therapies are highly demanded. 
Successful post-operative immunotherapy enabling immune recognition 
and destruction of residual or recurrent tumour cells would provide an enormous 
clinical value. Induction of a vaccine-induced immune response by adaptive immune 
lymphocytes initially requires efficient presentation, by antigen presenting cells, of 
tumour associated antigens (referred to as signal 1) together with costimulatory signals 
(called signal 2). Most TAAs are inherently poorly antigens and require an adjuvant 
to break immunological tolerance (Schijns and Lavelle, 2011). The studies described 
here included GM-CSF as an immunological adjuvant, which is able to facilitate both 
signal 1 and signal 2. The cytokine GM-CSF is well-known in supporting dendritic 
cell (DC) recruitment and development; hence enabling improved antigen uptake 
and subsequently the magnitude of antigen presentation. In addition, it stimulates 
maturation of DC, characterised by expression of co-stimulatory molecules (signal 2), 
as effective antigen–presenting cells for T cells (Min et al., 2010). GM-CSF is one of the 
most frequently used cytokines as immunological adjuvant in different types of cancer 
vaccines (Warren and Weiner, 2000; Chang et al., 2004; Parmiani et al., 2007). GM-CSF 
is commonly used today in the production of DCs from ex vivo isolated peripheral blood 
monocytes for the clinical use in DC cancer vaccines (Inaba et al., 1992; Schuler et al., 
2003). GM-CSF has also been shown to stimulate peripheral blood monocytes in vitro to 
become cytotoxic for the malignant cells (Grabstein et al., 1986). 
GM-CSF has been administered either as recombinant protein in 
conjunction with tumour antigens or as a transfected gene therapy product in cells 
genetically engineered to secrete biologically active GM-CSF (Jinushi and Tahara 2009; 
Parmiani et al., 2007; Dranoff et al., 1993). GM-CSF is also a component that is used in the 
first Food and Drug Administration-approved therapeutic cancer vaccine Sipuleucel-T 
against prostate cancer (Cheever and Higano, 2011). Notably, opposite immunological 
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functions have been reported for this cytokine (Parmani et al., 2007; Clive et al., 2010). 
For example, a high concentration of this cytokine may recruit immunosuppressive 
myeloid suppressor cells and depress the immune response (Serafini et al., 2004). 
Hence, as for most cytokines, the timing and dosing seems crucial for optimal clinical 
use. However, the significance of data in pre-clinical and clinical settings, demonstrating 
the beneficial adjuvant effects of GM-CSF in a variety of cancer vaccine approaches, 
make GM-CSF an attractive vaccine adjuvant because of its immune modulation effects 
and low toxicity profile. The safe pharmacological use of GM-CSF in patients is well-
established, which makes it very attractive and feasible for clinical use.  
The present study shows complete rejection of malignant gliomas as 
a result of active therapeutic immunization with a mix of allogeneic and syngeneic 
glioma tumour antigens in conjunction with low dose GM-CSF, following low-dose of 
cyclophosphamide treatment. The strong efficacy of this prototype immunotherapy 
supports future implementation in clinical studies. 
 Materials and methods
Tumour Model 
Glioma cells Both CNS-1 tumour cells and RG2 (ATCC, CRL-2433) rat 
glioma cells were cultured in Dulbecco’s modified Eagle (DMEM) medium containing 10 
% bovine fetal serum (FBS), 5 % antibiotics Penicillin, Streptomycin, and amphotericin B 
(Hyclone) in 175-mm2 flasks. The CNS-1 haplotype is RT1l and RG2 is RT1lvl.
Animals Rat CNS-1 cells (2 X 105 cells/200 μl) were implanted 
subcutaneously (SC) using a 21 gauge needle into the right flank of 8-12 week-old (300 
gram body weight) male Lewis rats. For each treatment group and control, 6 rats/group 
were used. All animal studies were approved by an independent ethical committee.
Monitoring Tumour Growth The sizes of the CNS-1 tumour volumes were 
measured using a caliper three times per week on Mondays, Wednesdays and Fridays to 
monitor the effects of each treatment group. 
Completion of experiment Tumour implanted rats were sacrificed if they 
showed signs of discomfort, as defined by the ethical committee. For example if they 
appeared moribund due to weight loss, lethargy, ruffled fur, or when tumours showed 
ulceration. A mixture of Rompun and ketamine was used for anesthesia, followed by a 
dose of sodium pentobarbital for euthansia. 
Vaccine The vaccine antigen preparation was composed of a mixture of 
haptenized CNS-1 cells and RG2 cells (1 X 10e6 CNS-1 syngeneic and 1 X 10e6 RG2 allogeneic 
glioma cells), together with lysates produced from 3 X 10e6 CNS-1 syngeneic cells and 
3 X 10e6 allogeneic RG2 glioma cells. After a low-dose cyclophosphamide (CY), given 3 
days before the first vaccine injection, this vaccine preparation was given subcutaneously 
in combination the immunostimulatory cytokine GM-CSF (Prospec, USA), which was co-
administered together with the vaccine in a dose of 30 µg/kg (corresponding to about 10 
µg/shot) according to the treatment schedule depicted in Figure 7.1. 
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Chemicals and reagents 
Immunomodulators and potentiators
Rats were subcutaneously (SC) injected with the vaccine preparation in 
the flank, contralateral to the tumour-implanted side. As a control Cyclophosphamide 
(CY; CalBiochem, 239785) was given once, at 30 mg/kg, on day 10 post tumour 
implantation, in combination with GM-CSF injections without vaccine. Rat-GM-CSF was 
purchased as an E. coli expression product from Prospec (USA, East Brunswick, NJ). We 
also tested the vaccine antigen preparation combined with cyclophosphamide (CY) only 
or with CY plus GM-CSF. Figure 7.1 shows a treatment schedule representing one cycle 
of the various immunotherapeutic injections.
Statistics For statistical analysis, we used ANOVA nonparametric testing 
followed by students t-tests to compare groups.  P values of < 0.05 (*), p < 0.01 (**), p 
< 0.001 (***) were considered statistically significant. (NB statistics needs to be done 
on final data).
 Results
Except for the untreated control group (CTRL), all animals received a low 
dose of cyclophosphamide (CY) in order to deplete immunosuppressive T regulatory 
cells (Daenen et al., 2009) as depicted in the treatment schedule of Figure 7.1.
Figure 7.1. Treatment schedule representing one cycle of the various immunotherapeutic injec-
tions. The Monday in week 1 is day 10 post implantation. One cycle takes about 2.5 weeks and 
ends at day 28 post tumour implantation. The numbers refer to the cellular components, with 1) 
allogeneic RG-2 cells, 2) syngeneic CNS-1 cells, 3) allogeneic C6 cells.  The second cycle D31-D49 
(= 2nd cycle). Treatment stopped at D=49 and the secondary challenge was given on D59.
We noted complete tumour regression only in the group of animals that 
received the vaccine in conjunction with GM-CSF (Figure 7.2). In the groups receiving Cy 
only, CY plus GM-CSF, or CY plus vaccine, some delay in measurable tumour growth was 
observed relative to the untreated control groups
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Figure 7.2. Average values of tumour growth as a function of time post-implantation for the dif-
ferent treatment groups. Rats were randomly injected with the CNS-1 tumours and divided into 
4 groups (n=6). Control groups (CTRL) were either left untreated (A), or treated with with low-
dose cyclophosphamide (CY) followed by vaccine antigen injections, that were prepared from the 
standardized allogeneic and syngeneic cells (B). Another group was treated with with low-dose 
CY and GM-CSF only (C). Another group received the same vaccine preparation given in combina-
tion with GM-CSF following the low-dose CY (D). The treatments were administered with 3-day 
intervals (see figure 7.1). Average values of tumour growth for individual rats as a function of time 
post-implantation for the different treatment groups.
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Immune anti-tumour memory against glioblastoma
In the animals that all survived the primary glioma implantation within 
the vaccine plus GM-CSF group (n = 6 out of 6), and in the group of animals that was 
able to reduce and delay the tumour growth following CY treatment (n = 6 from original 
group of 6), we tested antitumour immunity after re-inoculation of a secondary glioma 
challenge in the neck. It was compared to a naive (age-matched) control inoculated 
tumour group (n = 6). We noted that only rats with a measurable primary tumour, as 
depicted in Figure 7.3, developed a secondary tumour. Hence, 5 out of 6 rats from the 
complete vaccine plus GM-CSF therapy group develop no secondary tumour after re-
challenge (Figure 7.4c), while in the CY only group 3 out of 6 rats developed a secondary 
tumour as depicted in Figure 7.4B. It proved that the secondary tumour challenge 
evoked tumour growth only in animals that showed residual tumour volumes following 
the primary inoculation; i.e. in 3/6 animals the CY group, and only 1/6 in the GM-CSF 
plus vaccine group (Figure 7.4). The growth of the primary tumours, following the 
inoculation of the secondary tumour implantion, is likely due to less immune strength 
within a certain immune effector population as a result of less numbers of effector cells 
or less functional capacity.  
Figure 7.3. Primary tumour growth in animals initially controling tumour implantation in the CY 
only group (A) and vaccine plus GM-CSF group (B). At 10 days after treatment arrest (D49), all ani-
mals received a secondary tumour implantation; i.e. at day 59 post primary tumour implantation. 
Tumour volumes of animals which had to be sacrificied are indicated in red.
dead rat
control dead ratcontrol
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Figure 7.4. Secondary tumour growth in naïve untreated rats (A), rats controlling the primary 
tumour exposure following CY treatment (B), and controlling primary tumour growth after CY 
treatment followed by vaccination in conjunction with GM-CSF (C).
The second tumour was implanted in the neck at day 59 post primary tumour implantation, i.e. 
at 10 days after treatment arrest (D49). Tumour volumes of animals which had to be sacrificied 
because of primary tumour volumes are indicated in red. In group A all animals (n=6) devlop tu-
mours, while in 3/6 rats develop measurable tumours in group B, and only 1/6 rats develop the 
secondary tumour in group  C.
 Discussion
In the present study we confirmed the proof-of-concept for using mixed 
whole tumour tissue-derived allogenic and syngeneic antigens in an immunization 
therapy against glioblastoma, when administered together with GM-CSF as 
immunological adjuvant. We show that this treatment induces tumour regression, 
dead rat
control
dead rat
control
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which becomes visible as a reduction in tumour growth rate after about 2 weeks of 
initiation of immunotherapy, resulting in non-detectable tumour volumes after a peak 
volume at 21-24 days after the start of tumour growth. This anti-tumour responses 
resulted in immunological memory, since the majority of animals that controlled the 
tumour after treatment with vaccine plus GM-CSF, also rejected a secondary tumour 
without noticeable tumour growth.
Except for the untreated control group, all animals were pretreated with 
a low-dose CY in order to deplete the immunosuppressive regulatory T cells (Rozados 
et al., 2010). This dose proved partially effective in reducing tumour growth, either as a 
result of direct cytotoxic tumour killing or reduced immunosuppression and/or reduced 
angiogenesis, or a combination of all of these effects. However, following therapeutic 
immunization using an antigen preparation based on cells and lysates of synegeic CNS-
1 tumour cells and allogeneic rat glioma cells (C6 and RG-2) in conjunction with the 
immunological adjuvant GM-CSF we observed complete tumour regression.   
In a follow-up experiment we addressed the critical elements and 
dosing of the therapeutic regimen, by selectively changing the dose of antigen, and 
cyclophosphamide and the type of adjuvant, while leaving other therapeutic elements 
unaltered. It was noted that the dose of the antigen preparation could be lowered to 50 
%, without a clear reduction in efficacy if other components (vaccine plus GM-CSF) were 
unaltered (data not shown). We also noted that selective reduction in cyclophosphamide 
dose by 50 % still provided protection in combination with the unaltered vaccine plus 
GM-CSF, while treatment with 50 % of cyclophosphamide only (15 mg /dose) did not 
exert antitumour efficacy. However, a further reduction in cyclophosphamide (7.5 mg/
dose) failed to evoke antitumour responses in the context of the vaccination (data not 
shown). In addition, we tested the particulate saponin adjuvant (AbISCO, Isconova, 
Sweden) as alternative adjuvant for GM-CSF and observed a similar, though somewhat 
reduced, antitumour efficacy (not shown). 
In a clinical situation our therapy is reflected by a vaccine composed 
of autologous antigens, derived from the patient’s surgically removed tumour tissue, 
which is administered in conjunction with antigens from glioma tumour tissue surgically 
removed from allogenic donor patients. This allogenic tumour material provides a 
second source of antigens that can be isolated and subsequently stored in a tissue bank 
for “off-the shelf” use use. The allogenic TAAs may display partial HLA-matching with 
the patient. The mismatching HLA molecules serve to enhance the overall alloimmune 
response. Relevant unique or shared TAAs overexpressed by tumour cells are present 
among thousands of irrelevant immunotolerant non-tumour associated antigens. The 
broad range of TAAs is preferred over vaccines composed of a mono- or oligo-valent 
antigen. The multivalent vaccine will prevent or reduce escape of tumour cells, due to 
antigenic loss, or active MHC downregulation. In addition, a tumour antigen mixture is 
preferred above the use of monovalent synthetic peptides, because of the restricted 
use of peptides in patients with defined HLA types only.
GM-CSF is a frequently used cytokine known to augment immune 
responses for protein of peptide based vaccines (Disis et al., 1996), as well as tumour 
vaccines consisting of cells engineered to secrete GM-CSF (Dranoff et al., 2002). 
Intradermal or subcutaneous inoculation of GM-CSF results in an increase of class II-
positive cells, and “conditions” the inoculation site to enhanced responses to antigen 
(Disis et al., 1996). This cytokine has been used as a haematopoietic growth factor in 
Chapter 7
124
patients undergoing chemotherapy, and is well tolerated (Armitage et al., 1992). When 
given as adjuvant in the skin it is known to recruit and activate antigen presenting cells, 
including epidermal Langerhans cells (Kaplan et al., 1992). GM-CSF showed positive 
effects relative to other cytokines, or in synergy with other cytokines, in preclinical rat 
and mouse glioma vaccine studies (Herrlinger et al., 2004; Jean et al., 2004; Soiffer et 
al., 1998). Despite a wealth of positive reports on the use of GM-CSF, in a randomized 
trial in melanoma patients GM-CSF administration caused early death and reduced DTH 
responses following immunization with allogeneic tumour cells and BCG, relative to 
the arm without GM-CSF treatment (Faries et al., 2009). Also reduced CD4 and CD8 
responses against a melanoma peptide vaccine were observed in the arm receiving 
GM-CSF, relative to the non-GM-CSF receiving arm (Slingluff et al., 2009). These studies 
illustrated that the dose and schedule are very important parameters in the use of GM-
CSF during immunotherapy.
Immunological protection against gliomas has been ascribed to cell 
mediated immune reactions involving cytolytic CD8+ T lymphocytes (Ghulam et al., 
2009). In various preclinical models depletion of these cells by anti-CD8 treatment has 
demonstrated their critical role in vaccine-mediated antitumour immunity (Barcia et al., 
2009; Maes et al., 2009). Hence, in future studies we will examine the influence of these 
lymphocyte populations on protective antitumour efficacy in depletion- or adoptive 
transfer studies. 
In conclusion, we noted beneficial antitumour activity of a vaccine 
preparation that was repeatedly administered together with GM-CSF following a low-
dose cyclophosphamide injection 3 days before immunotherapy. 
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Chapter 8
8.1  Preclinical studies 
The hypothesis pertinent to this thesis is that glioma tumours can be 
therapeutically targeted by gene therapy and/or immunotherapy in order to eliminate or 
delay tumour progression. In our gene therapeutic approach, we observed that chronic 
expression of the C-terminal fusion of IsK with EGFP (enhanced green fluorescent 
protein) led to cell death of more than 50% of transfected U87-MG human astrocytoma 
cells as early as 2 days after transfection. Our results are consistent with activation of 
apoptotic pathways following IsK-mediated increase in K+ efflux. These data are in line 
with numerous encouraging results for gene therapy-based approaches, including those 
targeted to glioblastoma (Curtin et al., 2005). However, one of the largest challenges 
for gene therapy to become efficient is the need to selectively and efficiently infect/
transfect all malignant cells and/or to evoke a strong bystander immune response effect 
directed at neighboring cells in order to eliminate the non-infected tumour cells (Su et al., 
2005). Obviously, much more scientific effort is still necessary to turn gene therapy into 
a commonly used medical treatment (Fischer, 2000). We therefore changed our gene 
therapy approach to more attractive and promising (in our opinion) immunotherapeutic 
strategies for brain tumours, which are currently emerging as highly potential clinical 
options. 
Immunotherapy is a new, promising therapeutic approach that can 
specifically target tumour cells following administration of tumour-antigens together 
with immunostimulation (Hofman et al., 2010; Vauleon et al. (2010), or by administration 
of immunostimulants alone, resulting in a boost of endogenous anti-tumour immune 
reactions. Interestingly, we found a strong therapeutic antitumour efficacy for the innate 
immune response modifier Resiquimod, even as a stand-alone treatment. Resiquimod 
is a nucleoside analog structurally related to Imiquimod (R-837), which is licensed by 
the Food and Drug Administration (FDA) in the United States as active, topical treatment 
for genital warts, and superficial basal cell carcinoma (Urosevic et al., 2003) and which 
likely acts via the activation of Langerhans cell migration (Urosevic et al., 2005). The 
precise mode of action of Resiquimod in our setting requires further investigations. 
Resiquimod (R-848) is an immune response modifier, and has antiviral and 
antitumour activity (Urosevic et al., 2003). It is used as a topical cream in the treatment 
of skin lesions such as those caused by herpes simplex virus and as an adjuvant to 
increase the effectiveness of various vaccines. It has several mechanisms of action, such 
as being an agonist for toll-like receptor 7 and 8 and an upregulator of the opioid growth 
factor (OGF) receptor (McLaughlin et al., 1999). 
In our rat model we administered Resiquimod by subcutaneous injections. 
Unfortunately, Resiquimod is not licensed by regulatory authorities for parenteral 
administration, likely because of observed adverse systemic reactions. Also, local 
immune deficiencies resulting from R-848 administration have been noted, associated 
with a rapid and almost complete depletion of leukocytes from the blood (Gunzer et 
al., 2005).
Remarkably, our data demonstrate that immunotherapeutic parenteral 
treatment of established glioma tumours by Resiquimod, as defined in the protocol, 
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significantly improves anti-brain tumour immunity in a way that leads to immune memory. 
In parallel treatment groups, we also observed that high dose cyclophosphamide (CY) 
treatment, although initially effective as a chemotherapeutic agent, is deleterious to 
the maintenance of long-term antitumour immune memory. High-grade malignant 
gliomas are genetically unstable, heterogeneous and highly infiltrative, and all these 
characteristics lend glioma cells extremely resistant to conventional therapies. 
Immunosuppressive factors in the tumour microenvironment and effector immune 
cell suppressor populations may contribute to the overall immune suppression. Treg 
cells constitute a fairly low percentage (approximately 5 to 15%) of peripheral blood 
mononuclear cells (PBMC) and variable numbers have also been detected in a wide 
variety of tumours. The observation that glioma cells, unlike normal neurons and 
glia, express relatively abundant levels of HLA class I indicated that gliomas might be 
amenable to local adoptive immunotherapy with HLA-restricted alloreactive cytotoxic 
T lymphocytes and therefore there is a need for more comprehensive understanding 
of the factors involved in determining the sensitivity of glioma cells to adoptive T cell 
immunotherapy (Gomez and Kruse, 2006).
We found in different rat glioma models that a certain composition of 
antigens derived from syngeneic tumour cells and their lysates when therapeutically 
co-administered with allogeneic cells and their lysates, is able to confer anti-tumour 
immune responses and to cause tumour regression. For the syngeneic C6 model in 
Sprague Dawley (SD) rats therapeutic injections of allogeneic cells alone were sufficient 
to trigger tumour regression. This immunization approach may prove useful as an 
adjuvant therapy after resective surgery and standard radiation plus chemotherapy 
(temozolomide) (Stupp et al., 2005) in future malignant glioma treatment protocols, 
or as a stand-alone therapeutic tumour vaccination following surgical resection of 
recurrent tumours where no second-line treatment is available. 
Most tumour associated antigens (TAAs) are inherently poor immunogenic 
antigens and require an adjuvant to break immunological tolerance (Schijns and Lavelle, 
2011). In the syngeneic CNS-1 Lewis rat glioma model, we found that in order to cause 
tumour regression, specific innate immune response stimulating substances were 
required as immunological adjuvants. In our hands BCG and IL-2 (chapter 6) as well as 
the Toll-Like receptor (TLR) 7/8 activator Resiquimod (chapter 4) showed potent activity. 
Microglia/macrophages appear to be the predominant immune cell 
populations infiltrating gliomas (~1% of total cells). Although expressing substantial 
levels of Toll-like receptors (TLRs), these cells do not appear to be stimulated to produce 
pro-inflammatory cytokines (TNF-α, IL-β, or IL-6). In vitro, lipopolysaccharides could 
bind TLR-4, but could not induce microglia-mediated T-cell proliferation. Instead, there 
was a prominent population of regulatory CD4 T cells (CD4+CD25+FOXP3+) infiltrating 
the tumour. We conclude that while microglia cells present in glial tumours may have a 
few intact innate immune functions, including their capacity to be stimulated via TLRs, 
secrete cytokines, upregulate costimulatory molecules, and in turn activate antitumour 
effector T cells. However, this is not sufficient to initiate efficacious active anti-tumour 
immune responses. Furthermore, the presence of regulatory T cells may also contribute 
to the lack of effective immune activation against malignant human gliomas (Hussain 
et al., 2006). Consequently, proper immune system activating immunostimulants are 
considered essential to evoke durable active anti-tumour immune reactions (Schijns 
and Lavelle, 2011).
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Finally, we demonstrate that our prototype therapeutic vaccine, when co-
delivered in a specific regimen together with the cytokine GM-CSF as immunological 
adjuvant, is able to arrest the progression of glioma tumour growth, when therapeutically 
administered following a low-dose cyclophosphamide regimen. GM-CSF is an attractive 
vaccine adjuvant because of its proven immune modulatory effects and low toxicity 
profile (Disis et al., 1996). The safe pharmacological use of GM-CSF in patients is well-
established, which makes it feasible for clinical use. As a result of these preclinical 
findings the use of GM-CSF has been included in the first clinical studies based on the 
prototype allogeneic plus autologous combination vaccine, that have been recently 
been submitted and approved for an Investigational New Drug application (IND). 
Critical appraisal
Although our preclinical results are very encouraging they should be 
interpreted with caution. For example, glioma tumours transplanted subcutaneously 
can be easily monitored for growth, but the microenvironment of an intracranial tumour 
may be more complicated than the microenvironment of a transplanted tumour. For 
example, the intracranial tumour may have additional immune suppressing effects. 
Such immunotherapeutic effects on intracranial tumour growth are subject of our 
future investigation. In addition, the preclinical setting of our model may not exactly 
mimic the clinical situation, which involves standard surgery followed by radio- and 
chemotherapy.   
However, the results of our preclinical investigations demonstrate the 
feasibility of active immunotherapy in glioblastoma. In general, it is difficult to compare 
our immunotherapeutic strategy with those of other published successful treatments. 
However, we have identified several very exciting immunotherapeutic strategies 
resulting in complete responses of glioma rejection. Especially encouraging is the 
demonstration of several novel therapeutic strategies, based on the use of particular 
innate immune system stimulating substances, including a TLR7/8 agonist. Among them 
the GM-CSF-adjuvant vaccine may translate into feasible application in patients.   
8.2  Outlook of clinical strategies for 
immunotherapeutic glioblastoma treatment
Research in various rodent systems enabled us to gain insight into 
critical aspects of therapeutic intervention strategies against glial tumours (chapters 
4, 5, 6, and 7). These investigations provide the pre-clinical basis for the development 
of a therapeutic glioblastoma vaccine for patients diagnosed with GBM. The exact 
immunological mechanisms underlying the observed anti-tumour immunity, for 
example innate and adaptive cell-mediated or humoral reactions, remain to be 
researched in more details and determined in ongoing and future studies. These first 
clinical data will be extremely informative for the safety of this new therapeutic medical 
product. However, from our preclinical studies we were able to reach conclusive data 
needed to justify our rationale for the composition and design of our in progress clinical 
evaluation of our innovative immunotherapeutic immunization strategy against GBM. 
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We further plan to extend this strategy—if clinically successful—to the solid tumours 
where effective strategies are lacking. 
Recent promising clinical anti-glioma immunotherapies
Novel treatments for brain cancer (GBM) require a multimodular 
approach, which encompasses several mechanisms of action, including different 
modes of cell death and immune stimulation. Preferably, these novel therapies should 
work synergistically with the best treatment options currently available; i.e., surgery, 
radiotherapy and chemotherapy.
During the last few years, anti-cancer immunotherapy has significantly 
advanced. There are very encouraging results for immunobased therapies against 
lymphoma, leukemia, melanoma and renal cancer (Hudis et al., 2007; Ananthnarayan 
et al., 2008; Hodi et al., 2010; Buonerba et al., 2011). The methodology used is either 
through a simple vaccination of cells and radiated lysates of autologous cancer or 
through the injection of isolated lymphocytes in association with specific cytokines 
or using monoclonal antibodies. Any therapeutic approach using cells and aiming to 
replace, repair, increase or modify the biological activity of an impacted organ, is called 
cellular therapy. Our proposed approach is ‘cellular immunotherapy’, a form of cellular 
therapy utilizing the cells of the immune system.
Promising reports of active immunotherapy for glioblastoma patients 
have been described in literature.  For example, an early clinical trial performed by 
Mahaley and co-workers (Mahaley et al., 1983) showed favorable data.  Each patient 
received subcutaneous inoculations with one of two human glioma tissue culture cell 
lines (D-54MG or U-251MG) monthly, with 500 micrograms of bacillus Calmette-Guérin 
cell wall (BCG-CW) being included with the first inoculation as an immunostimulant. 
Each patient also received levamisole, 2.5 mg/kg 3 days per week every other week. 
Radiotherapy and chemotherapy with BCNU, which were the chemotherapy standard 
of care at that time, begun after the first month of immunization. Patients who were 
inoculated with the U-251MG cell line have showed a longer survival time compared 
to those inoculated with the D-54MG cell line (p less than 0.0590) or compared to 
58 historical cases of glioma patients treated with levamisole, radiation therapy, and 
chemotherapy alone (p less than 0.02). No evidence of allergic encephalomyelitis was 
noted clinically, nor was any gross or microscopic evidence of such pathology obtained 
upon autopsy of three of these patients. 
However, the majority of immunotherapy clinical trials for GBM still 
remained in the Phase I or I/II stage. No phase III clinical trials have been completed 
at this time. Another prominent example is DCVax®-Brain, an immunostimulant cancer 
vaccine, based on experimental autologous cellular therapy, produced by the Northwest 
Biotherapeutics, Inc. (Liau et al., 2005). DCVax-Brain vaccine is manufactured using a 
patient’s dendritic cells loaded with a tumour cell lysate prepared from surgically resected 
tumour tissue. The clinical data from a cohort of 141 newly-diagnosed glioblastoma 
patients treated in a Phase II study is still being collected, however, assessments from 
their Phase I trials suggest overall safety, with delayed time to disease recurrence and 
increased survival, especially in glioblastoma patients with stable disease at entry [see 
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http://www.nwbio.com/clinical_dcvax_brain.php]. Indeed, for those patients treated in 
the Phase I trials, the company is reporting that the median survival is 33.8 months, 
with 9 of 19 patients still alive at 8-82 months from initial surgery.
The company ImmunoCellular Therapeutics, Ltd (http://www.imuc.
com/) has supported a Phase I study using the product “ICT-107” for glioblastoma. 
This also a dendritic cell-based vaccine loaded with synthetic peptide antigens that 
targets multiple glioma associated antigens (Yu et al., 2004;  Wheeler and Black , 
2009). In a June 2010 IMUC company report it was stated that the median overall 
survival had not yet been reached at the 26.4 months analysis point, with 12 out of 
16 treated newly diagnosed patients alive (http://www.imuc.com/pdf/Brain-Cancer-
Vaccine-Looks-Promising-in-Small-Trial-1.pdf#zoom=100). See also Hu et al., 2011, 
and Yu et al., 2011)
Other clinical trials involving immunotherapy for brain gliomas can be 
found at www.clinicaltrials.gov by refining search terms using key words at that site.
8.3  Novel immunotherapeutic approaches 
presented on this thesis  
Our preclinical data have been performed with the aim to define the 
most appropriate composition of our antigens and the most favorable method of 
immunization. The details of our in-progress clinical strategy for active immunotherapy 
against GBM are described in detail below.
Tumour associated antigens (TAA)
Upon recognition and rejection of the allogeneic tumour preparation, 
the  immune system of the patient will develop an immune response by recognizing 
cancer cell associated-proteins, including the so-called tumour associated antigen 
(TAA), and consequently reject the patient’s own tumour. These tumour-associated 
antigens are antigens expressed by tumour cells and not/less (or very occasionally) 
by the normal cells (Lewis & Houghton, 1995). They can result from single-point 
mutations within open reading frames of the genome and giving rise to unique 
antigens expressed by the tumour cells of a single patient. They represent the genuine 
tumour-specific antigens. Moreover, tumours may show an abnormal expression 
of antigens that are normally associated with development and differentiation or 
with viral products. These abnormally expressed antigens are not unique to a single 
tumour but are found in many tumour types and across different patients. They are 
also named tumour-associated antigens (TAA).
In our strategy, the target antigens are not well defined (and they don’t 
need to be). But this multi-faceted approach increases the chances to induce a strong 
and broad immune response to multiple tumour antigens. Another advantage is that 
in the whole tumour antigen preparation, TAA are presented in combination with 
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both major histocompatibility complex (MHC) class I and II antigens (Kakimi et al., 
2009). These extracts and lysates are directly recognized as a source of antigen acting 
as an allograft, in order to trigger a strong immune rejection, and boosting a specific 
immunization against TAA. 
Tumour lysates and cells
Tumours can differ greatly  from each other on a genetic level (Hanahan 
and Weinberg, 2000). Hence, a typical, single biopsy reflects only part of a tumours 
molecular signature (Gerlinger et l., 2012). Since high-grade gliomas (HGGs), including 
GBM, are a heterogeneous group of primary brain tumours, we prefer poly-antigenic 
immunization over the monoantigenic approach. We are convinced that achieving 
clinically relevant antitumour immunity requires simultaneous stimulation of immune 
reactions against a wide range of tumour-associated antigens. Therefore, instead 
of a single-agent-targeted immunotherapy based on just one or a few proteins or 
peptide antigens, produced synthetically or by recombinant heterologous expression, 
we prefer a multi-modular antigen approach based on syngeneic lysates and cells, 
providing a “personalized” set of perfectly matching target antigens of the patient, 
mixed with lysates and cells from allogeneic tumours. This mixture of antigens is not 
defined, but expected to overlap to a large degree with the specific tumour antigens 
of each and every GBM patient. This strategy enables triggering of an immune 
response against a broad array of tumour antigens, having the ability to replicate 
not only the cellular heterogeneity at the time of treatment initiation, but also to 
predict tumour TAA variation at the time of possible recurrence. In addition, the 
tumour lysate is not human leukocyte antigen (HLA)-restricted and is available in 
most cases for each patient undergoing surgery, allowing treatment irrespective of 
the patient’s HLA type. The inclusion of alloantigens will also trigger allo-immune 
reactivity, a classical allograft-directed immune responses typical for non-matching 
major histocompatibility between graft cells and the host. 
The antigens are prepared freshly from the surgically removed tumour 
tissue from the patients and the tumour bank-derived allogeneic tissue from the GBM 
tumour donors. This prevents selection of certain cell types by in vitro culture and 
allows the introduction of extracellular proteins as immunological targets. 
Allogeneic antigens
In the case of an allogeneic immune response, an additional phenomenon 
occurs, the allorecognition (reviewed in Fabre, 2001; also in Gervais, 2009). 
Allorecognition is the mechanism responsible for allograft rejection. It is well known 
that unprimed T lymphocytes from one individual react with unusual strength against 
MHC antigens of other members of the same species, a phenomenon named “allo-
agression”. This process is based on a unique aspect of T-cell biology, the direct T-cell 
allorecognition. It reflects the capacity of T lymphocytes to recognize intact allogeneic 
MHC molecules on the surface of foreign cells. It is a powerful mechanism of T-cell 
activation, since about 1-10% of an individual’s T lymphocytes will respond to the 
foreign MHC antigens of another individual. By comparison, the frequencies of T-cell 
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precursors for “normal” environmental antigen (e.g. a virus protein) are of the order of 
1/10.000 or 1/100.000.
Allorecognition 
The use of allogeneic immunization in cancer therapy has several 
important mechanistic implications. These include:
1) Cross-reactivity: The vast number of T-cells reacting with allogeneic 
MHC molecules will also have a specificity for normal and environmental antigens 
presented in association with self MHC molecules, among which self TAAs. Therefore, 
T-cells activated by direct recognition of the allogeneic MHC class I and II molecules, 
may also cross-react with TAAs presented within self MHC molecules on the patients’-
own tumour cells.
2) CD8 and CD4-positive T cells are both implicated in the allorecognition 
phenomenon. CD4 T cells activated by direct recognition of MHC class II molecules 
during immunization may act as providers of T helper activity, triggering and 
sustaining a TAA specific immune response against the patient’s own tumour cells. 
In organ transplant rejection, this powerful activation of T helper cells is responsible 
for an early antibody response against the transplant. This is particularly important 
in tumour therapy, as it could theoretically bypass the need for presentation of 
TAA within self MHC class II molecules to activate T helper cells, and could induce a 
powerful cellular and humoral immune reaction against tumour cells displaying TAA 
within MHC class I antigens. 
3) In keeping with the above, it is worth mentioning that CD4 T-cell 
responses are not only necessary but may also be sufficient for allograft destruction. 
Mitchinson et al. (1987) have studied the requirements of T-helpers for the development 
of CD8 T-cells directed against MHC antigens. They showed that co-expression of helper 
and cytotoxic determinants by the same antigen presenting cell represents the most 
efficient mode of T-helper cell activation. 
4) Allogeneic responses have the potential to generate a milieu rich in 
cytokines sustaining both innate immune reaction and promoting T-cell response by 
providing T-cell costimulatory ligands. For example, allogeneic HLA molecules have 
been shown to act as ligands for KIR and consequently activate NK cells that exert 
cytolytic activity against mismatched tumour cells, and thereby provide additional help 
to bystander immune reactions by secreting high levels of cytokines (Chewning et al., 
2007). Also, CD1d-dependent NKT cells have also been described in the modulation of 
an alloreaction as helper cells for concurrent T cell responses (Patterson et al., 2005).
In summary, the rationale for the use of our allogeneic tumour tissue 
antigens in our immunization approach is briefly listed below:
 
- The induction of a combined immune reaction induced by the 
combination of both lysates of tumour cells and of entire cells prepared 
from autologous and allogeneic origin. This combination allows inducing 
of an immune reaction against a variety of whole cell and lysate antigens 
that are present at the different development stages of tumors within 
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the same type of glioma tumour, instead of an immune reaction against 
antigens limited only to antigens presented by cells or within lysates.
The immunological phenomena resemble a “graft rejection” due to the 
presentation of allogeneic cells, which are HLA-incompatible. In addition, autologous 
cells become more immunogenic as a result of chemical marking (haptenization). This 
mixture of antigens has the advantage that it exposes the patient’s immune system 
to a larger variety of tumour antigens, which increases the chance to trigger one of 
the essential immune effector cell populations, such as for example a cytotoxic T 
population. In a recent in vitro study using allogeneic dendritic cells, Gervais et al. 
(2009) showed a reduction of the Treg population in the mixed lymphocyte reaction 
following priming with selected allogeneic DCs and revealed an additional mechanism 
for breaking tolerance and sustaining the anti-tumour immune reaction.
- The presence of the totality of the “original” tumour cells. Indeed, 
contrary to what has been done until now using tumour cell products, 
our isolated tumour cells are not cultured, but directly filtered and 
conditioned for vaccine storage. This production aspect is particularly 
important, because in ex vivo tumour cultures only a percentage (about 
20%) of the tumour cells survive the switch towards a culture medium 
environment. Hence, the culture procedure reduces considerably the 
genetic and immunologic variety present in freshly isolated tumour cells. 
So, avoidance of an in vitro cell culture step facilitates the broadness of 
tumour target antigens in the final preparation, and, hence, the broadness 
of induced immune power against the target tumour.
- The availability of a critical quantity of product material. In contrast to 
immunizations based on cell lines only, the autologous/allogeneic biopsy-
based immunizations depends on the tumour size isolated during surgery 
from the patient and the donor. By using allogeneic donor tumour tissue, 
a theoretical limitation in product material is partially circumvented, since 
a large part of the finished product can be obtained from our glioma 
tumour tissue bank.
Bystander immune activation 
In the patient, “immunogenic” TAA are thought to be derived from tumour 
cells by active secretion, cellular necrosis or apoptosis. Tumour necrosis can be triggered 
by natural killer cells (NK cells), which are activated by cells presenting “non-self” 
motives, in our case, TAA associated with abnormal class I molecules or not associated 
with any MHC class I molecules. These released TAAs are engulfed by circulating, short 
lived, dendritic cells, which carry them to draining lymph nodes. The complex TAA-HLA 
Class I or II molecules are also phagocytosed and processed by resident, long-lived, 
DCs which can present these TAA-HLA class I –II complexes to CD8-positive cytolytic 
lymphocytes (class I restricted) and to CD4-positive T lymphocytes (class II restricted), 
which are able to activate in turn CD8 cells and B cell for the production of specific CTLs 
and antibodies, respectively, and provide the long term memory specific for the TAA. It 
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is important to remember that TAA have to be co-expressed with specific HLA alleles in 
order to be presented on the membrane of APCs: they are HLA class I and II restricted, 
and activated CD8 and CD4 cells, respectively. 
Collectively, it is apparent that allorecognition can be used as a potent 
mechanism to stimulate a TAA-specific immune reaction against one patient’s tumour 
cells. Hence, it is proposed that the intradermal injection of a preparation composed of 
a mix of ‘non-self and self’ haptenized and irradiated cell lysates, as well as ‘non-self and 
self’ haptenized and irradiated cells, can break the self anti-tumour immune tolerance, 
as these cells/lysates are likely to contain antigenic determinants in common with those 
expressed by the patients tumour.
Intradermal immunization may have the best efficacy
Applying vaccines to the upper layers of the skin stimulates a powerful 
immune system response, which is stronger than the traditional approach of injecting 
a vaccine into muscle, according to a growing body of research (Kupper and Fulbrigge, 
2004). Immune system cells stationed in the skin, such as resident innate immune 
cells (Langerhans cells (LCs), dermal dendritic cells (DCs) and mast cells), recognize 
the antigen components in the context of dander and stranger signals and stimulate 
downstream activation cascades. Activated Langerhans cells and dermal DCs are 
stimulated to mature and emigrate from the tissue to the draining lymph node, carrying 
antigen for presentation to naive and memory T cells. Moreover, recently important 
immune system cells called “resident memory T cells” have been found in the skin (Jiang 
et al., 2012).
Two different regimens for “conditioning” the inoculation site have been 
compared: GM-CSF was administered either intradermally (ID) or subcutaneously (SC) 
for five injections while a foreign antigen, tetanus toxoid (TT), was given at the beginning 
or the end of the immunization cycle in both the ID and the SC cohort. ID immunization 
was more effective than SC at eliciting TT specific immunity. In addition, GM-CSF ID, 
administered as a single dose with the antigen, compared favourably with the complete 
Freund’s adjuvant (CFA) and alum in eliciting TT specific antibody and cellular immunity 
(Disis et al., 1996).
In summary, we are proposing a personalized-medicine strategy, using 
freshly prepared, non-selected, patient-derived autologous tumour tissue (a source of 
multi-antigenic, antigens able to evoke a broad, non-HLA-restricted immune reaction) 
administered together with allogeneic tumour antigens (which trigger an allogeneic 
immune response). Both components will be delivered through the skin in order to 
evoke a stronger immune reaction, as suggested by our preclinical data.
Safety
Importantly, we now demonstrate that this product is safe and protective 
in early and advanced malignant glioblastomas in rats, as observed in pre-clinical studies 
and as published for example in Stathopoulos et al., 2008 (Chapter 5). 
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Early clinical data 
The Food and Drug Administration (FDA), Center for Biologicals Evaluation 
and Research (CBER), USA, has recently approved (March 7th, 2012) our Single Patient 
Investigational New Drug application (IND). The IND allowed the administration of 
our immunotherapy to a patient with GBM, grade IV, with a progressive tumour after 
second-line treatment with bevacizumab (Avastin) treated at University of California, 
Irvine (UCI).
In parallel, an application has been filed in Belgium to use our 
immunotherapy treatment under hospital exemption, engineered as defined by the 
CE N° 1394/2007 and as approved by EMEA. According to the description of the rule, 
for a drug prepared non-routinely, under controlled conditions of manufacturing (the 
sterile room of the Tissue bank), and used in the same European country (Belgium), in 
a clinical environment under the responsibility of a medical doctor following medical 
prescription, specifically for the patient (using autologous and immunostimulating 
allogeneic tissue). 
Summary of clinical results in May 2012
Methods: Eligible patients who were over 18 years of age and had 
histologically confirmed WHO grade IV malignant glioma were treated under IRB-
approved protocols. Only patients that have failed the standard of care regimens were 
treated. Primary end points are toxicity and 6-month progression-free survival (PFS) 
while secondary endpoints are median overall survival (OS) and radiographic response.
Results: To date, there were a total of 5 patients enrolled, three on a phase 
1 protocol at South Cliniques of Luxembourg-Belgium, one on compassionate/ single 
patient IND protocol at UC Irvine Medical Center, and one at University of Southern 
California (USC). Median age was 52, with 2/5 female patients. The average KPS was 
70 (50-80). Four patients are still alive, they are clinically and radiologically stable. One 
patient shows after three cycles of vaccination spectacular tumour regression which 
is observed after an average of 8 (4-12) weeks. One patient died of intra-cerebral 
hemorrhage may be due of the Bevacizumab, 4 weeks after the first treatment. The 
toxicities were mild: 2/5 patients developing grade 2 headaches and 5/5 grade 2 local 
erythema at the injection site.
 Conclusion: Based on the most recent studies, the 6 months progression 
free survival rate is 16% for the patients with recurrent GBM who failed Bevacizumab. 
Our preliminary data suggest that ERC-1671 might be superior to active treatment with 
other chemotherapy agents in that clinical setting. Updated results will be presented at 
the SNO 2012 meeting.
Case report:
A woman presented with headache and nausea, which proved a right-
sided temporal brain tumour as confirmed by brain magnetic resonance imaging 
(MRI), without any other neurological deficit. On 1st October 2010 she underwent 
primary brain surgery (right front-temporal craniotomy and total tumour resection) and 
pathological examination confirmed the GBM diagnosis. 
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From November 2010 to February 2012 – oncological treatment: Start-
up with Temodal (TMZ) concomitant with radiotherapy (concomitant phase): TMZ 
administered orally, in a dosage of 125 mg/d daily for 42 days, in association with 
focal radiotherapy. The patient handles the first phase well, the treatment continues. 
Monotherapy phase with Temodal – 6 cycles: (four weeks after finishing the concomitant 
treatment phase with TMZ + RT). In February 2012 the patient presents a large tumour 
recurrence, at the original right temporal site with an infiltrative hypercaptating 
formation, associated with an important perilesional edema, exercising a mass effect 
on the right lateral ventricle. The tumour recurrence demonstrates that previous 
standard treatments had failed. From February 6th to February 24th 2012: hospitalized 
for headaches and speech impairment of Wernicke motor aphasia type, without any 
other neurological deficit, in connection with a right cerebral temporal tumour. After 
a secondary, subtotal surgical tumour resection, she was treated by our immune 
intervention approach, under hospital exemption, engineered as defined by the CE N° 
1394/2007 and as approved by EMEA. Secondary surgery occurred on 10 February 2012 
and MRI scans were made on February 20th, 2012 (see Figure 8.1, left panel), revealing 
that the tumour size after surgery was approximately 62,5 cm3. Immunotherapeutic 
ATMP treatment was started on March 1st, 2012. According to published literature her 
expectancy of life is 0.4-1.1 month for recurrent Glioblastoma and prognosis without 
further treatment; Park et al., 2010). 
Figure 8.1. MRI scans 8 days before (left) and 15 days after the start of the vaccination schedule 
(right).
It proved that the tumour showed regression of about 50 % after 
immunotherapy. The tumour has since been shrinking. See also follow-up MRI scans of 
Figure 8.2 and 8.3, and another patient example in figure 8.4 after one treatment cycle.
Day 8 before vaccination
(Feb 20, 2012)
15 days post vaccination (= March 1) 
(March 15)
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Meningioma Tumor 
not proliferative
Same MRI level
Tumor Reduced Tumor
Meningioma Tumor 
not proliferative
Same MRI level
Figure 8.2. MRI scans of 20Feb2012 (left) versus 07May2012 (right), following 3 treatment cycles 
(coronal view)
Figure 8.3. MRI scans of 20Feb2012 (left) versus 07May2012 (right), following 3 treatment cycles 
(MRI scan, axial view)
Meningioma Tumor 
not proliferative
Same MRI level
Meningioma Tumor 
not proliferative
Same MRI level
Tumor Reduced Tumor
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Figure 8.5. Typical delayed type hypersensitivity reaction at the injection site. 
Figure 8.4. MRI scans of another patient made on June 19, 2012 (left) versus April  31, 07May2012 
(right), following 1 treatment cycle (MRI scan, axial view).
 143
Chapter 8 
8
Safety
The treatment related adverse effects were well-tolerated. They consisted 
of erythema, induration and swelling of the inoculation sites (Figure 8.5).
In conclusion
Immunotherapy is a promising tool to treat cancer. Similar to existing 
situations for difficult indications like HIV, TB, malaria, a multi-modular strategic 
treatment approach is required. Especially a mixture of allogeneic and autologous 
antigens is required to provide a spectrum of antigens to harness T cell immunity 
preventing tumour escape. For boosting immune responses it is advisable to include a 
rationally chosen adjuvant/immunostimulant. The rat glioblastoma model has proven 
to be very useful to select and establish a proof-of-concept for a highly efficacious 
immunotherapeutic strategy in patients.
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 Introduction
Glioblastoma Multiforme (GMB) is the most common primary brain 
tumour with an incidence of approximately 10,000 new cases annually in the United 
States1. Despite gross total resection, and treatment with radiation and chemotherapy - 
temozolomide followed by bevacizumab at the time of recurrence -, the median survival 
has improved only to 18 months in the last decade [1,2]. Once the GBM recur, they are 
universally fatal, with survival less than a few weeks, despite aggressive treatment [3]. 
The main cause for GBM recurrence is not precisely known, but recent 
research suggest that it involves the development (and/or persistence) of subpopulations 
of tumour cells with resistance to treatment [3]. GBM is characterized by the presence 
of multiple glioma cell populations [4,5] organized in a stem cell hierarchical order with 
different stages of differentiation [6]. The cell population situated at the apex of the 
cellular hierarchy - the glioma stem-like cells (GSC) have been the proposed reason for 
the recurrence of malignant gliomas after treatment [6-8]. 
It is hypothesized that glioma cancer stem cells (GSC) can arise either from 
neural stem or progenitor cells [9] after the accumulation of mutations in oncogenic 
pathways such as NF1, p53 and PTEN [10] (see Figure A.1). They have the ability to self-
renew and to initiate brain tumours9. In addition, they express neural stem cell markers 
and are multipotent [9]. They constitute only a minor subpopulation of the entire 
tumour. The progeny of GSC are progenitor like cells and differentiated cells, which 
divide rapidly, and form the bulk of the gliomas9. Several surface markers associated 
Neural Stem Cell 
Progenitor Cells  Neurons  
Astrocytes 
Oligodendrocytes 
Glioma Stem Cells 
     
Malignant Glioma (a mix of Glioma Stem Cells and  
More Diﬀerentiated, Highly Proliferative Tumor Cells)  
Glioma Stem Cell Hy oth sis: Malign nt Transformation of Neural Stem/
Progenitor Cells  
NF1 
P53 
PTEN 
Figure A.1: Glioma Stem Cell Hypothesis: Malignant Transformation of Neural Stem/Progenitor 
Cells. Under certain conditions such as acquiring a constellation of oncogenic mutations in various 
pathways (NF1, PTEN or p53), neural stem cells can become glioma stem cells. NF1=Neurofibromin 
1, PTEN=Phosphatase and tensin homolog.
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with GSC are known [9]. These markers, which include CD133/prominin, Musashi 
homolog, nestin and A2B5 [3,9], are useful for the isolation and enrichment of GSC. 
Previous experiments indicate that “non-stem” cells can produce 
tumours in orthotopic xenograft models only when implanted in very high numbers 
[11]. These experimental tumours lack the classical malignant glioma behaviors—
namely, an invasive phenotype, vascular proliferation-, and a limited capacity of tumour 
initiation [11]. However, orthotopic implantation of a small number of stem-like cells 
in appropriate animal models generate aggressive growth of tumours [12,13], bringing 
further support to the stem cell hypothesis for glioma formation [14]. 
In this review we will first summarize the current treatment modalities 
used for glioblastoma treatments and evaluate their effectiveness in controlling and 
eradicating the GCS. We will review the mechanisms involved in GSC-driven tumour 
proliferation, invasion and resistance to treatment and consider potential therapeutic 
targets that might hinder or block these oncogenic pathways. Finally, we will discuss 
potential avenues to target GSC in order to decrease the tumour burden and potentially 
provide a cure for this type of cancer. 
A. Current Therapeutic Modalities: Glioma stem cells resist 
the current, first-line treatments for malignant gliomas - 
radiation and temozolomide (TMZ).
The standard of care for malignant gliomas after resection is temozolomide 
(TMZ) plus radiation therapy. A phase III clinical study showed a survival benefit 
by adding TMZ to postoperative radiation treatment [2,15]. The upregulation of O6-
methylguanine-DNA methyltransferase (MGMT) expression counteracts the effects of 
alkylating agents [16], such as TMZ. In vivo, the expression of MGMT correlated well with 
the resistance of malignant gliomas to TMZ treatment [17]. Ultimately, almost all the 
patients relapsed after treatment with radiation and temozolomide, with a progression 
free survival of zero at 5 years  [18]. 
The main mechanism through which radiation damages and kills glioma 
cells is the induction of breakage of the hydrogen bonds within the DNA strands, 
altering the base pairs, inducing substitutes, destruction of sugars and forming dimers. 
However, GSC are resistant to radiation [13]. The mechanisms involved in this radio-
resistance are the following:
1. Selective cellular growth arrest, or quiescence, is described as the 
primary means by which the GSC evade the radiation and TMZ chemotherapy induced 
cellular damage [9,19]. During quiescence, GSC are maintained in growth arrest 
by various cellular processes and signalling pathways. Once the radiation and TMZ 
chemotherapy is completed, the arrested GSC can again become actively proliferating 
leading to fatal tumour recurrences [7,13,20,21]. 
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2. Activation of checkpoint proteins is a major mechanism for radio-
resistance of GBM. The most common checkpoint proteins overexpressed in GSC are 
ChK1 and ChK2 kinases [13]. These proteins are also expressed in high quantities in 
tumours isolated from population of cells enriched by radiation, such as CD133+ 
GSC populations [13]. Early analysis of tumour samples found that patients who had 
a high percentage of CD133+ GSC had a worse outcome than those patients with a 
lower percentage of CD133+ GSC [13]. Since the CD133+ GSC population was enriched 
after radiation suggested activation of DNA repair machinery in these cells. Further 
investigations showed that CD133+ cells were also able to repair the damage to their 
DNA more effectively than the CD133- GCS [13]. Treating CD133+ GSC with a specific 
ChK1 and ChK2 kinase inhibitors sensitized them to radiotherapy, suggesting that one 
of the main pathways for resistance to radiation therapy was the activation of the DNA 
damage checkpoint response in GSC [13]. 
Temozolomide (TMZ) is an alkylating agent that methylates the DNA 
thereby inhibiting DNA replication and cell proliferation. The GSC are resistant to TMZ, 
via multiple mechanisms of resistance [8].
1. GSC have higher levels of expression of O6 – methyl – guanine – DNA 
– methyltransferase (MGMT) [14] . MGMT is a DNA repair protein which reverses the 
alkylation in the O6 position of guanine and thus compensates for the DNA methylation 
effects [16]. In vivo, the expression of MGMT correlates well with the resistance of 
malignant gliomas to TMZ treatment [17]. Bleau et al showed that in a mouse model 
of glioma, treatment with TMZ increases the population of GSC [14] . However, GSC 
with normal levels of MGMT were resistant to TMZ [22] while only the MGMT negative 
GSC were killed by TMZ [23]. In the clinical setting, the patients who had methylation 
of the MGMT promoter – which leads to silencing of the promoter and prevents gene 
expression - benefited with the addition of TMZ to their treatment [15]. Chen et al 
showed that a restricted cell population propagates glioblastoma growth after TMZ 
chemotherapy [8]. A relatively quiescent GCS population was identified after TMZ 
chemotherapy, that subsequently produced the highly proliferative cells [8]. 
2. Another mechanism of resistance to TMZ treatments is expression of 
multiple drug transporting proteins including ABC (ATP binding cassette) transporters 
which expel out of the cell the chemotherapeutics. Hirsmachmann –Jax et al showed 
that a side population (SP) of cancer stem cells isolated from tumours and identified 
by flow cytometry contains these transporters and resists cytotoxic drug treatment. 
They also showed that ABCG2 and ABCA3 transporters were increased in GCS [24]. 
We showed that GSC have 10 times higher levels of ABCG2 than NSC [3]. Multidrug 
resistance 1 (MDR1) protein was also over-expressed in TMZ resistant CD133+ GSC 
[25]. CD133 was initially described as a marker which resisted the uptake of fluorescent 
markers, which coincidentally resemble chemotherapeutic drugs [26,27].
3. The evasion of the cell-death pathway is another important mechanism 
of resistance developed by GSC. By losing various proteins and overexpression of other 
proteins, GSC can modulate their response to chemotherapy and select the most resistant 
phenotype [9]. One mechanism of avoidance of cell-death pathways is the deletion of 
phosphatase and tensin homolog (PTEN) in glioma stem cells.[14,28] PTEN suppresses 
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the Akt phosphorylation in this pathway, by reversing the PI3K phosphorylation, thus 
inhibiting cell proliferation [28]. Therefore, loss of PTEN leads to uncontrolled activation 
of Akt and tumour growth [14,28]. Bleau et al showed treatment with TMZ selects for 
GSC that lack the PTEN gene [14]. This loss leads to activation of Akt, resistance to 
apoptosis, tumour progression, and poor prognosis for the patient. 
4. Several other mechanisms also contribute to the resistance to TMZ 
treatment. The apoptosis pathway is heavily exploited by GCS [29]. Anti-apoptotic 
genes, such as Bcl-2, were found to have higher expression in the GSC population 
which was resistant to TMZ [29]. The addition of XIAP inhibitors increases sensitivity to 
chemotherapy of the previously chemotherapy resistant GSC [30], thus suggesting that 
activation of antiapoptotic factors such as XIAPs, are involved in resistance of stem cells 
to TMZ chemotherapy. 
5. Constitutive activation of the Notch pathway also increases the 
oncogenic potential of these cells and maintains their stem cell status [31]. Wang et al 
showed that blocking Notch pathway leads to increased sensitivity of GSC to radiation 
[32]. By upregulating PI3K/AKT levels and increasing the levels of Bcl-2 family proteins, 
the Notch pathway produces radioresistance in GSC. The knockdown Notch models 
increase the sensitivity of GSC to radiation [32].
6. Insulin like growth factor binding protein 2 (IGFBP2) can mediate 
the activation of AKT pathway leading to resistance to radiation and conventional 
chemotherapy [33]. IGFBP2 upregulates metalloproteinase-2 and CD24, which increases 
the ability of GSC to invade adjacent tissues [33]. In vitro inhibition of IGFBP2 in GSC lead 
to decreased AKT activation, increased GSC sensitivity to radiation and chemotherapy, 
as well as decreased stem cell gene expression [34]. 
B. Therapeutic targets that may hinder or block GSC-driven 
tumour proliferation, invasion and resistance to treatment. 
1.  Tumour angiogenesis and glioblastoma stem cells
GSC induce vascular endothelial growth factor (VEGF) over-expression 
which increases  angiogenesis, leads to new formation of blood vessels to sustain 
tumour growth and therefore increases blood vessel density [7,9,35] (Figure A.2). 
Vascularization plays a significant role in the providing nutrition and oxygen for gliomas 
[9]. 
Bevacizumab (Avastin) is a humanized monoclonal antibody, that binds 
and inhibits the activity of VEGF both in vitro and in vivo [36,37]. Several groups showed 
that anti-VEGF therapy specifically blocked GSC pro-angiogenic effects [9]. Bevacizumab 
has been tested in clinical trials for GBM patients, and was approved by the FDA for 
patients who experienced first or second recurrence of GBM [38]. 
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VEGF expression is controlled by the hypoxia induced factors (HIFs). 
Under hypoxic conditions both GSC and non-stem cells gliomas express VEGF, but the 
expression was higher in the GSC group [39,40]. Li et al found the HIF-1α and HIF-2α 
separately controlled VEGF expression in GSC [39]. Hypoxic conditions also select for 
the GSC fraction of the tumour cells and can also induce expression of the certain stem 
cell markers [37,41,42].  
Transcription Factor Activation 
(cMyc, Olig2, Oct4, Sox2, TRRAP, NF-kB) 
Notch 
NICD 
BMPR 
BMP 
Smad1/5/8 
Smad4 
IL6 
gp130 
gp80 
JAK 
STAT3 
VEGF 
Ras Ras 
NF1 MEK 
ERK 
FT 
GTP 
Signaling Mechanisms Important in Glioma Stem Cells and Potential Therapeutic 
Targeting (Part 1) 
Bevacizumab 
Notch Pathway 
 Inhibitors 
TGF
Sox4 
Figure 2: Signalling Mechanisms Important in Glioma Stem Cells and Potential Therapeu-
tic Targeting (Part 1). Multiple stem cell and oncogenic pathways are involved in GSC-driven 
tumour proliferation, invasion and resistance to treatment. The most actively targeted by 
therapeutic agents are angiogenesis (VEGF inhibition) and differentiation (Notch inhibition). 
VEGF=Vascular endothelial growth factor, FT=Farnesyltransferas, RAS=Rat sarcoma gene fami-
ly, MEK=Mitogen-activated protein kinase, ERK=Extracellular regulated kinase, gp60/80=60 kD/ 
80 kD glycoprotein, JAK=Janus kinase, STAT3=Signal transducer and activator of transcription 3, 
BMP=Bone morphogenetic proteins, SMAD=Homolog of both the Drosophila protein, mothers 
against decapentaplegic (MAD) and the Caenorhabditis elegans protein SMA (small body size), 
TGFb=Transforming growth factor beta, Sox=Sry-related HMG box, NICD=Intracellular domain of 
Notch, cMYC=Myelocytomatosis viral oncogene, Olig2/Olig4=Oligodendrocyte lineage transcrip-
tion factor 2/4, TRRAP=Transformation/transcription domain-associated protein, NF-kB= nuclear 
factor kappa-light-chain-enhancer of activated B cells.
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Transcription Factor Activation 
(cMyc, Olig2, Oct4,TRRAP, NF-kB)  
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Figure 3: Signalling Mechanisms Important in Glioma Stem Cells and Potential Therapeutic Tar-
geting (Part 2). Aberrant Growth Factors Expression, Adhesion Molecules Modulation as well 
as Protein Degradation and Differentiation Pathways are involved in GSC-driven tumour prolife-
ration, invasion and resistance to treatment. The most actively targeted by therapeutic agents 
are aberrant growth factor receptor expression (EGF, PDGF, VEGF), adhesion (integrins), protein 
degradation (proteasome inhibitors) and differentiation (Hedgehog inhibitors).  HH= Hedgehog, 
Ptch1=Patched homolog 1, SMO=Smoothened, Gli1/2/3=Glioma protein 1/2/3, EGF=Epidermal 
growth factor, PDGF=Platelet-derived growth factor, PI3K= Phosphatidylinositol 3-kinase, 
PIP2/3=Plasma membrane aquaporin 2/3, PTEN=Phosphatase and tensin homolog, Akt=Protein 
Kinase B (PKB), VEGF= Vascular endothelial growth factor, TSC=Tuberous sclerosis complex 1 
gene, mTOR=Mammalian target of rapamycin cMYC=Myelocytomatosis viral oncogene, Olig2/
Olig4=Oligodendrocyte lineage transcription factor 2/4, TRRAP=Transformation/transcription do-
main-associated protein, NF-kB=Nuclear factor kappa-light-chain-enhancer of activated B cells.
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2.  Hypoxia inducible factor HIF-1α maintains the tumourigenic 
potential of gliomas stem cells and increases treatment 
resistance
Hypoxia is common in tumour growth, and for many years it was believed 
to inhibit tumour growth. However, recent studies indicate that hypoxia actually 
contributes to tumour growth and proliferation. In malignant gliomas, hypoxia was 
found to promote angiogenesis, tumour growth and radioresistance [43]. Hypoxic niches 
play an essential role in the maintenance of GSC [39,40,43]. These “hypoxic niches” 
were also involved in the maintenance of normal stem cells [9]. In embryonic stem cells, 
hypoxia maintains the self-renewal potential and prevents the differentiation of neural 
stem cells. Yoshida et al demonstrated that hypoxia enhanced production of induced 
pluripotent stem cells (iPSC) [44]. GBM frequently display numerous GSC around the 
areas of necrosis [39]. CD133 is also a marker for hypoxic stress [45]. This may be the 
reason why some GBM GSC might be selected for in the hypoxic regions. 
In addition, hypoxia increases the expression of GSC markers [37,43]. 
Previous work indicates that hypoxia increases CD133+ GSC [46,47]. In hypoxic 
conditions, GSC activate HIF-1α thus increasing their self-renewal ability and anti-
differentiated status of GSC [48]. Notch signalling is important in hypoxia, as it maintains 
the cells in an undifferentiated state. Activation of Notch signalling pathway occurs by 
recruiting HIF-1α at Notch responsive promoters [49]. In addition, multiple HIF regulated 
genes were reported to be expressed in GSC, but not in glioma tumour cells [48]. Studies 
showed that losing factors such as HIF-2α for example, leads to a significant decrease 
in both GSC proliferation and self-renewal in cultures, and decrease in tumourigenic 
potential in animals [48]. In addition expression of HIF-1α and HIF2α was found to lead 
to an increase in oncogeneity of GSCs [43]. Therefore HIF-1α family proteins represent 
a solution for targeting GSC populations. There are a number of HIF1a targeted agents 
such as polyamides, quinols and naphthoquinone spiroketal analogues, shikonin 
derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and 
bortezomib. Only bortezomib was tried in clinical studies of GBM patients with limited 
results [50].
3.  Signalling pathways in GSC not only lead to resistance to 
chemotherapy, but also induce new tumour formation and 
lead to recurrence
Malignant gliomas are highly infiltrative tumours displaying both radiation 
and conventional chemotherapy resistances. They frequently recur locally despite gross 
total surgical resection. As described above, cellular quiescence of the gliomas stem cells 
allows them to evade the TMZ chemotherapy and radiation induced damage. Several 
signalling pathways, including Notch, Hedgehog and transforming growth factors such 
as TGFβ, are involved in maintaining quiescence in GSC that helps these cells evade 
systemic treatments (Figure A.2). 
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3.1  Notch signalling pathway increases the oncogenic potential of GSCs
The Notch signalling pathway is believed to maintain the cellular 
quiescence of GSC [51]. This pathway was implicated in the self-renewal potential of 
the stem cells, inhibiting differentiation and protecting the cells from excessive usage of 
the proliferative potential [51]. In T cell acute lymphoblastic leukemia and in lymphoma, 
Notch was implicated in maintaining the cancer stem cells [52]. In gliomas, the Notch 
pathway activating mutations were associated with purified CD133+ GSC [53]. It is 
believed that in GSC Notch activation makes the cells quiescent and helps them escape 
radio-chemotherapy treatment [9]. These cells are then released from their quiescent 
dormancy and enter the cell cycle and differentiate into tumours [9]. In glioblastoma 
sphere cultures treated with gamma secretase inhibitors (GSIs), the CD133+ GCS were 
depleted and the putative GCS markers were downregulated (CD133, nestin, BMI1, 
Olig2) [54]. In these experiments, treatment with GSIs leads to the inhibition of tumour 
sphere formation in vitro and to reduced tumour size in the xenograft model [54]. Further 
investigations showed that Notch signalling blockade depletes oncogenic GSC through 
reduced cells proliferation and increased cell apoptosis associated with decreased 
levels of AKT phosphorylation and STAT3 [31] Inhibition of the Notch signalling pathway 
can also target the endothelial cells in malignant gliomas [55]. Hovinga et al showed 
that when the tumour endothelial cells were eliminated from a GBM explant, there was 
a simultaneous decrease in self-renewal of the tumour stem cells [55]. Combination 
treatments with Notch blockade and radiation therapy resulted in a decrease in 
proliferation and self-renewal of the tumour explants [55]. Thus the Notch pathway 
links angiogenesis and GSC; this allows a dual targeting approach for future treatments. 
RO4929097 is a gamma secretase inhibitor of Notch signalling which has been used in 
Phase I trial in patients with advanced solid malignancies with promising results [56] 
and could have immediate relevance for GBM.
3.2.  The Hedgehog – GLI is also involved in maintaining the oncogenic 
potential of gliomas stem cells  
Hedgehog (HH) –GLI signalling pathway regulates self – renewal and 
tumour-forming abilities in CD133+ GSC [57]. Blockade of the HH pathway using 
cyclopamine depletes GSC [22]. The homeobox gene, Nanog, was recently identified as 
a mediator for HH-GLI and contributes to the expansion of the CD133+ GSC population, 
and maintaining glioblastoma growth [57]. It has also been shown that a loss of p53 
contributes to up-regulation of Nanog by activating HH pathway and by negatively 
regulating the activity and level of GLI [57]. GLI was also found to upregulate Notch and 
downregulate BMP signalling, which is a pro-differentiation action on stem cells [58]. 
GANT61 is a preclinical molecule targeting the GLI1 and GLI2 in the HH –GLI pathway 
causes apoptosis in myeloid leukemia cells. [59] 
3.3.  Epidermal growth factor receptor (EGFR) signalling pathway is involved 
in maintaining the oncogenic potential of gliomas stem cells
Epidermal growth factor receptor (EGFR) signalling pathway is involved 
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in maintenance of GSC with a malignant phenotype [60]. Approximately 40-60 % of 
GBM tumours exhibit EGFR amplification along with a high EGFR protein expression 
levels [61]. The EGFR activation initiates the phosphatidylinositol-3-kinases (PI3K)/
Akt pathway. PI3K are lipid kinases that phosphorylate lipid phosphatidylinositol (4, 
5)-bisphosphate (PIP2) to generate phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) 
[62,63]. PIP3 recruits AKT to the cell membrane, which enhances cell growth, survival, 
and proliferation of the cells. EGFR variant III (EGFR vIII) possesses a hierarchical model 
of expression, which was restricted to epigenetic mechanisms which are characteristic 
of GSC [64]. Inhibition of the EGFR pathway via tyrosine kinase inhibitors induced 
apoptosis in CD133+ GSCs [65,66], while inhibition of AKT activity lead to suppression 
of self-renewal in GSC and CD133+ GSC apoptosis [67]. In vitro studies showed that it 
is possible to target only GSC and not NSC, due to lower levels of EGFR expression on 
the NSC surfaces [3]. Clinical trials targeting the EGFR variant III (EGFR vIII) have had 
promising results [68,69] in the GBM patient population. 
3.4. Transforming growth factor beta (TGFβ) enhances the tumour formation 
ability of glioma stem cells
Transforming growth factor beta (TGFβ) is a very powerful cytokine 
demonstrably involved in many cellular processes including embryonal development, 
cell growth, differentiation, morphogenesis, wound healing and immune system 
regulation [70]. When expressed within GSC, the expression of TGFβ is associated 
with self-renewal and tumourigenic potential of GSC. This occurs by the induction of 
LIF through Smad complex binding to LIF promoter [71] via the activation of JAK-STAT 
pathway [71]. Therefore decreasing the secretion of TGFβ and inhibiting the JAK-STAT 
pathway can lead to a decrease in self renewal and tumourigenic potential in GSC [71]. 
TGFβ signalling maintains the tumourigenic capacity of GSC via induction 
of SOX2 expression, which was promoted by induction of SOX4 [72]. SOX4 is a direct 
target gene of TGFb signalling, and SOX4 associates with SOX2 enhancer region, 
promoting its expression [72]. Silencing SOX2 leads to decrease in oncogeneity and self-
renewal in GSC73. The undifferentiated phenotype of GSC is one of the key criteria for 
retaining the tumourigenic potential of these cells [72,73].
3.5.  Platelet derived growth factor receptor (PDGFR) augments GSC 
tumourigenic capacity 
PDGFR plays an important role in the developing and adult brain. This 
protein is also over expressed in GBM at the transcriptional level. In vivo studies 
correlated abnormal PDGF signalling with glioma formation [74]. In animal studies, 
PDGF blocked neuroblast generation and enhanced neural stem cell proliferation in 
the subventricular zone with formation of glioma like hyperplasia [75]. PDGFRβ was 
recently reported to be highly expressed in GSC [76]. Pharmacological inhibition of 
PDGFRβ decreases GSC self-renewal potential, survival, tumour growth, and invasion 
[76]. Imatinib, a tyrosine kinase inhibitor, which inhibits the PDGF signalling pathway, 
reduces the ability of GSC to differentiate [77].
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3.6.  The c-Myc oncogene maintains the tumourigenic potential in glioma 
stem cells
The oncogenic transcription factor c-Myc, is involved in activating the 
expression of many genes through several mechanisms, such as recruitment of histone 
acetylase, chromatin remodeling factors, and interaction with basal transcription 
factors [78]. Guney et al showed that c-Myc inactivation induces telomere independent 
senescence [78]. C-Myc is highly expressed in GSC, and c-Myc knockdown reduces 
cell proliferation, induction of cell apoptosis and loss of oncogenic potential [41]. In 
addition, inactivation of p53 and PTEN – tumour suppressor genes – leads to increased 
expression of c-Myc and increase in oncogeneity of GSC [79]. Inhibitors of c-Myc were 
found to induce cells cycle arrest and apoptosis in acute myeloid leukemia cells [80]. To 
date, there are no c-Myc inhibitors used in the treatment of malignant gliomas.
3.7. Bmi1 contributes to the GSC maintenance and transformation
Bmi1 is an epigenetic silencer gene.[81] Under normal circumstances it is 
involved in determination of the differential of stem cell in several tissues [81] and it is 
a positive regulator of neural stem cells [81]. Bruggeman et al demonstrated that Bmi1 
was involved in malignant transformation of both neural and differentiated astrocytes 
[82]. Bmi1 is over-expressed malignant gliomas [82]. To date efforts are on the way to 
identify small molecule inhibitors to Bmi1.
3.8.  Over-expression of chemokine receptors leads to GSC migration.
Over-expression of chemokine receptors such as CXCR4, is a common 
mechanism related to GSC migration [26]. For glioma cells to migrate, a complex 
combination of multiple molecular mechanisms is needed, including alteration of tumour 
cell adhesion molecules, secretion of proteases, modification of actin cytoskeleton, 
and acquisition of resistance to apoptosis (by affecting PI3K, Akt, mTOR, NF-kappaB 
regulated pathways), and autophagy (programmed cell death type II) [83]. In vitro 
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas [84]. Inhibiting the 
migration of GCS contains the tumour and prevents invasion. There are several CXCR4 
inhibitors, developed for use specifically in HIV patients, but they have not yet been 
tested malignant gliomas. 
3.9.  Adhesion molecules play an important role in migration and thus are 
important in maintaining the oncogenic potential of glioma stem cells
Adhesion molecules play an important role in nervous system 
development, and in neural migration and differentiation [85]. One such molecule is 
L1CAM [85], which regulates neuronal cell growth, survival and migration and axonal 
outgrowth and neurite extension during development. It is expressed in gliomas 
and other cancers and makes it a good potential cell surface target [19]. The L1CAM 
knockdown expression in GSC disrupted the sphere formation ability of GSC, suppressed 
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tumour growth while inducing apoptosis [19]. L1CAM is found in association with 
CD133+ cells, while CD133– cells are L1CAM negative [19]. Studies involving lentiviral 
shRNA targeting of L1CAM disrupted neurosphere formation induced apoptosis and 
inhibited growth of CD133+ GSC [19]. Currently there are no drugs targeting specifically 
the L1CAM molecule. However, based on in vitro results, this is seems to be an attractive 
target for glioma growth inhibition. 
Integrins, another class of adhesion molecules, are cell surface receptors 
that are expressed during development and mediate development specific events 
by binding matrix ligands [86]. Integrin 6α was shown to be important in the neural 
migration during olfactory development [86]. Recently it was shown that integrin 
6α is highly expressed in GSC [87] and that by directly interacting with laminin on 
endothelial cells increases the oncogeneity of GSC. Disruption of the interaction and 
targeting of integrin 6α inhibits self-renewal, and proliferation and tumour formation 
potential [87]. Cilengitide is a specific inhibitor of αvβ3 and αvβ5 integrins and it was 
tested in phase II clinical trials with promising activity against glioma [88].
4.  CD133 is used for the identification and enrichment of GSC 
populations and is also a potential target for therapy 
CD133 is a cell surface protein found on the surface of a population of 
GSC. CD133+ GSC are tumourigenic and have proliferative activity [89], and that the 
presence of CD133+ cells is an independent risk factor for tumour recurrence and 
inversely correlates with patient survival in patients with malignant gliomas [90]. Liu et 
al found that purified CD133+ GSC express a series of genes which are associated with 
undifferentiated, slow-growing, migrating and an anti-inflammatory and anti-angiogenic 
phenotype [53]. Multiple studies have shown that CD133+ gliomas cells are resistant to 
chemotherapy [46,91] potentially because CD133+ GSC express higher levels of proteins 
associated with chemotherapy resistance, such as the DNA repair protein MGMT [14] 
and the drug transporter gene ABCG2/BCRP(breast cancer resistance protein) [24]. 
CD133+ cells also have high mRNA levels of other apoptosis inhibitors, including FLIP, 
Bcl-2, Bcl-X and some IAP family genes [26]. 
5.  Overcoming GSC immune surveillance escape- 
Immunomodulation therapy in the treatment of glio-
blastoma multiforme
Earlier studies in gliomas showed that CD133+ cells did not express 
detectable Major Histocompatibility Complex (MHC) class I or natural killer (NK) 
cell activating ligands [89], thus these cells were resistant to adaptive and innate 
immune surveillance. Incubating GSC with interferon gamma significantly increased 
the percentage of CD133+ cells that expressed MHC class 1 and natural killer ligands 
[89]. In addition, when the CD133+ cells were pretreated with interferon gamma, 
they became sensitive to NK cell-mediated lysis in vitro [89]. GSC can be attacked 
using active immunotherapy by designing vaccines that stimulate the host’s intrinsic 
immune response to the tumour. The initial immunotherapies against gliomas 
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included irradiated whole tumour cell inoculation engineered to secrete cytokines 
[92], or combined with cytokine secreting cells [93] or cytokines alone [94]. TR2-01849 
is a specific antibody to CD133 protein, specifically designed to target glioblastoma 
stem cells. Various immune strategies, such as adjuvants, heat shock proteins, γδ T 
cell treatments have been used as immunomodulators of the immune system in the 
treatment of GBM [95]. 
5.1.
 A newer method of triggering the active immunity is the development 
of a dendritic cell (DC) vaccine, which used patient-derived professional antigen 
presenting cells (APC), such as dendritic cells, to initiate the tumour-specific T-cell 
response when reinjected in the patients [96-100]. Using this procedure, the lysates 
of GSC produced a more robust immune system response than using lysates of GBM 
cells. The DC conditioned with GBM GCS lysates present a wide variety of antigens to T 
cells to stimulate effective anti-tumour immunity and it is believed that DC vaccination 
strategies using GSC lysates generate more effective stronger immune responses 
against a series of more specific epitopes. It has been known that in monoclonal 
gammopathy patients can develop an immune response against specific epitopes such 
as SOX2 [101]. In the case of gliomas, Pellegatta et al showed that the use of GSC lysates 
elicited a strong T cell immune response [102]. In addition, DC vaccination using the 
antigens/lysates derived from the “mesenchymal subtype” of GBM (which has a very 
poor prognosis when compared to the pro-neural GBM [103,104]) produced a better 
survival than those other types of GBM treated with their respective lysate-pulsed DC; 
i.e., classical or pro-neural types [105].
6.  miRNA can modulate tumour cell proliferation, invasion, 
apoptosis and senescence
The miRNA are small, non –coding RNAs, which down-regulate gene 
expression post transcriptionally during different cell processes such as apoptosis, 
differentiation and development [106]. miRNA were originally identified as potential 
tumour suppressor molecules which induces apoptosis in neuroblastoma cells [107]. 
The miRNA expression in gliomas is associated with GSC maintenance and growth 
[106,108]. For gliomas miR-34a was down-regulated when compared to normal brain 
[106,108]. Mutant p53 expressing glioma tumours had lower levels of miR-34a than 
wildtype p53 tumours. The presence of miR-34a within those gliomas inhibits their 
proliferation pathways, cell survival, migration and invasion [106,108]. Transfection of 
cells with miR-34a inhibited oncogene expression such as c-Met, Notch-1 and Notch2 
[106,108]. miR-34a expression induces gliomas stem cells differentiation and thus has 
the potential to be used in targeting the oncogenic pathways. Currently there are no 
clinical trials which use the miRNA concept. However, as technology advances, it is very 
likely that miRNA could be used as a treatment strategy. 
160
Annex   
Discussion and Conclusions
A significant challenge in designing treatment against GSC is to avoid 
damage to the neural stem cells and progenitor cells, which share many genetic 
similarity and antigen expression profiles with GCS [7]. The adult human stem cells 
serve important functions in tissue repair after injury, especially after traumatic brain 
injury, ischemic and tumour associated or treatment induced destruction [9]. These 
normal neural stem cells (NSC) also possess some intrinsic activity against tumour cells, 
they are attracted by glioma cells in vivo and they induce apoptosis and inhibit glioma 
stem cell growth [109]. The neural stem cells and the progenitor cells are, however, 
more sensitive than GSC to temozolomide and carboplatin chemotherapy [3]. Hypoxic 
conditions and EGFR expression seem to be most characteristic to GSC and not to NSC. 
We previously showed that Bortezomib, a proteasome inhibitor, and Erlotinib (ERL), an 
EGF tyrosine kinase inhibitor, decrease the viability of GSC, but not to affect NSC. 
New research also shows the need to target both the GSC and the bulk 
of the glioma cells. In their new paper, Chen et al indicated that if one targets only 
the GSC, the mice still die due to their tumour burden [8]. Therefore, there is a need 
for more effective drugs or immunotherapeutic strategies that target both GSC and 
the more differentiated glioma cell mass. More clinical trials focused on combination 
therapies against multiple oncogenic pathways involved in GSC maintenance, division 
and differentiation are still needed. 
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 Summary
The hypothesis pertinent to this thesis is that glioma tumours can be 
therapeutically targeted by gene and/or immunotherapy in order to eliminate or delay 
tumour recurrence leading to significant morbidity and mortality.
 
In our gene therapeutic approach, described in Chapter 2, we observed 
that chronic expression of the C-terminal fusion of IsK with EGFP (enhanced green 
fluorescent protein) led to cell death of more than 50% of transfected U87-MG human 
astrocytoma cells as early as 2 days after transfection. Our results are consistent with 
activation of apoptotic pathways following IsK-mediated increase in K+ efflux. 
However, we abandoned the gene therapy approach because of the more 
attractive  immunotherapeutic intervention strategies for of brain tumours, which is 
currently emerging as a highly potential clinical option as reviewed in Chapter 3.
Interestingly, as described in Chapter 4, we found a strong therapeutic 
antitumour efficacy for the innate immune response modifier Resiquimod, even as a 
stand-alone treatment, eventually leading to immunological memory against secondary 
tumour challenges. In parallel, we observed that cyclophosphamide treatment, although 
effective as chemotherapeutic agent, may be deleterious to maintenance of long-term 
antitumour immune memory. Our data also demonstrates that immunotherapeutic 
parenteral treatment of established glioma tumours by Resiquimod, as defined in the 
protocol, significantly improves anti-brain tumour immunity in a way that leads to 
immune memory, which is superior to cyclophosphamide treatment alone. Our studies 
have thereby identified a promising novel antitumour immunotherapy which may lead 
to clinical benefit.
In Chapter 5, we describe our finding that, in multiple rat glioma models, 
a certain composition of antigens derived from syngeneic tumour cells and their lysates 
when therapeutically co-administered with allogeneic cells and their lysates is able 
to confer anti-tumour immune responses and tumour regression. For the syngeneic 
C6 model in SD rats therapeutic injections of allogeneic cells alone were sufficient to 
trigger tumour regression. This immunization approach may prove useful as a post-
surgery adjuvant therapy in future cancer treatment protocols, or even as a stand-alone 
therapeutic tumour vaccination.
In another syngeneic rat glioma model, described in Chapter 6, we found 
that for regression of CNS-1 glioma tumours in Lewis rats specific innate immune 
response stimulating substances were required as immunological adjuvants. In our 
hands BCG and IL-2, the Toll-Like receptor (TLR) 7/8 activator Resiquimod, and the 
cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), showed potent 
activity.
Finally, as described in Chapter 7, we demonstrate that our prototype 
therapeutic vaccine, when co-delivered in a specific regimen together with the cytokine 
GM-CSF as immunological adjuvant, is able to arrest progression of glioma tumour 
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growth, when therapeutically administered following low-dose cyclophosphamide. 
GM-CSF is an attractive vaccine adjuvant because of its proven immune modulatory 
effects and low toxicity profile. The safe pharmacological use of GM-CSF in patients is 
well-established, which makes it feasible for clinical use.  The use of GM-CSF has been 
included in the first clinical studies that have been approved for an Investigational New 
Drug application (IND) for Single patient use in the U.S.. 
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In dit proefschrift werd de hypothese getoetst dat gliomatumouren 
dusdanig therapeutisch behandeld kunnen worden door middel van gen- of 
immunotherapie dat eliminatie of vertraging van tumourgroei optreedt resulterend in 
significante verlaging van morbiditeit en mortaliteit.
 
In de gen-therapeutische aanpak, beschreven in hoofdstuk 2, werd 
waargenomen dat chronische expressie van het C-terminale fusie-eiwit van IsK met 
EGFP (enhanced green fluorescent protein) resulteerde in meer dan 50% celdood van de 
getransfecteerde U87-MG humane astrocytoom cellen binnen 2 dagen na transfectie. 
Deze bevindingen duiden op activatie van apoptotische routes in tumourcellen als 
gevolg van een IsK-gemedieerde toename in K+ efflux. 
Omdat een immunotherapeutische interventiestrategie voor glioom-
hersentumouren op dat moment meer belovend leek werden deze gen-therapeutische 
studies niet verder doorgezet. In hoofdstuk 3 wordt deze immunotherapeutische 
aanpak als behandeloptie beschreven in een overzichtsartikel.
In hoofdstuk 4 beschrijven we een duidelijke therapeutische antitumour 
activiteit voor het middel Resiquimod, een zogenaamde “innate immune response 
modifier”, zelfs wanneer het werd toegediend in de vorm van een zogenaamde 
“stand-alone” behandeling. Deze behandeling resulteerde bovendien in een effectief 
immunologisch geheugen, zoals duidelijk werd door het uitblijven van tumourgroei na 
een latere secondaire blootstelling aan de tumour. In deze studie bleek dat de behandeling 
met het chemotherapeutische en immunosuppressieve agens cyclofosfamide eveneens 
een goede initiële antitumour werking bewerkstelligt. Echter na blootstelling aan 
een secondaire tumour bleek er een negatief effect op het lange-termijn antitumour 
immunologisch geheugen. Hieruit blijkt dat Resiquimod, volgens het beschreven 
protocol, een significant anti-glioom immuniteit induceert, leidend tot immunologisch 
geheugen, en dat dit middel superieur is ten opzichte van cyclofosfamide behandeling. 
In hoofdstuk 5 worden studies beschreven in verschillende rat glioom-
modellen, waarbij een bepaalde samenstelling van het antigeenmengsel, afkomstig van 
syngene tumourcellen en hun lysaten tezamen met therapeutisch toegediende  allogene 
cellen en hun lysaten, in staat is om een anti-tumour immuunrespons op te wekken 
en tumourregressie te induceren. Voor het syngene C6 model in SD ratten bleken 
therapeutische injecties van allogene cellen alleen al voldoende om tumourregressie te 
bewerkstellingen. Een dergelijke immunisatie-strategie lijkt belovend als postoperatieve 
adjuvant-therapie in toekomstige kankerbehandelingen, of zelfs als een “stand-alone” 
therapeutische tumourvaccinatie.
In een ander syngeen glioom rattenmodel, beschreven in hoofdstuk 
6, werd waargenomen dat regressie van CNS-1 glioom-tumouren in Lewis ratten 
opgewekt kon worden door middel van specifieke immuunstimulerende substanties, 
zogenaamde “immunologische adjuvantia”, die gericht werken op cellen van het 
aangeboren immuunapparaat. In dergelijke studies vertoonden met name BCG en IL-
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2, de Toll-Like receptor (TLR) 7/8 activator Resiquimod, en het cytokine granulocyte-
macrophage colony stimulating factor (GM-CSF), een duidelijke anti-tumour activiteit 
indien toegediend in combinatie met tumourantigenen bestaande uit cellen en hun 
lysaten.
In hoofdstuk 7 laten we zien dat ons prototype therapeutisch vaccin, 
in combinatie met een specifiek regime  van het cytokine GM-CSF als immunological 
adjuvant, in staat is om de progressie van glioom-tumourgroei te remmen, indien 
therapeutisch toegediend na een lage dosis cyclofosfamide. GM-CSF is een attractief 
vaccin-adjuvant vanwege zijn bewezen immunomodulerende effect en zijn lage 
toxiciteit. Het veilige farmacologische gebruik van GM-CSF is al duidelijk aangetoond in 
patiënten, hetgeen de haalbaarheid voor klinisch gebruik vergemakkelijkt. Het cytokine 
GM-CSF is daarom in de eerste klinische studies toegepast die onlangs zijn goedgekeurd 
voor een zogenaamde “Investigational New Drug application (IND)” voor het gebruik in 
individuele patienten in de Verenigde Staten van Amerika. 
In hoofdstuk 8 bediscussiëren wij de resultaten van ons onderzoek in relatie 
tot de internationale literatuur, speculeren we over een mogelijk werkingsmechanisme 
en vatten we de conclusies van ons onderzoek samen. Hierbij tonen wij ook de eerste 
resultaten van de klinische toepassing van een tumourvaccin, gemaakt volgens de 
gegevens van deze studie, bij patiënten met glioblastoma multiforme.  
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